<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000849</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>20</s160></s100><s200><s210>1</s210><s211>5879</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 1tcagaagaaa gccccgagat cacagagacc cggcgagatc acagagaccc ggcctgaagg     60aacgtggaaa gaccaatgta cctgttttga ccggttgcct ggagcaagaa gttccagttg    120gggagaattt tcagaagata aagtcggaga ttgtggaaag acttgacttg cagcattact    180ctactgactg gcagagacag gagaggtaga tgtccacgcc cacagaccct ggtgcgatgc    240cccacccagg gccttcgccg gggcctgggc cttcccctgg gccaattctt gggcctagtc    300caggaccagg accatcccca ggttccgtcc acagcatgat ggggccaagt cctggacctc    360caagtgtctc ccatcctatg ccgacgatgg ggtccacaga cttcccacag gaaggcatgc    420atcaaatgca taagcccatc gatggtatac atgacaaggg gattgtagaa gacatccatt    480gtggatccat gaagggcact ggtatgcgac cacctcaccc aggcatgggc cctccccaga    540gtccaatgga tcaacacagc caaggttata tgtcaccaca cccatctcca ttaggagccc    600cagagcacgt ctccagccct atgtctggag gaggcccaac tccacctcag atgccaccaa    660gccagccggg ggccctcatc ccaggtgatc cgcaggccat gagccagccc aacagaggtc    720cctcaccttt cagtcctgtc cagctgcatc agcttcgagc tcagatttta gcttataaaa    780tgctggcccg aggccagccc ctccccgaaa cgctgcagct tgcagtccag gggaaaagga    840cgttgcctgg cttgcagcaa caacagcagc agcaacagca gcagcagcag cagcagcagc    900agcagcagca gcagcaacag cagccgcagc agcagccgcc gcaaccacag acgcagcaac    960aacagcagcc ggcccttgtt aactacaaca gaccatctgg cccggggccg gagctgagcg   1020gcccgagcac cccgcagaag ctgccggtgc ccgcgcccgg cggccggccc tcgcccgcgc   1080cccccgcagc cgcgcagccg cccgcggccg cagtgcccgg gccctcagtg ccgcagccgg   1140ccccggggca gccctcgccc gtcctccagc tgcagcagaa gcagagccgc atcagcccca   1200tccagaaacc gcaaggcctg gaccccgtgg aaattctgca agagcgggaa tacagacttc   1260aggcccgcat agctcatagg atacaagaac tggaaaatct gcctggctct ttgccaccag   1320atttaagaac caaagcaacc gtggaactaa aagcacttcg gttactcaat ttccagcgtc   1380agctgagaca ggaggtggtg gcctgcatgc gcagggacac gaccctggag acggctctca   1440actccaaagc atacaaacgg agcaagcgcc agactctgag agaagctcgc atgaccgaga   1500agctggagaa gcagcagaag attgagcagg agaggaaacg ccgtcagaaa caccaggaat   1560acctgaacag tattttgcaa catgcaaaag attttaagga atatcatcgg tctgtggccg   1620gaaagatcca gaagctctcc aaagcagtgg caacttggca tgccaacact gaaagagagc   1680agaagaagga gacagagcgg attgaaaagg agagaatgcg gcgactgatg gctgaagatg   1740aggagggtta tagaaaactg attgatcaaa agaaagacag gcgtttagct taccttttgc   1800agcagaccga tgagtatgta gccaatctga ccaatctggt ttgggagcac aagcaagccc   1860aggcagccaa agagaagaag aagaggagga ggaggaagaa gaaggctgag gagaatgcag   1920agggtgggga gtctgccctg ggaccggatg gagagcccat agatgagagc agccagatga   1980gtgacctccc tgtcaaagtg actcacacag aaaccggcaa ggttctgttc ggaccagaag   2040cacccaaagc aagtcagctg gacgcctggc tggaaatgaa tcctggttat gaagttgccc   2100ctagatctga cagtgaagag agtgattctg attatgagga agaggatgag gaagaagagt   2160ccagtaggca ggaaaccgaa gagaaaatac tcctggatcc aaatagcgaa gaagtttctg   2220agaaggatgc taagcagatc attgagacag ctaagcaaga cgtggatgat gaatacagca   2280tgcagtacag tgccaggggc tcccagtcct actacaccgt ggctcatgcc atctcggaga   2340gggtggagaa acagtctgcc ctcctaatta atgggaccct aaagcattac cagctccagg   2400gcctggaatg gatggtttcc ctgtataata acaacttgaa cggaatctta gccgatgaaa   2460tggggcttgg aaagaccata cagaccattg cactcatcac ttatctgatg gagcacaaaa   2520gactcaatgg cccctatctc atcattgttc ccctttcgac tctatctaac tggacatatg   2580aatttgacaa atgggctcct tctgtggtga agatttctta caagggtact cctgccatgc   2640gtcgctccct tgtcccccag ctacggagtg gcaaattcaa tgtcctcttg actacttatg   2700agtatattat aaaagacaag cacattcttg caaagattcg gtggaaatac atgatagtgg   2760acgaaggcca ccgaatgaag aatcaccact gcaagctgac tcaggtcttg aacactcact   2820atgtggcccc cagaaggatc ctcttgactg ggaccccgct gcagaataag ctccctgaac   2880tctgggccct cctcaacttc ctcctcccaa caatttttaa gagctgcagc acatttgaac   2940aatggttcaa tgctccattt gccatgactg gtgaaagggt ggacttaaat gaagaagaaa   3000ctatattgat catcaggcgt ctacataagg tgttaagacc atttttacta aggagactga   3060agaaagaagt tgaatcccag cttcccgaaa aagtggaata tgtgatcaag tgtgacatgt   3120cagctctgca gaagattctg tatcgccata tgcaagccaa ggggatcctt ctcacagatg   3180gttctgagaa agataagaag gggaaaggag gtgctaagac acttatgaac actattatgc   3240agttgagaaa aatctgcaac cacccatata tgtttcagca cattgaggaa tcctttgctg   3300aacacctagg ctattcaaat ggggtcatca atggggctga actgtatcgg gcctcaggga   3360agtttgagct gcttgatcgt attctgccaa aattgagagc gactaatcac cgagtgctgc   3420ttttctgcca gatgacatct ctcatgacca tcatggagga ttattttgct tttcggaact   3480tcctttacct acgccttgat ggcaccacca agtctgaaga tcgtgctgct ttgctgaaga   3540aattcaatga acctggatcc cagtatttca ttttcttgct gagcacaaga gctggtggcc   3600tgggcttaaa tcttcaggca gctgatacag tggtcatctt tgacagcgac tggaatcctc   3660atcaggatct gcaggcccaa gaccgagctc accgcatcgg gcagcagaac gaggtccggg   3720tactgaggct ctgtaccgtg aacagcgtgg aggaaaagat cctcgcggcc gcaaaataca   3780agctgaacgt ggatcagaaa gtgatccagg cgggcatgtt tgaccaaaag tcttcaagcc   3840acgagcggag ggcattcctg caggccatct tggagcatga ggaggaaaat gaggaagaag   3900atgaagtacc ggacgatgag actctgaacc aaatgattgc tcgacgagaa gaagaatttg   3960acctttttat gcggatggac atggaccggc ggagggaaga tgcccggaac ccgaaacgga   4020agccccgttt aatggaggag gatgagctgc cctcctggat cattaaggat gacgctgaag   4080tagaaaggct cacctgtgaa gaagaggagg agaaaatatt tgggaggggg tcccgccagc   4140gccgtgacgt ggactacagt gacgccctca cggagaagca gtggctaagg gccatcgaag   4200acggcaattt ggaggaaatg gaagaggaag tacggcttaa gaagcgaaaa agacgaagaa   4260atgtggataa agatcctgca aaagaagatg tggaaaaagc taagaagaga agaggccgcc   4320ctcccgctga gaaactgtca ccaaatcccc ccaaactgac aaagcagatg aacgctatca   4380tcgatactgt gataaactac aaagataggt gtaacgtgga gaaggtgccc agtaattctc   4440agttggaaat agaaggaaac agttcagggc gacagctcag tgaagtcttc attcagttac   4500cttcaaggaa agaattacca gaatactatg aattaattag gaagccagtg gatttcaaaa   4560aaataaagga aaggattcgt aatcataagt accggagcct aggcgacctg gagaaggatg   4620tcatgcttct ctgtcacaac gctcagacgt tcaacctgga gggatcccag atctatgaag   4680actccatcgt cttacagtca gtgtttaaga gtgcccggca gaaaattgcc aaagaggaag   4740agagtgagga tgaaagcaat gaagaggagg aagaggaaga tgaagaagag tcagagtccg   4800aggcaaaatc agtcaaggtg aaaattaagc tcaataaaaa agatgacaaa ggccgggaca   4860aagggaaagg caagaaaagg ccaaatcgag gaaaagccaa acctgtagtg agcgattttg   4920acagcgatga ggagcaggat gaacgtgaac agtcagaagg aagtgggacg gatgatgagt   4980gatcagtatg gacctttttc cttggtagaa ctgaattcct tcctcccctg tctcatttct   5040acccagtgag ttcatttgtc atataggcac tgggttgttt ctatatcatc atcgtctata   5100aactagcttt aggatagtgc cagacaaaca tatgatatca tggtgtaaaa aacacacaca   5160tacacaaata tttgtaacat attgtgacca aatgggcctc aaagattcag attgaaacaa   5220acaaaaagct tttgatggaa aatatgtggg tggatagtat atttctatgg gtgggtctaa   5280tttggtaacg gtttgattgt gcctggtttt atcacctgtt cagatgagaa gatttttgtc   5340ttttgtagca ctgataacca ggagaagcca ttaaaagcca ctggttattt tatttttcat   5400caggcaattt tcgaggtttt tatttgttcg gtattgtttt tttacactgt ggtacatata   5460agcaacttta ataggtgata aatgtacagt agttagattt cacctgcata tacatttttc   5520cattttatgc tctatgatct gaacaaaagc tttttgaatt gtataagatt tatgtctact   5580gtaaacattg cttaattttt ttgctcttga tttaaaaaaa agttttgttg aaagcgctat   5640tgaatattgc aatctatata gtgtattgga tggcttcttt tgtcaccctg atctcctatg   5700ttaccaatgt gtatcgtctc cttctcccta aagtgtactt aatctttgct ttctttgcac   5760aatgtctttg gttgcaagtc ataagcctga ggcaaataaa attccagtaa tttcgaagaa   5820tgtggtgttg gtgctttcct aataaagaaa taatttagct tgacaaaaaa aaaaaaaaa    5879</s400><s200><s210>2</s210><s211>5838</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 2gcgtcttccg gcgcccgcgg aggaggcgag ggtgggacgc tgggcggagc ccgagtttag     60gaagaggagg ggacggctgt catcaatgaa gtcatattca taatctagtc ctctctccct    120ctgtttctgt actctgggtg actcagagag ggaagagatt cagccagcac actcctcgcg    180agcaagcatt actctactga ctggcagaga caggagaggt agatgtccac gcccacagac    240cctggtgcga tgccccaccc agggccttcg ccggggcctg ggccttcccc tgggccaatt    300cttgggccta gtccaggacc aggaccatcc ccaggttccg tccacagcat gatggggcca    360agtcctggac ctccaagtgt ctcccatcct atgccgacga tggggtccac agacttccca    420caggaaggca tgcatcaaat gcataagccc atcgatggta tacatgacaa ggggattgta    480gaagacatcc attgtggatc catgaagggc actggtatgc gaccacctca cccaggcatg    540ggccctcccc agagtccaat ggatcaacac agccaaggtt atatgtcacc acacccatct    600ccattaggag ccccagagca cgtctccagc cctatgtctg gaggaggccc aactccacct    660cagatgccac caagccagcc gggggccctc atcccaggtg atccgcaggc catgagccag    720cccaacagag gtccctcacc tttcagtcct gtccagctgc atcagcttcg agctcagatt    780ttagcttata aaatgctggc ccgaggccag cccctccccg aaacgctgca gcttgcagtc    840caggggaaaa ggacgttgcc tggcttgcag caacaacagc agcagcaaca gcagcagcag    900cagcagcagc agcagcagca gcagcagcaa cagcagccgc agcagcagcc gccgcaacca    960cagacgcagc aacaacagca gccggccctt gttaactaca acagaccatc tggcccgggg   1020ccggagctga gcggcccgag caccccgcag aagctgccgg tgcccgcgcc cggcggccgg   1080ccctcgcccg cgccccccgc agccgcgcag ccgcccgcgg ccgcagtgcc cgggccctca   1140gtgccgcagc cggccccggg gcagccctcg cccgtcctcc agctgcagca gaagcagagc   1200cgcatcagcc ccatccagaa accgcaaggc ctggaccccg tggaaattct gcaagagcgg   1260gaatacagac ttcaggcccg catagctcat aggatacaag aactggaaaa tctgcctggc   1320tctttgccac cagatttaag aaccaaagca accgtggaac taaaagcact tcggttactc   1380aatttccagc gtcagctgag acaggaggtg gtggcctgca tgcgcaggga cacgaccctg   1440gagacggctc tcaactccaa agcatacaaa cggagcaagc gccagactct gagagaagct   1500cgcatgaccg agaagctgga gaagcagcag aagattgagc aggagaggaa acgccgtcag   1560aaacaccagg aatacctgaa cagtattttg caacatgcaa aagattttaa ggaatatcat   1620cggtctgtgg ccggaaagat ccagaagctc tccaaagcag tggcaacttg gcatgccaac   1680actgaaagag agcagaagaa ggagacagag cggattgaaa aggagagaat gcggcgactg   1740atggctgaag atgaggaggg ttatagaaaa ctgattgatc aaaagaaaga caggcgttta   1800gcttaccttt tgcagcagac cgatgagtat gtagccaatc tgaccaatct ggtttgggag   1860cacaagcaag cccaggcagc caaagagaag aagaagagga ggaggaggaa gaagaaggct   1920gaggagaatg cagagggtgg ggagtctgcc ctgggaccgg atggagagcc catagatgag   1980agcagccaga tgagtgacct ccctgtcaaa gtgactcaca cagaaaccgg caaggttctg   2040ttcggaccag aagcacccaa agcaagtcag ctggacgcct ggctggaaat gaatcctggt   2100tatgaagttg cccctagatc tgacagtgaa gagagtgatt ctgattatga ggaagaggat   2160gaggaagaag agtccagtag gcaggaaacc gaagagaaaa tactcctgga tccaaatagc   2220gaagaagttt ctgagaagga tgctaagcag atcattgaga cagctaagca agacgtggat   2280gatgaataca gcatgcagta cagtgccagg ggctcccagt cctactacac cgtggctcat   2340gccatctcgg agagggtgga gaaacagtct gccctcctaa ttaatgggac cctaaagcat   2400taccagctcc agggcctgga atggatggtt tccctgtata ataacaactt gaacggaatc   2460ttagccgatg aaatggggct tggaaagacc atacagacca ttgcactcat cacttatctg   2520atggagcaca aaagactcaa tggcccctat ctcatcattg ttcccctttc gactctatct   2580aactggacat atgaatttga caaatgggct ccttctgtgg tgaagatttc ttacaagggt   2640actcctgcca tgcgtcgctc ccttgtcccc cagctacgga gtggcaaatt caatgtcctc   2700ttgactactt atgagtatat tataaaagac aagcacattc ttgcaaagat tcggtggaaa   2760tacatgatag tggacgaagg ccaccgaatg aagaatcacc actgcaagct gactcaggtc   2820ttgaacactc actatgtggc ccccagaagg atcctcttga ctgggacccc gctgcagaat   2880aagctccctg aactctgggc cctcctcaac ttcctcctcc caacaatttt taagagctgc   2940agcacatttg aacaatggtt caatgctcca tttgccatga ctggtgaaag ggtggactta   3000aatgaagaag aaactatatt gatcatcagg cgtctacata aggtgttaag accattttta   3060ctaaggagac tgaagaaaga agttgaatcc cagcttcccg aaaaagtgga atatgtgatc   3120aagtgtgaca tgtcagctct gcagaagatt ctgtatcgcc atatgcaagc caaggggatc   3180cttctcacag atggttctga gaaagataag aaggggaaag gaggtgctaa gacacttatg   3240aacactatta tgcagttgag aaaaatctgc aaccacccat atatgtttca gcacattgag   3300gaatcctttg ctgaacacct aggctattca aatggggtca tcaatggggc tgaactgtat   3360cgggcctcag ggaagtttga gctgcttgat cgtattctgc caaaattgag agcgactaat   3420caccgagtgc tgcttttctg ccagatgaca tctctcatga ccatcatgga ggattatttt   3480gcttttcgga acttccttta cctacgcctt gatggcacca ccaagtctga agatcgtgct   3540gctttgctga agaaattcaa tgaacctgga tcccagtatt tcattttctt gctgagcaca   3600agagctggtg gcctgggctt aaatcttcag gcagctgata cagtggtcat ctttgacagc   3660gactggaatc ctcatcagga tctgcaggcc caagaccgag ctcaccgcat cgggcagcag   3720aacgaggtcc gggtactgag gctctgtacc gtgaacagcg tggaggaaaa gatcctcgcg   3780gccgcaaaat acaagctgaa cgtggatcag aaagtgatcc aggcgggcat gtttgaccaa   3840aagtcttcaa gccacgagcg gagggcattc ctgcaggcca tcttggagca tgaggaggaa   3900aatgaggaag aagatgaagt accggacgat gagactctga accaaatgat tgctcgacga   3960gaagaagaat ttgacctttt tatgcggatg gacatggacc ggcggaggga agatgcccgg   4020aacccgaaac ggaagccccg tttaatggag gaggatgagc tgccctcctg gatcattaag   4080gatgacgctg aagtagaaag gctcacctgt gaagaagagg aggagaaaat atttgggagg   4140gggtcccgcc agcgccgtga cgtggactac agtgacgccc tcacggagaa gcagtggcta   4200agggccatcg aagacggcaa tttggaggaa atggaagagg aagtacggct taagaagcga   4260aaaagacgaa gaaatgtgga taaagatcct gcaaaagaag atgtggaaaa agctaagaag   4320agaagaggcc gccctcccgc tgagaaactg tcaccaaatc cccccaaact gacaaagcag   4380atgaacgcta tcatcgatac tgtgataaac tacaaagata gttcagggcg acagctcagt   4440gaagtcttca ttcagttacc ttcaaggaaa gaattaccag aatactatga attaattagg   4500aagccagtgg atttcaaaaa aataaaggaa aggattcgta atcataagta ccggagccta   4560ggcgacctgg agaaggatgt catgcttctc tgtcacaacg ctcagacgtt caacctggag   4620ggatcccaga tctatgaaga ctccatcgtc ttacagtcag tgtttaagag tgcccggcag   4680aaaattgcca aagaggaaga gagtgaggat gaaagcaatg aagaggagga agaggaagat   4740gaagaagagt cagagtccga ggcaaaatca gtcaaggtga aaattaagct caataaaaaa   4800gatgacaaag gccgggacaa agggaaaggc aagaaaaggc caaatcgagg aaaagccaaa   4860cctgtagtga gcgattttga cagcgatgag gagcaggatg aacgtgaaca gtcagaagga   4920agtgggacgg atgatgagtg atcagtatgg acctttttcc ttggtagaac tgaattcctt   4980cctcccctgt ctcatttcta cccagtgagt tcatttgtca tataggcact gggttgtttc   5040tatatcatca tcgtctataa actagcttta ggatagtgcc agacaaacat atgatatcat   5100ggtgtaaaaa acacacacat acacaaatat ttgtaacata ttgtgaccaa atgggcctca   5160aagattcaga ttgaaacaaa caaaaagctt ttgatggaaa atatgtgggt ggatagtata   5220tttctatggg tgggtctaat ttggtaacgg tttgattgtg cctggtttta tcacctgttc   5280agatgagaag atttttgtct tttgtagcac tgataaccag gagaagccat taaaagccac   5340tggttatttt atttttcatc aggcaatttt cgaggttttt atttgttcgg tattgttttt   5400ttacactgtg gtacatataa gcaactttaa taggtgataa atgtacagta gttagatttc   5460acctgcatat acatttttcc attttatgct ctatgatctg aacaaaagct ttttgaattg   5520tataagattt atgtctactg taaacattgc ttaatttttt tgctcttgat ttaaaaaaaa   5580gttttgttga aagcgctatt gaatattgca atctatatag tgtattggat ggcttctttt   5640gtcaccctga tctcctatgt taccaatgtg tatcgtctcc ttctccctaa agtgtactta   5700atctttgctt tctttgcaca atgtctttgg ttgcaagtca taagcctgag gcaaataaaa   5760ttccagtaat ttcgaagaat gtggtgttgg tgctttccta ataaagaaat aatttagctt   5820gacaaaaaaa aaaaaaaa                                                 5838</s400><s200><s210>3</s210><s211>5664</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 3gcgtcttccg gcgcccgcgg aggaggcgag ggtgggacgc tgggcggagc ccgagtttag     60gaagaggagg ggacggctgt catcaatgaa gtcatattca taatctagtc ctctctccct    120ctgtttctgt actctgggtg actcagagag ggaagagatt cagccagcac actcctcgcg    180agcaagcatt actctactga ctggcagaga caggagaggt agatgtccac gcccacagac    240cctggtgcga tgccccaccc agggccttcg ccggggcctg ggccttcccc tgggccaatt    300cttgggccta gtccaggacc aggaccatcc ccaggttccg tccacagcat gatggggcca    360agtcctggac ctccaagtgt ctcccatcct atgccgacga tggggtccac agacttccca    420caggaaggca tgcatcaaat gcataagccc atcgatggta tacatgacaa ggggattgta    480gaagacatcc attgtggatc catgaagggc actggtatgc gaccacctca cccaggcatg    540ggccctcccc agagtccaat ggatcaacac agccaaggtt atatgtcacc acacccatct    600ccattaggag ccccagagca cgtctccagc cctatgtctg gaggaggccc aactccacct    660cagatgccac caagccagcc gggggccctc atcccaggtg atccgcaggc catgagccag    720cccaacagag gtccctcacc tttcagtcct gtccagctgc atcagcttcg agctcagatt    780ttagcttata aaatgctggc ccgaggccag cccctccccg aaacgctgca gcttgcagtc    840caggggaaaa ggacgttgcc tggcttgcag caacaacagc agcagcaaca gcagcagcag    900cagcagcagc agcagcagca gcagcagcaa cagcagccgc agcagcagcc gccgcaacca    960cagacgcagc aacaacagca gccggccctt gttaactaca acagaccatc tggcccgggg   1020ccggagctga gcggcccgag caccccgcag aagctgccgg tgcccgcgcc cggcggccgg   1080ccctcgcccg cgccccccgc agccgcgcag ccgcccgcgg ccgcagtgcc cgggccctca   1140gtgccgcagc cggccccggg gcagccctcg cccgtcctcc agctgcagca gaagcagagc   1200cgcatcagcc ccatccagaa accgcaaggc ctggaccccg tggaaattct gcaagagcgg   1260gaatacagac ttcaggcccg catagctcat aggatacaag aactggaaaa tctgcctggc   1320tctttgccac cagatttaag aaccaaagca accgtggaac taaaagcact tcggttactc   1380aatttccagc gtcagctgag acaggaggtg gtggcctgca tgcgcaggga cacgaccctg   1440gagacggctc tcaactccaa agcatacaaa cggagcaagc gccagactct gagagaagct   1500cgcatgaccg agaagctgga gaagcagcag aagattgagc aggagaggaa acgccgtcag   1560aaacaccagg aatacctgaa cagtattttg caacatgcaa aagattttaa ggaatatcat   1620cggtctgtgg ccggaaagat ccagaagctc tccaaagcag tggcaacttg gcatgccaac   1680actgaaagag agcagaagaa ggagacagag cggattgaaa aggagagaat gcggcgactg   1740atggctgaag atgaggaggg ttatagaaaa ctgattgatc aaaagaaaga caggcgttta   1800gcttaccttt tgcagcagac cgatgagtat gtagccaatc tgaccaatct ggtttgggag   1860cacaagcaag cccaggcagc caaagagaag aagaagagga ggaggaggaa gaagaaggct   1920gaggagaatg cagagggtgg ggagtctgcc ctgggaccgg atggagagcc catagatgag   1980agcagccaga tgagtgacct ccctgtcaaa gtgactcaca cagaaaccgg caaggttctg   2040ttcggaccag aagcacccaa agcaagtcag ctggacgcct ggctggaaat gaatcctggt   2100tatgaagttg cccctagatc tgacagtgaa gagagtgatt ctgattatga ggaagaggat   2160gaggaagaag agtccagtag gcaggaaacc gaagagaaaa tactcctgga tccaaatagc   2220gaagaagttt ctgagaagga tgctaagcag atcattgaga cagctaagca agacgtggat   2280gatgaataca gcatgcagta cagtgccagg ggctcccagt cctactacac cgtggctcat   2340gccatctcgg agagggtgga gaaacagtct gccctcctaa ttaatgggac cctaaagcat   2400taccagctcc agggcctgga atggatggtt tccctgtata ataacaactt gaacggaatc   2460ttagccgatg aaatggggct tggaaagacc atacagacca ttgcactcat cacttatctg   2520atggagcaca aaagactcaa tggcccctat ctcatcattg ttcccctttc gactctatct   2580aactggacat atgaatttga caaatgggct ccttctgtgg tgaagatttc ttacaagggt   2640actcctgcca tgcgtcgctc ccttgtcccc cagctacgga gtggcaaatt caatgtcctc   2700ttgactactt atgagtatat tataaaagac aagcacattc ttgcaaagat tcggtggaaa   2760tacatgatag tggacgaagg ccaccgaatg aagaatcacc actgcaagct gactcaggtg   2820gacttaaatg aagaagaaac tatattgatc atcaggcgtc tacataaggt gttaagacca   2880tttttactaa ggagactgaa gaaagaagtt gaatcccagc ttcccgaaaa agtggaatat   2940gtgatcaagt gtgacatgtc agctctgcag aagattctgt atcgccatat gcaagccaag   3000gggatccttc tcacagatgg ttctgagaaa gataagaagg ggaaaggagg tgctaagaca   3060cttatgaaca ctattatgca gttgagaaaa atctgcaacc acccatatat gtttcagcac   3120attgaggaat cctttgctga acacctaggc tattcaaatg gggtcatcaa tggggctgaa   3180ctgtatcggg cctcagggaa gtttgagctg cttgatcgta ttctgccaaa attgagagcg   3240actaatcacc gagtgctgct tttctgccag atgacatctc tcatgaccat catggaggat   3300tattttgctt ttcggaactt cctttaccta cgccttgatg gcaccaccaa gtctgaagat   3360cgtgctgctt tgctgaagaa attcaatgaa cctggatccc agtatttcat tttcttgctg   3420agcacaagag ctggtggcct gggcttaaat cttcaggcag ctgatacagt ggtcatcttt   3480gacagcgact ggaatcctca tcaggatctg caggcccaag accgagctca ccgcatcggg   3540cagcagaacg aggtccgggt actgaggctc tgtaccgtga acagcgtgga ggaaaagatc   3600ctcgcggccg caaaatacaa gctgaacgtg gatcagaaag tgatccaggc gggcatgttt   3660gaccaaaagt cttcaagcca cgagcggagg gcattcctgc aggccatctt ggagcatgag   3720gaggaaaatg aggaagaaga tgaagtaccg gacgatgaga ctctgaacca aatgattgct   3780cgacgagaag aagaatttga cctttttatg cggatggaca tggaccggcg gagggaagat   3840gcccggaacc cgaaacggaa gccccgttta atggaggagg atgagctgcc ctcctggatc   3900attaaggatg acgctgaagt agaaaggctc acctgtgaag aagaggagga gaaaatattt   3960gggagggggt cccgccagcg ccgtgacgtg gactacagtg acgccctcac ggagaagcag   4020tggctaaggg ccatcgaaga cggcaatttg gaggaaatgg aagaggaagt acggcttaag   4080aagcgaaaaa gacgaagaaa tgtggataaa gatcctgcaa aagaagatgt ggaaaaagct   4140aagaagagaa gaggccgccc tcccgctgag aaactgtcac caaatccccc caaactgaca   4200aagcagatga acgctatcat cgatactgtg ataaactaca aagatagttc agggcgacag   4260ctcagtgaag tcttcattca gttaccttca aggaaagaat taccagaata ctatgaatta   4320attaggaagc cagtggattt caaaaaaata aaggaaagga ttcgtaatca taagtaccgg   4380agcctaggcg acctggagaa ggatgtcatg cttctctgtc acaacgctca gacgttcaac   4440ctggagggat cccagatcta tgaagactcc atcgtcttac agtcagtgtt taagagtgcc   4500cggcagaaaa ttgccaaaga ggaagagagt gaggatgaaa gcaatgaaga ggaggaagag   4560gaagatgaag aagagtcaga gtccgaggca aaatcagtca aggtgaaaat taagctcaat   4620aaaaaagatg acaaaggccg ggacaaaggg aaaggcaaga aaaggccaaa tcgaggaaaa   4680gccaaacctg tagtgagcga ttttgacagc gatgaggagc aggatgaacg tgaacagtca   4740gaaggaagtg ggacggatga tgagtgatca gtatggacct ttttccttgg tagaactgaa   4800ttccttcctc ccctgtctca tttctaccca gtgagttcat ttgtcatata ggcactgggt   4860tgtttctata tcatcatcgt ctataaacta gctttaggat agtgccagac aaacatatga   4920tatcatggtg taaaaaacac acacatacac aaatatttgt aacatattgt gaccaaatgg   4980gcctcaaaga ttcagattga aacaaacaaa aagcttttga tggaaaatat gtgggtggat   5040agtatatttc tatgggtggg tctaatttgg taacggtttg attgtgcctg gttttatcac   5100ctgttcagat gagaagattt ttgtcttttg tagcactgat aaccaggaga agccattaaa   5160agccactggt tattttattt ttcatcaggc aattttcgag gtttttattt gttcggtatt   5220gtttttttac actgtggtac atataagcaa ctttaatagg tgataaatgt acagtagtta   5280gatttcacct gcatatacat ttttccattt tatgctctat gatctgaaca aaagcttttt   5340gaattgtata agatttatgt ctactgtaaa cattgcttaa tttttttgct cttgatttaa   5400aaaaaagttt tgttgaaagc gctattgaat attgcaatct atatagtgta ttggatggct   5460tcttttgtca ccctgatctc ctatgttacc aatgtgtatc gtctccttct ccctaaagtg   5520tacttaatct ttgctttctt tgcacaatgt ctttggttgc aagtcataag cctgaggcaa   5580ataaaattcc agtaatttcg aagaatgtgg tgttggtgct ttcctaataa agaaataatt   5640tagcttgaca aaaaaaaaaa aaaa                                          5664</s400><s200><s210>4</s210><s211>1846</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 4cttggagagg cggaggtgga aacgatgcgc aggagttggc ttggggcttt ttgtttgcgt     60gtccctgttt acctattcat aatcatggat cccctctgct ttgtgatact gtgaaccacg    120cataacagca attctttaca ccaccgggtt gagaagaagg cgcctgaggc tgactttctg    180gacctgccgt cacgcagtaa agatgtggtt ggccatcgaa gacggcaatt tggaggaaat    240ggaagaggaa gtacggctta agaagcgaaa aagacgaaga aatgtggata aagatcctgc    300aaaagaagat gtggaaaaag ctaagaagag aagaggccgc cctcccgctg agaaactgtc    360accaaatccc cccaaactga caaagcagat gaacgctatc atcgatactg tgataaacta    420caaagatagt tcagggcgac agctcagtga agtcttcatt cagttacctt caaggaaaga    480attaccagaa tactatgaat taattaggaa gccagtggat ttcaaaaaaa taaaggaaag    540gattcgtaat cataagtacc ggagcctagg cgacctggag aaggatgtca tgcttctctg    600tcacaacgct cagacgttca acctggaggg atcccagatc tatgaagact ccatcgtctt    660acagtcagtg tttaagagtg cccggcagaa aattgccaaa gaggaagaga gtgaggatga    720aagcaatgaa gaggaggaag aggaagatga agaagagtca gagtccgagg caaaatcagt    780caaggtgaaa attaagctca ataaaaaaga tgacaaaggc cgggacaaag ggaaaggcaa    840gaaaaggcca aatcgaggaa aagccaaacc tgtagtgagc gattttgaca gcgatgagga    900gcaggatgaa cgtgaacagt cagaaggaag tgggacggat gatgagtgat cagtatggac    960ctttttcctt ggtagaactg aattccttcc tcccctgtct catttctacc cagtgagttc   1020atttgtcata taggcactgg gttgtttcta tatcatcatc gtctataaac tagctttagg   1080atagtgccag acaaacatat gatatcatgg tgtaaaaaac acacacatac acaaatattt   1140gtaacatatt gtgaccaaat gggcctcaaa gattcagatt gaaacaaaca aaaagctttt   1200gatggaaaat atgtgggtgg atagtatatt tctatgggtg ggtctaattt ggtaacggtt   1260tgattgtgcc tggttttatc acctgttcag atgagaagat ttttgtcttt tgtagcactg   1320ataaccagga gaagccatta aaagccactg gttattttat ttttcatcag gcaattttcg   1380aggtttttat ttgttcggta ttgttttttt acactgtggt acatataagc aactttaata   1440ggtgataaat gtacagtagt tagatttcac ctgcatatac atttttccat tttatgctct   1500atgatctgaa caaaagcttt ttgaattgta taagatttat gtctactgta aacattgctt   1560aatttttttg ctcttgattt aaaaaaaagt tttgttgaaa gcgctattga atattgcaat   1620ctatatagtg tattggatgg cttcttttgt caccctgatc tcctatgtta ccaatgtgta   1680tcgtctcctt ctccctaaag tgtacttaat ctttgctttc tttgcacaat gtctttggtt   1740gcaagtcata agcctgaggc aaataaaatt ccagtaattt cgaagaatgt ggtgttggtg   1800ctttcctaat aaagaaataa tttagcttga caaaaaaaaa aaaaaa                  1846</s400><s200><s210>5</s210><s211>1590</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 5Met Ser Thr Pro Thr Asp Pro Gly Ala Met Pro His Pro Gly Pro Ser1               5                   10                  15Pro Gly Pro Gly Pro Ser Pro Gly Pro Ile Leu Gly Pro Ser Pro Gly            20                  25                  30Pro Gly Pro Ser Pro Gly Ser Val His Ser Met Met Gly Pro Ser Pro        35                  40                  45Gly Pro Pro Ser Val Ser His Pro Met Pro Thr Met Gly Ser Thr Asp    50                  55                  60Phe Pro Gln Glu Gly Met His Gln Met His Lys Pro Ile Asp Gly Ile65                  70                  75                  80His Asp Lys Gly Ile Val Glu Asp Ile His Cys Gly Ser Met Lys Gly                85                  90                  95Thr Gly Met Arg Pro Pro His Pro Gly Met Gly Pro Pro Gln Ser Pro            100                 105                 110Met Asp Gln His Ser Gln Gly Tyr Met Ser Pro His Pro Ser Pro Leu        115                 120                 125Gly Ala Pro Glu His Val Ser Ser Pro Met Ser Gly Gly Gly Pro Thr    130                 135                 140Pro Pro Gln Met Pro Pro Ser Gln Pro Gly Ala Leu Ile Pro Gly Asp145                 150                 155                 160Pro Gln Ala Met Ser Gln Pro Asn Arg Gly Pro Ser Pro Phe Ser Pro                165                 170                 175Val Gln Leu His Gln Leu Arg Ala Gln Ile Leu Ala Tyr Lys Met Leu            180                 185                 190Ala Arg Gly Gln Pro Leu Pro Glu Thr Leu Gln Leu Ala Val Gln Gly        195                 200                 205Lys Arg Thr Leu Pro Gly Leu Gln Gln Gln Gln Gln Gln Gln Gln Gln    210                 215                 220Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Pro Gln225                 230                 235                 240Gln Gln Pro Pro Gln Pro Gln Thr Gln Gln Gln Gln Gln Pro Ala Leu                245                 250                 255Val Asn Tyr Asn Arg Pro Ser Gly Pro Gly Pro Glu Leu Ser Gly Pro            260                 265                 270Ser Thr Pro Gln Lys Leu Pro Val Pro Ala Pro Gly Gly Arg Pro Ser        275                 280                 285Pro Ala Pro Pro Ala Ala Ala Gln Pro Pro Ala Ala Ala Val Pro Gly    290                 295                 300Pro Ser Val Pro Gln Pro Ala Pro Gly Gln Pro Ser Pro Val Leu Gln305                 310                 315                 320Leu Gln Gln Lys Gln Ser Arg Ile Ser Pro Ile Gln Lys Pro Gln Gly                325                 330                 335Leu Asp Pro Val Glu Ile Leu Gln Glu Arg Glu Tyr Arg Leu Gln Ala            340                 345                 350Arg Ile Ala His Arg Ile Gln Glu Leu Glu Asn Leu Pro Gly Ser Leu        355                 360                 365Pro Pro Asp Leu Arg Thr Lys Ala Thr Val Glu Leu Lys Ala Leu Arg    370                 375                 380Leu Leu Asn Phe Gln Arg Gln Leu Arg Gln Glu Val Val Ala Cys Met385                 390                 395                 400Arg Arg Asp Thr Thr Leu Glu Thr Ala Leu Asn Ser Lys Ala Tyr Lys                405                 410                 415Arg Ser Lys Arg Gln Thr Leu Arg Glu Ala Arg Met Thr Glu Lys Leu            420                 425                 430Glu Lys Gln Gln Lys Ile Glu Gln Glu Arg Lys Arg Arg Gln Lys His        435                 440                 445Gln Glu Tyr Leu Asn Ser Ile Leu Gln His Ala Lys Asp Phe Lys Glu    450                 455                 460Tyr His Arg Ser Val Ala Gly Lys Ile Gln Lys Leu Ser Lys Ala Val465                 470                 475                 480Ala Thr Trp His Ala Asn Thr Glu Arg Glu Gln Lys Lys Glu Thr Glu                485                 490                 495Arg Ile Glu Lys Glu Arg Met Arg Arg Leu Met Ala Glu Asp Glu Glu            500                 505                 510Gly Tyr Arg Lys Leu Ile Asp Gln Lys Lys Asp Arg Arg Leu Ala Tyr        515                 520                 525Leu Leu Gln Gln Thr Asp Glu Tyr Val Ala Asn Leu Thr Asn Leu Val    530                 535                 540Trp Glu His Lys Gln Ala Gln Ala Ala Lys Glu Lys Lys Lys Arg Arg545                 550                 555                 560Arg Arg Lys Lys Lys Ala Glu Glu Asn Ala Glu Gly Gly Glu Ser Ala                565                 570                 575Leu Gly Pro Asp Gly Glu Pro Ile Asp Glu Ser Ser Gln Met Ser Asp            580                 585                 590Leu Pro Val Lys Val Thr His Thr Glu Thr Gly Lys Val Leu Phe Gly        595                 600                 605Pro Glu Ala Pro Lys Ala Ser Gln Leu Asp Ala Trp Leu Glu Met Asn    610                 615                 620Pro Gly Tyr Glu Val Ala Pro Arg Ser Asp Ser Glu Glu Ser Asp Ser625                 630                 635                 640Asp Tyr Glu Glu Glu Asp Glu Glu Glu Glu Ser Ser Arg Gln Glu Thr                645                 650                 655Glu Glu Lys Ile Leu Leu Asp Pro Asn Ser Glu Glu Val Ser Glu Lys            660                 665                 670Asp Ala Lys Gln Ile Ile Glu Thr Ala Lys Gln Asp Val Asp Asp Glu        675                 680                 685Tyr Ser Met Gln Tyr Ser Ala Arg Gly Ser Gln Ser Tyr Tyr Thr Val    690                 695                 700Ala His Ala Ile Ser Glu Arg Val Glu Lys Gln Ser Ala Leu Leu Ile705                 710                 715                 720Asn Gly Thr Leu Lys His Tyr Gln Leu Gln Gly Leu Glu Trp Met Val                725                 730                 735Ser Leu Tyr Asn Asn Asn Leu Asn Gly Ile Leu Ala Asp Glu Met Gly            740                 745                 750Leu Gly Lys Thr Ile Gln Thr Ile Ala Leu Ile Thr Tyr Leu Met Glu        755                 760                 765His Lys Arg Leu Asn Gly Pro Tyr Leu Ile Ile Val Pro Leu Ser Thr    770                 775                 780Leu Ser Asn Trp Thr Tyr Glu Phe Asp Lys Trp Ala Pro Ser Val Val785                 790                 795                 800Lys Ile Ser Tyr Lys Gly Thr Pro Ala Met Arg Arg Ser Leu Val Pro                805                 810                 815Gln Leu Arg Ser Gly Lys Phe Asn Val Leu Leu Thr Thr Tyr Glu Tyr            820                 825                 830Ile Ile Lys Asp Lys His Ile Leu Ala Lys Ile Arg Trp Lys Tyr Met        835                 840                 845Ile Val Asp Glu Gly His Arg Met Lys Asn His His Cys Lys Leu Thr    850                 855                 860Gln Val Leu Asn Thr His Tyr Val Ala Pro Arg Arg Ile Leu Leu Thr865                 870                 875                 880Gly Thr Pro Leu Gln Asn Lys Leu Pro Glu Leu Trp Ala Leu Leu Asn                885                 890                 895Phe Leu Leu Pro Thr Ile Phe Lys Ser Cys Ser Thr Phe Glu Gln Trp            900                 905                 910Phe Asn Ala Pro Phe Ala Met Thr Gly Glu Arg Val Asp Leu Asn Glu        915                 920                 925Glu Glu Thr Ile Leu Ile Ile Arg Arg Leu His Lys Val Leu Arg Pro    930                 935                 940Phe Leu Leu Arg Arg Leu Lys Lys Glu Val Glu Ser Gln Leu Pro Glu945                 950                 955                 960Lys Val Glu Tyr Val Ile Lys Cys Asp Met Ser Ala Leu Gln Lys Ile                965                 970                 975Leu Tyr Arg His Met Gln Ala Lys Gly Ile Leu Leu Thr Asp Gly Ser            980                 985                 990Glu Lys Asp Lys Lys Gly Lys Gly  Gly Ala Lys Thr Leu  Met Asn Thr        995                 1000                 1005Ile Met  Gln Leu Arg Lys Ile  Cys Asn His Pro Tyr  Met Phe Gln    1010                 1015                 1020His Ile  Glu Glu Ser Phe Ala  Glu His Leu Gly Tyr  Ser Asn Gly    1025                 1030                 1035Val Ile  Asn Gly Ala Glu Leu  Tyr Arg Ala Ser Gly  Lys Phe Glu    1040                 1045                 1050Leu Leu  Asp Arg Ile Leu Pro  Lys Leu Arg Ala Thr  Asn His Arg    1055                 1060                 1065Val Leu  Leu Phe Cys Gln Met  Thr Ser Leu Met Thr  Ile Met Glu    1070                 1075                 1080Asp Tyr  Phe Ala Phe Arg Asn  Phe Leu Tyr Leu Arg  Leu Asp Gly    1085                 1090                 1095Thr Thr  Lys Ser Glu Asp Arg  Ala Ala Leu Leu Lys  Lys Phe Asn    1100                 1105                 1110Glu Pro  Gly Ser Gln Tyr Phe  Ile Phe Leu Leu Ser  Thr Arg Ala    1115                 1120                 1125Gly Gly  Leu Gly Leu Asn Leu  Gln Ala Ala Asp Thr  Val Val Ile    1130                 1135                 1140Phe Asp  Ser Asp Trp Asn Pro  His Gln Asp Leu Gln  Ala Gln Asp    1145                 1150                 1155Arg Ala  His Arg Ile Gly Gln  Gln Asn Glu Val Arg  Val Leu Arg    1160                 1165                 1170Leu Cys  Thr Val Asn Ser Val  Glu Glu Lys Ile Leu  Ala Ala Ala    1175                 1180                 1185Lys Tyr  Lys Leu Asn Val Asp  Gln Lys Val Ile Gln  Ala Gly Met    1190                 1195                 1200Phe Asp  Gln Lys Ser Ser Ser  His Glu Arg Arg Ala  Phe Leu Gln    1205                 1210                 1215Ala Ile  Leu Glu His Glu Glu  Glu Asn Glu Glu Glu  Asp Glu Val    1220                 1225                 1230Pro Asp  Asp Glu Thr Leu Asn  Gln Met Ile Ala Arg  Arg Glu Glu    1235                 1240                 1245Glu Phe  Asp Leu Phe Met Arg  Met Asp Met Asp Arg  Arg Arg Glu    1250                 1255                 1260Asp Ala  Arg Asn Pro Lys Arg  Lys Pro Arg Leu Met  Glu Glu Asp    1265                 1270                 1275Glu Leu  Pro Ser Trp Ile Ile  Lys Asp Asp Ala Glu  Val Glu Arg    1280                 1285                 1290Leu Thr  Cys Glu Glu Glu Glu  Glu Lys Ile Phe Gly  Arg Gly Ser    1295                 1300                 1305Arg Gln  Arg Arg Asp Val Asp  Tyr Ser Asp Ala Leu  Thr Glu Lys    1310                 1315                 1320Gln Trp  Leu Arg Ala Ile Glu  Asp Gly Asn Leu Glu  Glu Met Glu    1325                 1330                 1335Glu Glu  Val Arg Leu Lys Lys  Arg Lys Arg Arg Arg  Asn Val Asp    1340                 1345                 1350Lys Asp  Pro Ala Lys Glu Asp  Val Glu Lys Ala Lys  Lys Arg Arg    1355                 1360                 1365Gly Arg  Pro Pro Ala Glu Lys  Leu Ser Pro Asn Pro  Pro Lys Leu    1370                 1375                 1380Thr Lys  Gln Met Asn Ala Ile  Ile Asp Thr Val Ile  Asn Tyr Lys    1385                 1390                 1395Asp Arg  Cys Asn Val Glu Lys  Val Pro Ser Asn Ser  Gln Leu Glu    1400                 1405                 1410Ile Glu  Gly Asn Ser Ser Gly  Arg Gln Leu Ser Glu  Val Phe Ile    1415                 1420                 1425Gln Leu  Pro Ser Arg Lys Glu  Leu Pro Glu Tyr Tyr  Glu Leu Ile    1430                 1435                 1440Arg Lys  Pro Val Asp Phe Lys  Lys Ile Lys Glu Arg  Ile Arg Asn    1445                 1450                 1455His Lys  Tyr Arg Ser Leu Gly  Asp Leu Glu Lys Asp  Val Met Leu    1460                 1465                 1470Leu Cys  His Asn Ala Gln Thr  Phe Asn Leu Glu Gly  Ser Gln Ile    1475                 1480                 1485Tyr Glu  Asp Ser Ile Val Leu  Gln Ser Val Phe Lys  Ser Ala Arg    1490                 1495                 1500Gln Lys  Ile Ala Lys Glu Glu  Glu Ser Glu Asp Glu  Ser Asn Glu    1505                 1510                 1515Glu Glu  Glu Glu Glu Asp Glu  Glu Glu Ser Glu Ser  Glu Ala Lys    1520                 1525                 1530Ser Val  Lys Val Lys Ile Lys  Leu Asn Lys Lys Asp  Asp Lys Gly    1535                 1540                 1545Arg Asp  Lys Gly Lys Gly Lys  Lys Arg Pro Asn Arg  Gly Lys Ala    1550                 1555                 1560Lys Pro  Val Val Ser Asp Phe  Asp Ser Asp Glu Glu  Gln Asp Glu    1565                 1570                 1575Arg Glu  Gln Ser Glu Gly Ser  Gly Thr Asp Asp Glu    1580                 1585                 1590</s400><s200><s210>6</s210><s211>1572</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 6Met Ser Thr Pro Thr Asp Pro Gly Ala Met Pro His Pro Gly Pro Ser1               5                   10                  15Pro Gly Pro Gly Pro Ser Pro Gly Pro Ile Leu Gly Pro Ser Pro Gly            20                  25                  30Pro Gly Pro Ser Pro Gly Ser Val His Ser Met Met Gly Pro Ser Pro        35                  40                  45Gly Pro Pro Ser Val Ser His Pro Met Pro Thr Met Gly Ser Thr Asp    50                  55                  60Phe Pro Gln Glu Gly Met His Gln Met His Lys Pro Ile Asp Gly Ile65                  70                  75                  80His Asp Lys Gly Ile Val Glu Asp Ile His Cys Gly Ser Met Lys Gly                85                  90                  95Thr Gly Met Arg Pro Pro His Pro Gly Met Gly Pro Pro Gln Ser Pro            100                 105                 110Met Asp Gln His Ser Gln Gly Tyr Met Ser Pro His Pro Ser Pro Leu        115                 120                 125Gly Ala Pro Glu His Val Ser Ser Pro Met Ser Gly Gly Gly Pro Thr    130                 135                 140Pro Pro Gln Met Pro Pro Ser Gln Pro Gly Ala Leu Ile Pro Gly Asp145                 150                 155                 160Pro Gln Ala Met Ser Gln Pro Asn Arg Gly Pro Ser Pro Phe Ser Pro                165                 170                 175Val Gln Leu His Gln Leu Arg Ala Gln Ile Leu Ala Tyr Lys Met Leu            180                 185                 190Ala Arg Gly Gln Pro Leu Pro Glu Thr Leu Gln Leu Ala Val Gln Gly        195                 200                 205Lys Arg Thr Leu Pro Gly Leu Gln Gln Gln Gln Gln Gln Gln Gln Gln    210                 215                 220Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Pro Gln225                 230                 235                 240Gln Gln Pro Pro Gln Pro Gln Thr Gln Gln Gln Gln Gln Pro Ala Leu                245                 250                 255Val Asn Tyr Asn Arg Pro Ser Gly Pro Gly Pro Glu Leu Ser Gly Pro            260                 265                 270Ser Thr Pro Gln Lys Leu Pro Val Pro Ala Pro Gly Gly Arg Pro Ser        275                 280                 285Pro Ala Pro Pro Ala Ala Ala Gln Pro Pro Ala Ala Ala Val Pro Gly    290                 295                 300Pro Ser Val Pro Gln Pro Ala Pro Gly Gln Pro Ser Pro Val Leu Gln305                 310                 315                 320Leu Gln Gln Lys Gln Ser Arg Ile Ser Pro Ile Gln Lys Pro Gln Gly                325                 330                 335Leu Asp Pro Val Glu Ile Leu Gln Glu Arg Glu Tyr Arg Leu Gln Ala            340                 345                 350Arg Ile Ala His Arg Ile Gln Glu Leu Glu Asn Leu Pro Gly Ser Leu        355                 360                 365Pro Pro Asp Leu Arg Thr Lys Ala Thr Val Glu Leu Lys Ala Leu Arg    370                 375                 380Leu Leu Asn Phe Gln Arg Gln Leu Arg Gln Glu Val Val Ala Cys Met385                 390                 395                 400Arg Arg Asp Thr Thr Leu Glu Thr Ala Leu Asn Ser Lys Ala Tyr Lys                405                 410                 415Arg Ser Lys Arg Gln Thr Leu Arg Glu Ala Arg Met Thr Glu Lys Leu            420                 425                 430Glu Lys Gln Gln Lys Ile Glu Gln Glu Arg Lys Arg Arg Gln Lys His        435                 440                 445Gln Glu Tyr Leu Asn Ser Ile Leu Gln His Ala Lys Asp Phe Lys Glu    450                 455                 460Tyr His Arg Ser Val Ala Gly Lys Ile Gln Lys Leu Ser Lys Ala Val465                 470                 475                 480Ala Thr Trp His Ala Asn Thr Glu Arg Glu Gln Lys Lys Glu Thr Glu                485                 490                 495Arg Ile Glu Lys Glu Arg Met Arg Arg Leu Met Ala Glu Asp Glu Glu            500                 505                 510Gly Tyr Arg Lys Leu Ile Asp Gln Lys Lys Asp Arg Arg Leu Ala Tyr        515                 520                 525Leu Leu Gln Gln Thr Asp Glu Tyr Val Ala Asn Leu Thr Asn Leu Val    530                 535                 540Trp Glu His Lys Gln Ala Gln Ala Ala Lys Glu Lys Lys Lys Arg Arg545                 550                 555                 560Arg Arg Lys Lys Lys Ala Glu Glu Asn Ala Glu Gly Gly Glu Ser Ala                565                 570                 575Leu Gly Pro Asp Gly Glu Pro Ile Asp Glu Ser Ser Gln Met Ser Asp            580                 585                 590Leu Pro Val Lys Val Thr His Thr Glu Thr Gly Lys Val Leu Phe Gly        595                 600                 605Pro Glu Ala Pro Lys Ala Ser Gln Leu Asp Ala Trp Leu Glu Met Asn    610                 615                 620Pro Gly Tyr Glu Val Ala Pro Arg Ser Asp Ser Glu Glu Ser Asp Ser625                 630                 635                 640Asp Tyr Glu Glu Glu Asp Glu Glu Glu Glu Ser Ser Arg Gln Glu Thr                645                 650                 655Glu Glu Lys Ile Leu Leu Asp Pro Asn Ser Glu Glu Val Ser Glu Lys            660                 665                 670Asp Ala Lys Gln Ile Ile Glu Thr Ala Lys Gln Asp Val Asp Asp Glu        675                 680                 685Tyr Ser Met Gln Tyr Ser Ala Arg Gly Ser Gln Ser Tyr Tyr Thr Val    690                 695                 700Ala His Ala Ile Ser Glu Arg Val Glu Lys Gln Ser Ala Leu Leu Ile705                 710                 715                 720Asn Gly Thr Leu Lys His Tyr Gln Leu Gln Gly Leu Glu Trp Met Val                725                 730                 735Ser Leu Tyr Asn Asn Asn Leu Asn Gly Ile Leu Ala Asp Glu Met Gly            740                 745                 750Leu Gly Lys Thr Ile Gln Thr Ile Ala Leu Ile Thr Tyr Leu Met Glu        755                 760                 765His Lys Arg Leu Asn Gly Pro Tyr Leu Ile Ile Val Pro Leu Ser Thr    770                 775                 780Leu Ser Asn Trp Thr Tyr Glu Phe Asp Lys Trp Ala Pro Ser Val Val785                 790                 795                 800Lys Ile Ser Tyr Lys Gly Thr Pro Ala Met Arg Arg Ser Leu Val Pro                805                 810                 815Gln Leu Arg Ser Gly Lys Phe Asn Val Leu Leu Thr Thr Tyr Glu Tyr            820                 825                 830Ile Ile Lys Asp Lys His Ile Leu Ala Lys Ile Arg Trp Lys Tyr Met        835                 840                 845Ile Val Asp Glu Gly His Arg Met Lys Asn His His Cys Lys Leu Thr    850                 855                 860Gln Val Leu Asn Thr His Tyr Val Ala Pro Arg Arg Ile Leu Leu Thr865                 870                 875                 880Gly Thr Pro Leu Gln Asn Lys Leu Pro Glu Leu Trp Ala Leu Leu Asn                885                 890                 895Phe Leu Leu Pro Thr Ile Phe Lys Ser Cys Ser Thr Phe Glu Gln Trp            900                 905                 910Phe Asn Ala Pro Phe Ala Met Thr Gly Glu Arg Val Asp Leu Asn Glu        915                 920                 925Glu Glu Thr Ile Leu Ile Ile Arg Arg Leu His Lys Val Leu Arg Pro    930                 935                 940Phe Leu Leu Arg Arg Leu Lys Lys Glu Val Glu Ser Gln Leu Pro Glu945                 950                 955                 960Lys Val Glu Tyr Val Ile Lys Cys Asp Met Ser Ala Leu Gln Lys Ile                965                 970                 975Leu Tyr Arg His Met Gln Ala Lys Gly Ile Leu Leu Thr Asp Gly Ser            980                 985                 990Glu Lys Asp Lys Lys Gly Lys Gly  Gly Ala Lys Thr Leu  Met Asn Thr        995                 1000                 1005Ile Met  Gln Leu Arg Lys Ile  Cys Asn His Pro Tyr  Met Phe Gln    1010                 1015                 1020His Ile  Glu Glu Ser Phe Ala  Glu His Leu Gly Tyr  Ser Asn Gly    1025                 1030                 1035Val Ile  Asn Gly Ala Glu Leu  Tyr Arg Ala Ser Gly  Lys Phe Glu    1040                 1045                 1050Leu Leu  Asp Arg Ile Leu Pro  Lys Leu Arg Ala Thr  Asn His Arg    1055                 1060                 1065Val Leu  Leu Phe Cys Gln Met  Thr Ser Leu Met Thr  Ile Met Glu    1070                 1075                 1080Asp Tyr  Phe Ala Phe Arg Asn  Phe Leu Tyr Leu Arg  Leu Asp Gly    1085                 1090                 1095Thr Thr  Lys Ser Glu Asp Arg  Ala Ala Leu Leu Lys  Lys Phe Asn    1100                 1105                 1110Glu Pro  Gly Ser Gln Tyr Phe  Ile Phe Leu Leu Ser  Thr Arg Ala    1115                 1120                 1125Gly Gly  Leu Gly Leu Asn Leu  Gln Ala Ala Asp Thr  Val Val Ile    1130                 1135                 1140Phe Asp  Ser Asp Trp Asn Pro  His Gln Asp Leu Gln  Ala Gln Asp    1145                 1150                 1155Arg Ala  His Arg Ile Gly Gln  Gln Asn Glu Val Arg  Val Leu Arg    1160                 1165                 1170Leu Cys  Thr Val Asn Ser Val  Glu Glu Lys Ile Leu  Ala Ala Ala    1175                 1180                 1185Lys Tyr  Lys Leu Asn Val Asp  Gln Lys Val Ile Gln  Ala Gly Met    1190                 1195                 1200Phe Asp  Gln Lys Ser Ser Ser  His Glu Arg Arg Ala  Phe Leu Gln    1205                 1210                 1215Ala Ile  Leu Glu His Glu Glu  Glu Asn Glu Glu Glu  Asp Glu Val    1220                 1225                 1230Pro Asp  Asp Glu Thr Leu Asn  Gln Met Ile Ala Arg  Arg Glu Glu    1235                 1240                 1245Glu Phe  Asp Leu Phe Met Arg  Met Asp Met Asp Arg  Arg Arg Glu    1250                 1255                 1260Asp Ala  Arg Asn Pro Lys Arg  Lys Pro Arg Leu Met  Glu Glu Asp    1265                 1270                 1275Glu Leu  Pro Ser Trp Ile Ile  Lys Asp Asp Ala Glu  Val Glu Arg    1280                 1285                 1290Leu Thr  Cys Glu Glu Glu Glu  Glu Lys Ile Phe Gly  Arg Gly Ser    1295                 1300                 1305Arg Gln  Arg Arg Asp Val Asp  Tyr Ser Asp Ala Leu  Thr Glu Lys    1310                 1315                 1320Gln Trp  Leu Arg Ala Ile Glu  Asp Gly Asn Leu Glu  Glu Met Glu    1325                 1330                 1335Glu Glu  Val Arg Leu Lys Lys  Arg Lys Arg Arg Arg  Asn Val Asp    1340                 1345                 1350Lys Asp  Pro Ala Lys Glu Asp  Val Glu Lys Ala Lys  Lys Arg Arg    1355                 1360                 1365Gly Arg  Pro Pro Ala Glu Lys  Leu Ser Pro Asn Pro  Pro Lys Leu    1370                 1375                 1380Thr Lys  Gln Met Asn Ala Ile  Ile Asp Thr Val Ile  Asn Tyr Lys    1385                 1390                 1395Asp Ser  Ser Gly Arg Gln Leu  Ser Glu Val Phe Ile  Gln Leu Pro    1400                 1405                 1410Ser Arg  Lys Glu Leu Pro Glu  Tyr Tyr Glu Leu Ile  Arg Lys Pro    1415                 1420                 1425Val Asp  Phe Lys Lys Ile Lys  Glu Arg Ile Arg Asn  His Lys Tyr    1430                 1435                 1440Arg Ser  Leu Gly Asp Leu Glu  Lys Asp Val Met Leu  Leu Cys His    1445                 1450                 1455Asn Ala  Gln Thr Phe Asn Leu  Glu Gly Ser Gln Ile  Tyr Glu Asp    1460                 1465                 1470Ser Ile  Val Leu Gln Ser Val  Phe Lys Ser Ala Arg  Gln Lys Ile    1475                 1480                 1485Ala Lys  Glu Glu Glu Ser Glu  Asp Glu Ser Asn Glu  Glu Glu Glu    1490                 1495                 1500Glu Glu  Asp Glu Glu Glu Ser  Glu Ser Glu Ala Lys  Ser Val Lys    1505                 1510                 1515Val Lys  Ile Lys Leu Asn Lys  Lys Asp Asp Lys Gly  Arg Asp Lys    1520                 1525                 1530Gly Lys  Gly Lys Lys Arg Pro  Asn Arg Gly Lys Ala  Lys Pro Val    1535                 1540                 1545Val Ser  Asp Phe Asp Ser Asp  Glu Glu Gln Asp Glu  Arg Glu Gln    1550                 1555                 1560Ser Glu  Gly Ser Gly Thr Asp  Asp Glu    1565                 1570</s400><s200><s210>7</s210><s211>1514</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 7Met Ser Thr Pro Thr Asp Pro Gly Ala Met Pro His Pro Gly Pro Ser1               5                   10                  15Pro Gly Pro Gly Pro Ser Pro Gly Pro Ile Leu Gly Pro Ser Pro Gly            20                  25                  30Pro Gly Pro Ser Pro Gly Ser Val His Ser Met Met Gly Pro Ser Pro        35                  40                  45Gly Pro Pro Ser Val Ser His Pro Met Pro Thr Met Gly Ser Thr Asp    50                  55                  60Phe Pro Gln Glu Gly Met His Gln Met His Lys Pro Ile Asp Gly Ile65                  70                  75                  80His Asp Lys Gly Ile Val Glu Asp Ile His Cys Gly Ser Met Lys Gly                85                  90                  95Thr Gly Met Arg Pro Pro His Pro Gly Met Gly Pro Pro Gln Ser Pro            100                 105                 110Met Asp Gln His Ser Gln Gly Tyr Met Ser Pro His Pro Ser Pro Leu        115                 120                 125Gly Ala Pro Glu His Val Ser Ser Pro Met Ser Gly Gly Gly Pro Thr    130                 135                 140Pro Pro Gln Met Pro Pro Ser Gln Pro Gly Ala Leu Ile Pro Gly Asp145                 150                 155                 160Pro Gln Ala Met Ser Gln Pro Asn Arg Gly Pro Ser Pro Phe Ser Pro                165                 170                 175Val Gln Leu His Gln Leu Arg Ala Gln Ile Leu Ala Tyr Lys Met Leu            180                 185                 190Ala Arg Gly Gln Pro Leu Pro Glu Thr Leu Gln Leu Ala Val Gln Gly        195                 200                 205Lys Arg Thr Leu Pro Gly Leu Gln Gln Gln Gln Gln Gln Gln Gln Gln    210                 215                 220Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Pro Gln225                 230                 235                 240Gln Gln Pro Pro Gln Pro Gln Thr Gln Gln Gln Gln Gln Pro Ala Leu                245                 250                 255Val Asn Tyr Asn Arg Pro Ser Gly Pro Gly Pro Glu Leu Ser Gly Pro            260                 265                 270Ser Thr Pro Gln Lys Leu Pro Val Pro Ala Pro Gly Gly Arg Pro Ser        275                 280                 285Pro Ala Pro Pro Ala Ala Ala Gln Pro Pro Ala Ala Ala Val Pro Gly    290                 295                 300Pro Ser Val Pro Gln Pro Ala Pro Gly Gln Pro Ser Pro Val Leu Gln305                 310                 315                 320Leu Gln Gln Lys Gln Ser Arg Ile Ser Pro Ile Gln Lys Pro Gln Gly                325                 330                 335Leu Asp Pro Val Glu Ile Leu Gln Glu Arg Glu Tyr Arg Leu Gln Ala            340                 345                 350Arg Ile Ala His Arg Ile Gln Glu Leu Glu Asn Leu Pro Gly Ser Leu        355                 360                 365Pro Pro Asp Leu Arg Thr Lys Ala Thr Val Glu Leu Lys Ala Leu Arg    370                 375                 380Leu Leu Asn Phe Gln Arg Gln Leu Arg Gln Glu Val Val Ala Cys Met385                 390                 395                 400Arg Arg Asp Thr Thr Leu Glu Thr Ala Leu Asn Ser Lys Ala Tyr Lys                405                 410                 415Arg Ser Lys Arg Gln Thr Leu Arg Glu Ala Arg Met Thr Glu Lys Leu            420                 425                 430Glu Lys Gln Gln Lys Ile Glu Gln Glu Arg Lys Arg Arg Gln Lys His        435                 440                 445Gln Glu Tyr Leu Asn Ser Ile Leu Gln His Ala Lys Asp Phe Lys Glu    450                 455                 460Tyr His Arg Ser Val Ala Gly Lys Ile Gln Lys Leu Ser Lys Ala Val465                 470                 475                 480Ala Thr Trp His Ala Asn Thr Glu Arg Glu Gln Lys Lys Glu Thr Glu                485                 490                 495Arg Ile Glu Lys Glu Arg Met Arg Arg Leu Met Ala Glu Asp Glu Glu            500                 505                 510Gly Tyr Arg Lys Leu Ile Asp Gln Lys Lys Asp Arg Arg Leu Ala Tyr        515                 520                 525Leu Leu Gln Gln Thr Asp Glu Tyr Val Ala Asn Leu Thr Asn Leu Val    530                 535                 540Trp Glu His Lys Gln Ala Gln Ala Ala Lys Glu Lys Lys Lys Arg Arg545                 550                 555                 560Arg Arg Lys Lys Lys Ala Glu Glu Asn Ala Glu Gly Gly Glu Ser Ala                565                 570                 575Leu Gly Pro Asp Gly Glu Pro Ile Asp Glu Ser Ser Gln Met Ser Asp            580                 585                 590Leu Pro Val Lys Val Thr His Thr Glu Thr Gly Lys Val Leu Phe Gly        595                 600                 605Pro Glu Ala Pro Lys Ala Ser Gln Leu Asp Ala Trp Leu Glu Met Asn    610                 615                 620Pro Gly Tyr Glu Val Ala Pro Arg Ser Asp Ser Glu Glu Ser Asp Ser625                 630                 635                 640Asp Tyr Glu Glu Glu Asp Glu Glu Glu Glu Ser Ser Arg Gln Glu Thr                645                 650                 655Glu Glu Lys Ile Leu Leu Asp Pro Asn Ser Glu Glu Val Ser Glu Lys            660                 665                 670Asp Ala Lys Gln Ile Ile Glu Thr Ala Lys Gln Asp Val Asp Asp Glu        675                 680                 685Tyr Ser Met Gln Tyr Ser Ala Arg Gly Ser Gln Ser Tyr Tyr Thr Val    690                 695                 700Ala His Ala Ile Ser Glu Arg Val Glu Lys Gln Ser Ala Leu Leu Ile705                 710                 715                 720Asn Gly Thr Leu Lys His Tyr Gln Leu Gln Gly Leu Glu Trp Met Val                725                 730                 735Ser Leu Tyr Asn Asn Asn Leu Asn Gly Ile Leu Ala Asp Glu Met Gly            740                 745                 750Leu Gly Lys Thr Ile Gln Thr Ile Ala Leu Ile Thr Tyr Leu Met Glu        755                 760                 765His Lys Arg Leu Asn Gly Pro Tyr Leu Ile Ile Val Pro Leu Ser Thr    770                 775                 780Leu Ser Asn Trp Thr Tyr Glu Phe Asp Lys Trp Ala Pro Ser Val Val785                 790                 795                 800Lys Ile Ser Tyr Lys Gly Thr Pro Ala Met Arg Arg Ser Leu Val Pro                805                 810                 815Gln Leu Arg Ser Gly Lys Phe Asn Val Leu Leu Thr Thr Tyr Glu Tyr            820                 825                 830Ile Ile Lys Asp Lys His Ile Leu Ala Lys Ile Arg Trp Lys Tyr Met        835                 840                 845Ile Val Asp Glu Gly His Arg Met Lys Asn His His Cys Lys Leu Thr    850                 855                 860Gln Val Asp Leu Asn Glu Glu Glu Thr Ile Leu Ile Ile Arg Arg Leu865                 870                 875                 880His Lys Val Leu Arg Pro Phe Leu Leu Arg Arg Leu Lys Lys Glu Val                885                 890                 895Glu Ser Gln Leu Pro Glu Lys Val Glu Tyr Val Ile Lys Cys Asp Met            900                 905                 910Ser Ala Leu Gln Lys Ile Leu Tyr Arg His Met Gln Ala Lys Gly Ile        915                 920                 925Leu Leu Thr Asp Gly Ser Glu Lys Asp Lys Lys Gly Lys Gly Gly Ala    930                 935                 940Lys Thr Leu Met Asn Thr Ile Met Gln Leu Arg Lys Ile Cys Asn His945                 950                 955                 960Pro Tyr Met Phe Gln His Ile Glu Glu Ser Phe Ala Glu His Leu Gly                965                 970                 975Tyr Ser Asn Gly Val Ile Asn Gly Ala Glu Leu Tyr Arg Ala Ser Gly            980                 985                 990Lys Phe Glu Leu Leu Asp Arg Ile  Leu Pro Lys Leu Arg  Ala Thr Asn        995                 1000                 1005His Arg  Val Leu Leu Phe Cys  Gln Met Thr Ser Leu  Met Thr Ile    1010                 1015                 1020Met Glu  Asp Tyr Phe Ala Phe  Arg Asn Phe Leu Tyr  Leu Arg Leu    1025                 1030                 1035Asp Gly  Thr Thr Lys Ser Glu  Asp Arg Ala Ala Leu  Leu Lys Lys    1040                 1045                 1050Phe Asn  Glu Pro Gly Ser Gln  Tyr Phe Ile Phe Leu  Leu Ser Thr    1055                 1060                 1065Arg Ala  Gly Gly Leu Gly Leu  Asn Leu Gln Ala Ala  Asp Thr Val    1070                 1075                 1080Val Ile  Phe Asp Ser Asp Trp  Asn Pro His Gln Asp  Leu Gln Ala    1085                 1090                 1095Gln Asp  Arg Ala His Arg Ile  Gly Gln Gln Asn Glu  Val Arg Val    1100                 1105                 1110Leu Arg  Leu Cys Thr Val Asn  Ser Val Glu Glu Lys  Ile Leu Ala    1115                 1120                 1125Ala Ala  Lys Tyr Lys Leu Asn  Val Asp Gln Lys Val  Ile Gln Ala    1130                 1135                 1140Gly Met  Phe Asp Gln Lys Ser  Ser Ser His Glu Arg  Arg Ala Phe    1145                 1150                 1155Leu Gln  Ala Ile Leu Glu His  Glu Glu Glu Asn Glu  Glu Glu Asp    1160                 1165                 1170Glu Val  Pro Asp Asp Glu Thr  Leu Asn Gln Met Ile  Ala Arg Arg    1175                 1180                 1185Glu Glu  Glu Phe Asp Leu Phe  Met Arg Met Asp Met  Asp Arg Arg    1190                 1195                 1200Arg Glu  Asp Ala Arg Asn Pro  Lys Arg Lys Pro Arg  Leu Met Glu    1205                 1210                 1215Glu Asp  Glu Leu Pro Ser Trp  Ile Ile Lys Asp Asp  Ala Glu Val    1220                 1225                 1230Glu Arg  Leu Thr Cys Glu Glu  Glu Glu Glu Lys Ile  Phe Gly Arg    1235                 1240                 1245Gly Ser  Arg Gln Arg Arg Asp  Val Asp Tyr Ser Asp  Ala Leu Thr    1250                 1255                 1260Glu Lys  Gln Trp Leu Arg Ala  Ile Glu Asp Gly Asn  Leu Glu Glu    1265                 1270                 1275Met Glu  Glu Glu Val Arg Leu  Lys Lys Arg Lys Arg  Arg Arg Asn    1280                 1285                 1290Val Asp  Lys Asp Pro Ala Lys  Glu Asp Val Glu Lys  Ala Lys Lys    1295                 1300                 1305Arg Arg  Gly Arg Pro Pro Ala  Glu Lys Leu Ser Pro  Asn Pro Pro    1310                 1315                 1320Lys Leu  Thr Lys Gln Met Asn  Ala Ile Ile Asp Thr  Val Ile Asn    1325                 1330                 1335Tyr Lys  Asp Ser Ser Gly Arg  Gln Leu Ser Glu Val  Phe Ile Gln    1340                 1345                 1350Leu Pro  Ser Arg Lys Glu Leu  Pro Glu Tyr Tyr Glu  Leu Ile Arg    1355                 1360                 1365Lys Pro  Val Asp Phe Lys Lys  Ile Lys Glu Arg Ile  Arg Asn His    1370                 1375                 1380Lys Tyr  Arg Ser Leu Gly Asp  Leu Glu Lys Asp Val  Met Leu Leu    1385                 1390                 1395Cys His  Asn Ala Gln Thr Phe  Asn Leu Glu Gly Ser  Gln Ile Tyr    1400                 1405                 1410Glu Asp  Ser Ile Val Leu Gln  Ser Val Phe Lys Ser  Ala Arg Gln    1415                 1420                 1425Lys Ile  Ala Lys Glu Glu Glu  Ser Glu Asp Glu Ser  Asn Glu Glu    1430                 1435                 1440Glu Glu  Glu Glu Asp Glu Glu  Glu Ser Glu Ser Glu  Ala Lys Ser    1445                 1450                 1455Val Lys  Val Lys Ile Lys Leu  Asn Lys Lys Asp Asp  Lys Gly Arg    1460                 1465                 1470Asp Lys  Gly Lys Gly Lys Lys  Arg Pro Asn Arg Gly  Lys Ala Lys    1475                 1480                 1485Pro Val  Val Ser Asp Phe Asp  Ser Asp Glu Glu Gln  Asp Glu Arg    1490                 1495                 1500Glu Gln  Ser Glu Gly Ser Gly  Thr Asp Asp Glu    1505                 1510</s400><s200><s210>8</s210><s211>248</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 8Met Trp Leu Ala Ile Glu Asp Gly Asn Leu Glu Glu Met Glu Glu Glu1               5                   10                  15Val Arg Leu Lys Lys Arg Lys Arg Arg Arg Asn Val Asp Lys Asp Pro            20                  25                  30Ala Lys Glu Asp Val Glu Lys Ala Lys Lys Arg Arg Gly Arg Pro Pro        35                  40                  45Ala Glu Lys Leu Ser Pro Asn Pro Pro Lys Leu Thr Lys Gln Met Asn    50                  55                  60Ala Ile Ile Asp Thr Val Ile Asn Tyr Lys Asp Ser Ser Gly Arg Gln65                  70                  75                  80Leu Ser Glu Val Phe Ile Gln Leu Pro Ser Arg Lys Glu Leu Pro Glu                85                  90                  95Tyr Tyr Glu Leu Ile Arg Lys Pro Val Asp Phe Lys Lys Ile Lys Glu            100                 105                 110Arg Ile Arg Asn His Lys Tyr Arg Ser Leu Gly Asp Leu Glu Lys Asp        115                 120                 125Val Met Leu Leu Cys His Asn Ala Gln Thr Phe Asn Leu Glu Gly Ser    130                 135                 140Gln Ile Tyr Glu Asp Ser Ile Val Leu Gln Ser Val Phe Lys Ser Ala145                 150                 155                 160Arg Gln Lys Ile Ala Lys Glu Glu Glu Ser Glu Asp Glu Ser Asn Glu                165                 170                 175Glu Glu Glu Glu Glu Asp Glu Glu Glu Ser Glu Ser Glu Ala Lys Ser            180                 185                 190Val Lys Val Lys Ile Lys Leu Asn Lys Lys Asp Asp Lys Gly Arg Asp        195                 200                 205Lys Gly Lys Gly Lys Lys Arg Pro Asn Arg Gly Lys Ala Lys Pro Val    210                 215                 220Val Ser Asp Phe Asp Ser Asp Glu Glu Gln Asp Glu Arg Glu Gln Ser225                 230                 235                 240Glu Gly Ser Gly Thr Asp Asp Glu                245</s400><s200><s210>9</s210><s211>5589</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 9ggcgggggag gcgccgggaa gtcgacggcg ccggcggctc ctgcaggagg ccactgtctg     60cagctcccgt gaagatgtcc actccagacc cacccctggg cggaactcct cggccaggtc    120cttccccggg ccctggccct tcccctggag ccatgctggg ccctagcccg ggtccctcgc    180cgggctccgc ccacagcatg atggggccca gcccagggcc gccctcagca ggacacccca    240tccccaccca ggggcctgga gggtaccctc aggacaacat gcaccagatg cacaagccca    300tggagtccat gcatgagaag ggcatgtcgg acgacccgcg ctacaaccag atgaaaggaa    360tggggatgcg gtcagggggc catgctggga tggggccccc gcccagcccc atggaccagc    420actcccaagg ttacccctcg cccctgggtg gctctgagca tgcctctagt ccagttccag    480ccagtggccc gtcttcgggg ccccagatgt cttccgggcc aggaggtgcc ccgctggatg    540gtgctgaccc ccaggccttg gggcagcaga accggggccc aaccccattt aaccagaacc    600agctgcacca gctcagagct cagatcatgg cctacaagat gctggccagg gggcagcccc    660tccccgacca cctgcagatg gcggtgcagg gcaagcggcc gatgcccggg atgcagcagc    720agatgccaac gctacctcca ccctcggtgt ccgcaacagg acccggccct ggccctggcc    780ctggccccgg cccgggtccc ggcccggcac ctccaaatta cagcaggcct catggtatgg    840gagggcccaa catgcctccc ccaggaccct cgggcgtgcc ccccgggatg ccaggccagc    900ctcctggagg gcctcccaag ccctggcctg aaggacccat ggcgaatgct gctgccccca    960cgagcacccc tcagaagctg attcccccgc agccaacggg ccgcccttcc cccgcgcccc   1020ctgccgtccc acccgccgcc tcgcccgtga tgccaccgca gacccagtcc cccgggcagc   1080cggcccagcc cgcgcccatg gtgccactgc accagaagca gagccgcatc acccccatcc   1140agaagccgcg gggcctcgac cctgtggaga tcctgcagga gcgcgagtac aggctgcagg   1200ctcgcatcgc acaccgaatt caggaacttg aaaaccttcc cgggtccctg gccggggatt   1260tgcgaaccaa agcgaccatt gagctcaagg ccctcaggct gctgaacttc cagaggcagc   1320tgcgccagga ggtggtggtg tgcatgcgga gggacacagc gctggagaca gccctcaatg   1380ctaaggccta caagcgcagc aagcgccagt ccctgcgcga ggcccgcatc actgagaagc   1440tggagaagca gcagaagatc gagcaggagc gcaagcgccg gcagaagcac caggaatacc   1500tcaatagcat tctccagcat gccaaggatt tcaaggaata tcacagatcc gtcacaggca   1560aaatccagaa gctgaccaag gcagtggcca cgtaccatgc caacacggag cgggagcaga   1620agaaagagaa cgagcggatc gagaaggagc gcatgcggag gctcatggct gaagatgagg   1680aggggtaccg caagctcatc gaccagaaga aggacaagcg cctggcctac ctcttgcagc   1740agacagacga gtacgtggct aacctcacgg agctggtgcg gcagcacaag gctgcccagg   1800tcgccaagga gaaaaagaag aaaaagaaaa agaagaaggc agaaaatgca gaaggacaga   1860cgcctgccat tgggccggat ggcgagcctc tggacgagac cagccagatg agcgacctcc   1920cggtgaaggt gatccacgtg gagagtggga agatcctcac aggcacagat gcccccaaag   1980ccgggcagct ggaggcctgg ctcgagatga acccggggta tgaagtagct ccgaggtctg   2040atagtgaaga aagtggctca gaagaagagg aagaggagga ggaggaagag cagccgcagg   2100cagcacagcc tcccaccctg cccgtggagg agaagaagaa gattccagat ccagacagcg   2160atgacgtctc tgaggtggac gcgcggcaca tcattgagaa tgccaagcaa gatgtcgatg   2220atgaatatgg cgtgtcccag gcccttgcac gtggcctgca gtcctactat gccgtggccc   2280atgctgtcac tgagagagtg gacaagcagt cagcgcttat ggtcaatggt gtcctcaaac   2340agtaccagat caaaggtttg gagtggctgg tgtccctgta caacaacaac ctgaacggca   2400tcctggccga cgagatgggc ctggggaaga ccatccagac catcgcgctc atcacgtacc   2460tcatggagca caaacgcatc aatgggccct tcctcatcat cgtgcctctc tcaacgctgt   2520ccaactgggc gtacgagttt gacaagtggg ccccctccgt ggtgaaggtg tcttacaagg   2580gatccccagc agcaagacgg gcctttgtcc cccagctccg gagtgggaag ttcaacgtct   2640tgctgacgac gtacgagtac atcatcaaag acaagcacat cctcgccaag atccgttgga   2700agtacatgat tgtggacgaa ggtcaccgca tgaagaacca ccactgcaag ctgacgcagg   2760tgctcaacac gcactatgtg gcaccccgcc gcctgctgct gacgggcaca ccgctgcaga   2820acaagcttcc cgagctctgg gcgctgctca acttcctgct gcccaccatc ttcaagagct   2880gcagcacctt cgagcagtgg tttaacgcac cctttgccat gaccggggaa aaggtggacc   2940tgaatgagga ggaaaccatt ctcatcatcc ggcgtctcca caaagtgctg cggcccttct   3000tgctccgacg actcaagaag gaagtcgagg cccagttgcc cgaaaaggtg gagtacgtca   3060tcaagtgcga catgtctgcg ctgcagcgag tgctctaccg ccacatgcag gccaagggcg   3120tgctgctgac tgatggctcc gagaaggaca agaagggcaa aggcggcacc aagaccctga   3180tgaacaccat catgcagctg cggaagatct gcaaccaccc ctacatgttc cagcacatcg   3240aggagtcctt ttccgagcac ttggggttca ctggcggcat tgtccaaggg ctggacctgt   3300accgagcctc gggtaaattt gagcttcttg atagaattct tcccaaactc cgagcaacca   3360accacaaagt gctgctgttc tgccaaatga cctccctcat gaccatcatg gaagattact   3420ttgcgtatcg cggctttaaa tacctcaggc ttgatggaac cacgaaggcg gaggaccggg   3480gcatgctgct gaaaaccttc aacgagcccg gctctgagta cttcatcttc ctgctcagca   3540cccgggctgg ggggctcggc ctgaacctcc agtcggcaga cactgtgatc atttttgaca   3600gcgactggaa tcctcaccag gacctgcaag cgcaggaccg agcccaccgc atcgggcagc   3660agaacgaggt gcgtgtgctc cgcctctgca ccgtcaacag cgtggaggag aagatcctag   3720ctgcagccaa gtacaagctc aacgtggacc agaaggtgat ccaggccggc atgttcgacc   3780agaagtcctc cagccatgag cggcgcgcct tcctgcaggc catcctggag cacgaggagc   3840aggatgagag cagacactgc agcacgggca gcggcagtgc cagcttcgcc cacactgccc   3900ctccgccagc gggcgtcaac cccgacttgg aggagccacc tctaaaggag gaagacgagg   3960tgcccgacga cgagaccgtc aaccagatga tcgcccggca cgaggaggag tttgatctgt   4020tcatgcgcat ggacctggac cgcaggcgcg aggaggcccg caaccccaag cggaagccgc   4080gcctcatgga ggaggacgag ctcccctcgt ggatcatcaa ggacgacgcg gaggtggagc   4140ggctgacctg tgaggaggag gaggagaaga tgttcggccg tggctcccgc caccgcaagg   4200aggtggacta cagcgactca ctgacggaga agcagtggct caagaaaatt acaggaaaag   4260atatccatga cacagccagc agtgtggcac gtgggctaca attccagcgt ggccttcagt   4320tctgcacacg tgcgtcaaag gccatcgagg agggcacgct ggaggagatc gaagaggagg   4380tccggcagaa gaaatcatca cggaagcgca agcgagacag cgacgccggc tcctccaccc   4440cgaccaccag cacccgcagc cgcgacaagg acgacgagag caagaagcag aagaagcgcg   4500ggcggccgcc tgccgagaaa ctctccccta acccacccaa cctcaccaag aagatgaaga   4560agattgtgga tgccgtgatc aagtacaagg acagcagcag tggacgtcag ctcagcgagg   4620tcttcatcca gctgccctcg cgaaaggagc tgcccgagta ctacgagctc atccgcaagc   4680ccgtggactt caagaagata aaggagcgca ttcgcaacca caagtaccgc agcctcaacg   4740acctagagaa ggacgtcatg ctcctgtgcc agaacgcaca gaccttcaac ctggagggct   4800ccctgatcta tgaagactcc atcgtcttgc agtcggtctt caccagcgtg cggcagaaaa   4860tcgagaagga ggatgacagt gaaggcgagg agagtgagga ggaggaagag ggcgaggagg   4920aaggctccga atccgaatct cggtccgtca aagtgaagat caagcttggc cggaaggaga   4980aggcacagga ccggctgaag ggcggccggc ggcggccgag ccgagggtcc cgagccaagc   5040cggtcgtgag tgacgatgac agtgaggagg aacaagagga ggaccgctca ggaagtggca   5100gcgaagaaga ctgagccccg acattccagt ctcgaccccg agcccctcgt tccagagctg   5160agatggcata ggccttagca gtaacgggta gcagcagatg tagtttcaga cttggagtaa   5220aactgtataa acaaaagaat cttccatatt tatacagcag agaagctgta ggactgtttg   5280tgactggccc tgtcctggca tcagtagcat ctgtaacagc attaactgtc ttaaagagag   5340agagagagaa ttccgaattg gggaacacac gatacctgtt tttcttttcc gttgctggca   5400gtactgttgc gccgcagttt ggagtcactg tagttaagtg tggatgcatg tgcgtcaccg   5460tccactcctc ctactgtatt ttattggaca ggtcagactc gccgggggcc cggcgagggt   5520atgtcagtgt cactggatgt caaacagtaa taaattaaac caacaacaaa acgcacagcc   5580aaaaaaaaa                                                           5589</s400><s200><s210>10</s210><s211>5779</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 10ggagaggccg ccgcggtgct gagggggagg ggagccggcg agcgcgcgcg cagcgggggc     60gcgggtggcg cgcgtgtgtg tgaagggggg gcggtggccg aggcgggcgg gcgcgcgcgc    120gaggcttccc ctcgtttggc ggcggcggcg gcttctttgt ttcgtgaaga gaagcgagac    180gcccattctg cccccggccc cgcgcggagg ggcgggggag gcgccgggaa gtcgacggcg    240ccggcggctc ctgcgtctcg cccttttgcc caggctagag tgcagtggtg cggtcatggt    300tcactgcagc ctcaacctcc tggactcagc aggaggccac tgtctgcagc tcccgtgaag    360atgtccactc cagacccacc cctgggcgga actcctcggc caggtccttc cccgggccct    420ggcccttccc ctggagccat gctgggccct agcccgggtc cctcgccggg ctccgcccac    480agcatgatgg ggcccagccc agggccgccc tcagcaggac accccatccc cacccagggg    540cctggagggt accctcagga caacatgcac cagatgcaca agcccatgga gtccatgcat    600gagaagggca tgtcggacga cccgcgctac aaccagatga aaggaatggg gatgcggtca    660gggggccatg ctgggatggg gcccccgccc agccccatgg accagcactc ccaaggttac    720ccctcgcccc tgggtggctc tgagcatgcc tctagtccag ttccagccag tggcccgtct    780tcggggcccc agatgtcttc cgggccagga ggtgccccgc tggatggtgc tgacccccag    840gccttggggc agcagaaccg gggcccaacc ccatttaacc agaaccagct gcaccagctc    900agagctcaga tcatggccta caagatgctg gccagggggc agcccctccc cgaccacctg    960cagatggcgg tgcagggcaa gcggccgatg cccgggatgc agcagcagat gccaacgcta   1020cctccaccct cggtgtccgc aacaggaccc ggccctggcc ctggccctgg ccccggcccg   1080ggtcccggcc cggcacctcc aaattacagc aggcctcatg gtatgggagg gcccaacatg   1140cctcccccag gaccctcggg cgtgcccccc gggatgccag gccagcctcc tggagggcct   1200cccaagccct ggcctgaagg acccatggcg aatgctgctg cccccacgag cacccctcag   1260aagctgattc ccccgcagcc aacgggccgc ccttcccccg cgccccctgc cgtcccaccc   1320gccgcctcgc ccgtgatgcc accgcagacc cagtcccccg ggcagccggc ccagcccgcg   1380cccatggtgc cactgcacca gaagcagagc cgcatcaccc ccatccagaa gccgcggggc   1440ctcgaccctg tggagatcct gcaggagcgc gagtacaggc tgcaggctcg catcgcacac   1500cgaattcagg aacttgaaaa ccttcccggg tccctggccg gggatttgcg aaccaaagcg   1560accattgagc tcaaggccct caggctgctg aacttccaga ggcagctgcg ccaggaggtg   1620gtggtgtgca tgcggaggga cacagcgctg gagacagccc tcaatgctaa ggcctacaag   1680cgcagcaagc gccagtccct gcgcgaggcc cgcatcactg agaagctgga gaagcagcag   1740aagatcgagc aggagcgcaa gcgccggcag aagcaccagg aatacctcaa tagcattctc   1800cagcatgcca aggatttcaa ggaatatcac agatccgtca caggcaaaat ccagaagctg   1860accaaggcag tggccacgta ccatgccaac acggagcggg agcagaagaa agagaacgag   1920cggatcgaga aggagcgcat gcggaggctc atggctgaag atgaggaggg gtaccgcaag   1980ctcatcgacc agaagaagga caagcgcctg gcctacctct tgcagcagac agacgagtac   2040gtggctaacc tcacggagct ggtgcggcag cacaaggctg cccaggtcgc caaggagaaa   2100aagaagaaaa agaaaaagaa gaaggcagaa aatgcagaag gacagacgcc tgccattggg   2160ccggatggcg agcctctgga cgagaccagc cagatgagcg acctcccggt gaaggtgatc   2220cacgtggaga gtgggaagat cctcacaggc acagatgccc ccaaagccgg gcagctggag   2280gcctggctcg agatgaaccc ggggtatgaa gtagctccga ggtctgatag tgaagaaagt   2340ggctcagaag aagaggaaga ggaggaggag gaagagcagc cgcaggcagc acagcctccc   2400accctgcccg tggaggagaa gaagaagatt ccagatccag acagcgatga cgtctctgag   2460gtggacgcgc ggcacatcat tgagaatgcc aagcaagatg tcgatgatga atatggcgtg   2520tcccaggccc ttgcacgtgg cctgcagtcc tactatgccg tggcccatgc tgtcactgag   2580agagtggaca agcagtcagc gcttatggtc aatggtgtcc tcaaacagta ccagatcaaa   2640ggtttggagt ggctggtgtc cctgtacaac aacaacctga acggcatcct ggccgacgag   2700atgggcctgg ggaagaccat ccagaccatc gcgctcatca cgtacctcat ggagcacaaa   2760cgcatcaatg ggcccttcct catcatcgtg cctctctcaa cgctgtccaa ctgggcgtac   2820gagtttgaca agtgggcccc ctccgtggtg aaggtgtctt acaagggatc cccagcagca   2880agacgggcct ttgtccccca gctccggagt gggaagttca acgtcttgct gacgacgtac   2940gagtacatca tcaaagacaa gcacatcctc gccaagatcc gttggaagta catgattgtg   3000gacgaaggtc accgcatgaa gaaccaccac tgcaagctga cgcaggtgct caacacgcac   3060tatgtggcac cccgccgcct gctgctgacg ggcacaccgc tgcagaacaa gcttcccgag   3120ctctgggcgc tgctcaactt cctgctgccc accatcttca agagctgcag caccttcgag   3180cagtggttta acgcaccctt tgccatgacc ggggaaaagg tggacctgaa tgaggaggaa   3240accattctca tcatccggcg tctccacaaa gtgctgcggc ccttcttgct ccgacgactc   3300aagaaggaag tcgaggccca gttgcccgaa aaggtggagt acgtcatcaa gtgcgacatg   3360tctgcgctgc agcgagtgct ctaccgccac atgcaggcca agggcgtgct gctgactgat   3420ggctccgaga aggacaagaa gggcaaaggc ggcaccaaga ccctgatgaa caccatcatg   3480cagctgcgga agatctgcaa ccacccctac atgttccagc acatcgagga gtccttttcc   3540gagcacttgg ggttcactgg cggcattgtc caagggctgg acctgtaccg agcctcgggt   3600aaatttgagc ttcttgatag aattcttccc aaactccgag caaccaacca caaagtgctg   3660ctgttctgcc aaatgacctc cctcatgacc atcatggaag attactttgc gtatcgcggc   3720tttaaatacc tcaggcttga tggaaccacg aaggcggagg accggggcat gctgctgaaa   3780accttcaacg agcccggctc tgagtacttc atcttcctgc tcagcacccg ggctgggggg   3840ctcggcctga acctccagtc ggcagacact gtgatcattt ttgacagcga ctggaatcct   3900caccaggacc tgcaagcgca ggaccgagcc caccgcatcg ggcagcagaa cgaggtgcgt   3960gtgctccgcc tctgcaccgt caacagcgtg gaggagaaga tcctagctgc agccaagtac   4020aagctcaacg tggaccagaa ggtgatccag gccggcatgt tcgaccagaa gtcctccagc   4080catgagcggc gcgccttcct gcaggccatc ctggagcacg aggagcagga tgagagcaga   4140cactgcagca cgggcagcgg cagtgccagc ttcgcccaca ctgcccctcc gccagcgggc   4200gtcaaccccg acttggagga gccacctcta aaggaggaag acgaggtgcc cgacgacgag   4260accgtcaacc agatgatcgc ccggcacgag gaggagtttg atctgttcat gcgcatggac   4320ctggaccgca ggcgcgagga ggcccgcaac cccaagcgga agccgcgcct catggaggag   4380gacgagctcc cctcgtggat catcaaggac gacgcggagg tggagcggct gacctgtgag   4440gaggaggagg agaagatgtt cggccgtggc tcccgccacc gcaaggaggt ggactacagc   4500gactcactga cggagaagca gtggctcaag gccatcgagg agggcacgct ggaggagatc   4560gaagaggagg tccggcagaa gaaatcatca cggaagcgca agcgagacag cgacgccggc   4620tcctccaccc cgaccaccag cacccgcagc cgcgacaagg acgacgagag caagaagcag   4680aagaagcgcg ggcggccgcc tgccgagaaa ctctccccta acccacccaa cctcaccaag   4740aagatgaaga agattgtgga tgccgtgatc aagtacaagg acagcagcag tggacgtcag   4800ctcagcgagg tcttcatcca gctgccctcg cgaaaggagc tgcccgagta ctacgagctc   4860atccgcaagc ccgtggactt caagaagata aaggagcgca ttcgcaacca caagtaccgc   4920agcctcaacg acctagagaa ggacgtcatg ctcctgtgcc agaacgcaca gaccttcaac   4980ctggagggct ccctgatcta tgaagactcc atcgtcttgc agtcggtctt caccagcgtg   5040cggcagaaaa tcgagaagga ggatgacagt gaaggcgagg agagtgagga ggaggaagag   5100ggcgaggagg aaggctccga atccgaatct cggtccgtca aagtgaagat caagcttggc   5160cggaaggaga aggcacagga ccggctgaag ggcggccggc ggcggccgag ccgagggtcc   5220cgagccaagc cggtcgtgag tgacgatgac agtgaggagg aacaagagga ggaccgctca   5280ggaagtggca gcgaagaaga ctgagccccg acattccagt ctcgaccccg agcccctcgt   5340tccagagctg agatggcata ggccttagca gtaacgggta gcagcagatg tagtttcaga   5400cttggagtaa aactgtataa acaaaagaat cttccatatt tatacagcag agaagctgta   5460ggactgtttg tgactggccc tgtcctggca tcagtagcat ctgtaacagc attaactgtc   5520ttaaagagag agagagagaa ttccgaattg gggaacacac gatacctgtt tttcttttcc   5580gttgctggca gtactgttgc gccgcagttt ggagtcactg tagttaagtg tggatgcatg   5640tgcgtcaccg tccactcctc ctactgtatt ttattggaca ggtcagactc gccgggggcc   5700cggcgagggt atgtcagtgt cactggatgt caaacagtaa taaattaaac caacaacaaa   5760acgcacagcc aaaaaaaaa                                                5779</s400><s200><s210>11</s210><s211>5329</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 11atgtccactc cagacccacc cctgggcgga actcctcggc caggtccttc cccgggccct     60ggcccttccc ctggagccat gctgggccct agcccgggtc cctcgccggg ctccgcccac    120agcatgatgg ggcccagccc agggccgccc tcagcaggac accccatccc cacccagggg    180cctggagggt accctcagga caacatgcac cagatgcaca agcccatgga gtccatgcat    240gagaagggca tgtcggacga cccgcgctac aaccagatga aaggaatggg gatgcggtca    300gggggccatg ctgggatggg gcccccgccc agccccatgg accagcactc ccaaggttac    360ccctcgcccc tgggtggctc tgagcatgcc tctagtccag ttccagccag tggcccgtct    420tcggggcccc agatgtcttc cgggccagga ggtgccccgc tggatggtgc tgacccccag    480gccttggggc agcagaaccg gggcccaacc ccatttaacc agaaccagct gcaccagctc    540agagctcaga tcatggccta caagatgctg gccagggggc agcccctccc cgaccacctg    600cagatggcgg tgcagggcaa gcggccgatg cccgggatgc agcagcagat gccaacgcta    660cctccaccct cggtgtccgc aacaggaccc ggccctggcc ctggccctgg ccccggcccg    720ggtcccggcc cggcacctcc aaattacagc aggcctcatg gtatgggagg gcccaacatg    780cctcccccag gaccctcggg cgtgcccccc gggatgccag gccagcctcc tggagggcct    840cccaagccct ggcctgaagg acccatggcg aatgctgctg cccccacgag cacccctcag    900aagctgattc ccccgcagcc aacgggccgc ccttcccccg cgccccctgc cgtcccaccc    960gccgcctcgc ccgtgatgcc accgcagacc cagtcccccg ggcagccggc ccagcccgcg   1020cccatggtgc cactgcacca gaagcagagc cgcatcaccc ccatccagaa gccgcggggc   1080ctcgaccctg tggagatcct gcaggagcgc gagtacaggc tgcaggctcg catcgcacac   1140cgaattcagg aacttgaaaa ccttcccggg tccctggccg gggatttgcg aaccaaagcg   1200accattgagc tcaaggccct caggctgctg aacttccaga ggcagctgcg ccaggaggtg   1260gtggtgtgca tgcggaggga cacagcgctg gagacagccc tcaatgctaa ggcctacaag   1320cgcagcaagc gccagtccct gcgcgaggcc cgcatcactg agaagctgga gaagcagcag   1380aagatcgagc aggagcgcaa gcgccggcag aagcaccagg aatacctcaa tagcattctc   1440cagcatgcca aggatttcaa ggaatatcac agatccgtca caggcaaaat ccagaagctg   1500accaaggcag tggccacgta ccatgccaac acggagcggg agcagaagaa agagaacgag   1560cggatcgaga aggagcgcat gcggaggctc atggctgaag atgaggaggg gtaccgcaag   1620ctcatcgacc agaagaagga caagcgcctg gcctacctct tgcagcagac agacgagtac   1680gtggctaacc tcacggagct ggtgcggcag cacaaggctg cccaggtcgc caaggagaaa   1740aagaagaaaa agaaaaagaa gaaggcagaa aatgcagaag gacagacgcc tgccattggg   1800ccggatggcg agcctctgga cgagaccagc cagatgagcg acctcccggt gaaggtgatc   1860cacgtggaga gtgggaagat cctcacaggc acagatgccc ccaaagccgg gcagctggag   1920gcctggctcg agatgaaccc ggggtatgaa gtagctccga ggtctgatag tgaagaaagt   1980ggctcagaag aagaggaaga ggaggaggag gaagagcagc cgcaggcagc acagcctccc   2040accctgcccg tggaggagaa gaagaagatt ccagatccag acagcgatga cgtctctgag   2100gtggacgcgc ggcacatcat tgagaatgcc aagcaagatg tcgatgatga atatggcgtg   2160tcccaggccc ttgcacgtgg cctgcagtcc tactatgccg tggcccatgc tgtcactgag   2220agagtggaca agcagtcagc gcttatggtc aatggtgtcc tcaaacagta ccagatcaaa   2280ggtttggagt ggctggtgtc cctgtacaac aacaacctga acggcatcct ggccgacgag   2340atgggcctgg ggaagaccat ccagaccatc gcgctcatca cgtacctcat ggagcacaaa   2400cgcatcaatg ggcccttcct catcatcgtg cctctctcaa cgctgtccaa ctgggcgtac   2460gagtttgaca agtgggcccc ctccgtggtg aaggtgtctt acaagggatc cccagcagca   2520agacgggcct ttgtccccca gctccggagt gggaagttca acgtcttgct gacgacgtac   2580gagtacatca tcaaagacaa gcacatcctc gccaagatcc gttggaagta catgattgtg   2640gacgaaggtc accgcatgaa gaaccaccac tgcaagctga cgcaggtgct caacacgcac   2700tatgtggcac cccgccgcct gctgctgacg ggcacaccgc tgcagaacaa gcttcccgag   2760ctctgggcgc tgctcaactt cctgctgccc accatcttca agagctgcag caccttcgag   2820cagtggttta acgcaccctt tgccatgacc ggggaaaagg tggacctgaa tgaggaggaa   2880accattctca tcatccggcg tctccacaaa gtgctgcggc ccttcttgct ccgacgactc   2940aagaaggaag tcgaggccca gttgcccgaa aaggtggagt acgtcatcaa gtgcgacatg   3000tctgcgctgc agcgagtgct ctaccgccac atgcaggcca agggcgtgct gctgactgat   3060ggctccgaga aggacaagaa gggcaaaggc ggcaccaaga ccctgatgaa caccatcatg   3120cagctgcgga agatctgcaa ccacccctac atgttccagc acatcgagga gtccttttcc   3180gagcacttgg ggttcactgg cggcattgtc caagggctgg acctgtaccg agcctcgggt   3240aaatttgagc ttcttgatag aattcttccc aaactccgag caaccaacca caaagtgctg   3300ctgttctgcc aaatgacctc cctcatgacc atcatggaag attactttgc gtatcgcggc   3360tttaaatacc tcaggcttga tggaaccacg aaggcggagg accggggcat gctgctgaaa   3420accttcaacg agcccggctc tgagtacttc atcttcctgc tcagcacccg ggctgggggg   3480ctcggcctga acctccagtc ggcagacact gtgatcattt ttgacagcga ctggaatcct   3540caccaggacc tgcaagcgca ggaccgagcc caccgcatcg ggcagcagaa cgaggtgcgt   3600gtgctccgcc tctgcaccgt caacagcgtg gaggagaaga tcctagctgc agccaagtac   3660aagctcaacg tggaccagaa ggtgatccag gccggcatgt tcgaccagaa gtcctccagc   3720catgagcggc gcgccttcct gcaggccatc ctggagcacg aggagcagga tgaggaggaa   3780gacgaggtgc ccgacgacga gaccgtcaac cagatgatcg cccggcacga ggaggagttt   3840gatctgttca tgcgcatgga cctggaccgc aggcgcgagg aggcccgcaa ccccaagcgg   3900aagccgcgcc tcatggagga ggacgagctc ccctcgtgga tcatcaagga cgacgcggag   3960gtggagcggc tgacctgtga ggaggaggag gagaagatgt tcggccgtgg ctcccgccac   4020cgcaaggagg tggactacag cgactcactg acggagaagc agtggctcaa gaccctgaag   4080gccatcgagg agggcacgct ggaggagatc gaagaggagg tccggcagaa gaaatcatca   4140cggaagcgca agcgagacag cgacgccggc tcctccaccc cgaccaccag cacccgcagc   4200cgcgacaagg acgacgagag caagaagcag aagaagcgcg ggcggccgcc tgccgagaaa   4260ctctccccta acccacccaa cctcaccaag aagatgaaga agattgtgga tgccgtgatc   4320aagtacaagg acagcagcag tggacgtcag ctcagcgagg tcttcatcca gctgccctcg   4380cgaaaggagc tgcccgagta ctacgagctc atccgcaagc ccgtggactt caagaagata   4440aaggagcgca ttcgcaacca caagtaccgc agcctcaacg acctagagaa ggacgtcatg   4500ctcctgtgcc agaacgcaca gaccttcaac ctggagggct ccctgatcta tgaagactcc   4560atcgtcttgc agtcggtctt caccagcgtg cggcagaaaa tcgagaagga ggatgacagt   4620gaaggcgagg agagtgagga ggaggaagag ggcgaggagg aaggctccga atccgaatct   4680cggtccgtca aagtgaagat caagcttggc cggaaggaga aggcacagga ccggctgaag   4740ggcggccggc ggcggccgag ccgagggtcc cgagccaagc cggtcgtgag tgacgatgac   4800agtgaggagg aacaagagga ggaccgctca ggaagtggca gcgaagaaga ctgagccccg   4860acattccagt ctcgaccccg agcccctcgt tccagagctg agatggcata ggccttagca   4920gtaacgggta gcagcagatg tagtttcaga cttggagtaa aactgtataa acaaaagaat   4980cttccatatt tatacagcag agaagctgta ggactgtttg tgactggccc tgtcctggca   5040tcagtagcat ctgtaacagc attaactgtc ttaaagagag agagagagaa ttccgaattg   5100gggaacacac gatacctgtt tttcttttcc gttgctggca gtactgttgc gccgcagttt   5160ggagtcactg tagttaagtg tggatgcatg tgcgtcaccg tccactcctc ctactgtatt   5220ttattggaca ggtcagactc gccgggggcc cggcgagggt atgtcagtgt cactggatgt   5280caaacagtaa taaattaaac caacaacaaa acgcacagcc aaaaaaaaa               5329</s400><s200><s210>12</s210><s211>5326</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 12atgtccactc cagacccacc cctgggcgga actcctcggc caggtccttc cccgggccct     60ggcccttccc ctggagccat gctgggccct agcccgggtc cctcgccggg ctccgcccac    120agcatgatgg ggcccagccc agggccgccc tcagcaggac accccatccc cacccagggg    180cctggagggt accctcagga caacatgcac cagatgcaca agcccatgga gtccatgcat    240gagaagggca tgtcggacga cccgcgctac aaccagatga aaggaatggg gatgcggtca    300gggggccatg ctgggatggg gcccccgccc agccccatgg accagcactc ccaaggttac    360ccctcgcccc tgggtggctc tgagcatgcc tctagtccag ttccagccag tggcccgtct    420tcggggcccc agatgtcttc cgggccagga ggtgccccgc tggatggtgc tgacccccag    480gccttggggc agcagaaccg gggcccaacc ccatttaacc agaaccagct gcaccagctc    540agagctcaga tcatggccta caagatgctg gccagggggc agcccctccc cgaccacctg    600cagatggcgg tgcagggcaa gcggccgatg cccgggatgc agcagcagat gccaacgcta    660cctccaccct cggtgtccgc aacaggaccc ggccctggcc ctggccctgg ccccggcccg    720ggtcccggcc cggcacctcc aaattacagc aggcctcatg gtatgggagg gcccaacatg    780cctcccccag gaccctcggg cgtgcccccc gggatgccag gccagcctcc tggagggcct    840cccaagccct ggcctgaagg acccatggcg aatgctgctg cccccacgag cacccctcag    900aagctgattc ccccgcagcc aacgggccgc ccttcccccg cgccccctgc cgtcccaccc    960gccgcctcgc ccgtgatgcc accgcagacc cagtcccccg ggcagccggc ccagcccgcg   1020cccatggtgc cactgcacca gaagcagagc cgcatcaccc ccatccagaa gccgcggggc   1080ctcgaccctg tggagatcct gcaggagcgc gagtacaggc tgcaggctcg catcgcacac   1140cgaattcagg aacttgaaaa ccttcccggg tccctggccg gggatttgcg aaccaaagcg   1200accattgagc tcaaggccct caggctgctg aacttccaga ggcagctgcg ccaggaggtg   1260gtggtgtgca tgcggaggga cacagcgctg gagacagccc tcaatgctaa ggcctacaag   1320cgcagcaagc gccagtccct gcgcgaggcc cgcatcactg agaagctgga gaagcagcag   1380aagatcgagc aggagcgcaa gcgccggcag aagcaccagg aatacctcaa tagcattctc   1440cagcatgcca aggatttcaa ggaatatcac agatccgtca caggcaaaat ccagaagctg   1500accaaggcag tggccacgta ccatgccaac acggagcggg agcagaagaa agagaacgag   1560cggatcgaga aggagcgcat gcggaggctc atggctgaag atgaggaggg gtaccgcaag   1620ctcatcgacc agaagaagga caagcgcctg gcctacctct tgcagcagac agacgagtac   1680gtggctaacc tcacggagct ggtgcggcag cacaaggctg cccaggtcgc caaggagaaa   1740aagaagaaaa agaaaaagaa gaaggcagaa aatgcagaag gacagacgcc tgccattggg   1800ccggatggcg agcctctgga cgagaccagc cagatgagcg acctcccggt gaaggtgatc   1860cacgtggaga gtgggaagat cctcacaggc acagatgccc ccaaagccgg gcagctggag   1920gcctggctcg agatgaaccc ggggtatgaa gtagctccga ggtctgatag tgaagaaagt   1980ggctcagaag aagaggaaga ggaggaggag gaagagcagc cgcaggcagc acagcctccc   2040accctgcccg tggaggagaa gaagaagatt ccagatccag acagcgatga cgtctctgag   2100gtggacgcgc ggcacatcat tgagaatgcc aagcaagatg tcgatgatga atatggcgtg   2160tcccaggccc ttgcacgtgg cctgcagtcc tactatgccg tggcccatgc tgtcactgag   2220agagtggaca agcagtcagc gcttatggtc aatggtgtcc tcaaacagta ccagatcaaa   2280ggtttggagt ggctggtgtc cctgtacaac aacaacctga acggcatcct ggccgacgag   2340atgggcctgg ggaagaccat ccagaccatc gcgctcatca cgtacctcat ggagcacaaa   2400cgcatcaatg ggcccttcct catcatcgtg cctctctcaa cgctgtccaa ctgggcgtac   2460gagtttgaca agtgggcccc ctccgtggtg aaggtgtctt acaagggatc cccagcagca   2520agacgggcct ttgtccccca gctccggagt gggaagttca acgtcttgct gacgacgtac   2580gagtacatca tcaaagacaa gcacatcctc gccaagatcc gttggaagta catgattgtg   2640gacgaaggtc accgcatgaa gaaccaccac tgcaagctga cgcaggtgct caacacgcac   2700tatgtggcac cccgccgcct gctgctgacg ggcacaccgc tgcagaacaa gcttcccgag   2760ctctgggcgc tgctcaactt cctgctgccc accatcttca agagctgcag caccttcgag   2820cagtggttta acgcaccctt tgccatgacc ggggaaaagg tggacctgaa tgaggaggaa   2880accattctca tcatccggcg tctccacaaa gtgctgcggc ccttcttgct ccgacgactc   2940aagaaggaag tcgaggccca gttgcccgaa aaggtggagt acgtcatcaa gtgcgacatg   3000tctgcgctgc agcgagtgct ctaccgccac atgcaggcca agggcgtgct gctgactgat   3060ggctccgaga aggacaagaa gggcaaaggc ggcaccaaga ccctgatgaa caccatcatg   3120cagctgcgga agatctgcaa ccacccctac atgttccagc acatcgagga gtccttttcc   3180gagcacttgg ggttcactgg cggcattgtc caagggctgg acctgtaccg agcctcgggt   3240aaatttgagc ttcttgatag aattcttccc aaactccgag caaccaacca caaagtgctg   3300ctgttctgcc aaatgacctc cctcatgacc atcatggaag attactttgc gtatcgcggc   3360tttaaatacc tcaggcttga tggaaccacg aaggcggagg accggggcat gctgctgaaa   3420accttcaacg agcccggctc tgagtacttc atcttcctgc tcagcacccg ggctgggggg   3480ctcggcctga acctccagtc ggcagacact gtgatcattt ttgacagcga ctggaatcct   3540caccaggacc tgcaagcgca ggaccgagcc caccgcatcg ggcagcagaa cgaggtgcgt   3600gtgctccgcc tctgcaccgt caacagcgtg gaggagaaga tcctagctgc agccaagtac   3660aagctcaacg tggaccagaa ggtgatccag gccggcatgt tcgaccagaa gtcctccagc   3720catgagcggc gcgccttcct gcaggccatc ctggagcacg aggagcagga tgaggaggaa   3780gacgaggtgc ccgacgacga gaccgtcaac cagatgatcg cccggcacga ggaggagttt   3840gatctgttca tgcgcatgga cctggaccgc aggcgcgagg aggcccgcaa ccccaagcgg   3900aagccgcgcc tcatggagga ggacgagctc ccctcgtgga tcatcaagga cgacgcggag   3960gtggagcggc tgacctgtga ggaggaggag gagaagatgt tcggccgtgg ctcccgccac   4020cgcaaggagg tggactacag cgactcactg acggagaagc agtggctcaa gaccctgaag   4080gccatcgagg agggcacgct ggaggagatc gaagaggagg tccggcagaa gaaatcatca   4140cggaagcgca agcgagacag cgacgccggc tcctccaccc cgaccaccag cacccgcagc   4200cgcgacaagg acgacgagag caagaagcag aagaagcgcg ggcggccgcc tgccgagaaa   4260ctctccccta acccacccaa cctcaccaag aagatgaaga agattgtgga tgccgtgatc   4320aagtacaagg acagcagtgg acgtcagctc agcgaggtct tcatccagct gccctcgcga   4380aaggagctgc ccgagtacta cgagctcatc cgcaagcccg tggacttcaa gaagataaag   4440gagcgcattc gcaaccacaa gtaccgcagc ctcaacgacc tagagaagga cgtcatgctc   4500ctgtgccaga acgcacagac cttcaacctg gagggctccc tgatctatga agactccatc   4560gtcttgcagt cggtcttcac cagcgtgcgg cagaaaatcg agaaggagga tgacagtgaa   4620ggcgaggaga gtgaggagga ggaagagggc gaggaggaag gctccgaatc cgaatctcgg   4680tccgtcaaag tgaagatcaa gcttggccgg aaggagaagg cacaggaccg gctgaagggc   4740ggccggcggc ggccgagccg agggtcccga gccaagccgg tcgtgagtga cgatgacagt   4800gaggaggaac aagaggagga ccgctcagga agtggcagcg aagaagactg agccccgaca   4860ttccagtctc gaccccgagc ccctcgttcc agagctgaga tggcataggc cttagcagta   4920acgggtagca gcagatgtag tttcagactt ggagtaaaac tgtataaaca aaagaatctt   4980ccatatttat acagcagaga agctgtagga ctgtttgtga ctggccctgt cctggcatca   5040gtagcatctg taacagcatt aactgtctta aagagagaga gagagaattc cgaattgggg   5100aacacacgat acctgttttt cttttccgtt gctggcagta ctgttgcgcc gcagtttgga   5160gtcactgtag ttaagtgtgg atgcatgtgc gtcaccgtcc actcctccta ctgtatttta   5220ttggacaggt cagactcgcc gggggcccgg cgagggtatg tcagtgtcac tggatgtcaa   5280acagtaataa attaaaccaa caacaaaacg cacagccaaa aaaaaa                  5326</s400><s200><s210>13</s210><s211>5320</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 13atgtccactc cagacccacc cctgggcgga actcctcggc caggtccttc cccgggccct     60ggcccttccc ctggagccat gctgggccct agcccgggtc cctcgccggg ctccgcccac    120agcatgatgg ggcccagccc agggccgccc tcagcaggac accccatccc cacccagggg    180cctggagggt accctcagga caacatgcac cagatgcaca agcccatgga gtccatgcat    240gagaagggca tgtcggacga cccgcgctac aaccagatga aaggaatggg gatgcggtca    300gggggccatg ctgggatggg gcccccgccc agccccatgg accagcactc ccaaggttac    360ccctcgcccc tgggtggctc tgagcatgcc tctagtccag ttccagccag tggcccgtct    420tcggggcccc agatgtcttc cgggccagga ggtgccccgc tggatggtgc tgacccccag    480gccttggggc agcagaaccg gggcccaacc ccatttaacc agaaccagct gcaccagctc    540agagctcaga tcatggccta caagatgctg gccagggggc agcccctccc cgaccacctg    600cagatggcgg tgcagggcaa gcggccgatg cccgggatgc agcagcagat gccaacgcta    660cctccaccct cggtgtccgc aacaggaccc ggccctggcc ctggccctgg ccccggcccg    720ggtcccggcc cggcacctcc aaattacagc aggcctcatg gtatgggagg gcccaacatg    780cctcccccag gaccctcggg cgtgcccccc gggatgccag gccagcctcc tggagggcct    840cccaagccct ggcctgaagg acccatggcg aatgctgctg cccccacgag cacccctcag    900aagctgattc ccccgcagcc aacgggccgc ccttcccccg cgccccctgc cgtcccaccc    960gccgcctcgc ccgtgatgcc accgcagacc cagtcccccg ggcagccggc ccagcccgcg   1020cccatggtgc cactgcacca gaagcagagc cgcatcaccc ccatccagaa gccgcggggc   1080ctcgaccctg tggagatcct gcaggagcgc gagtacaggc tgcaggctcg catcgcacac   1140cgaattcagg aacttgaaaa ccttcccggg tccctggccg gggatttgcg aaccaaagcg   1200accattgagc tcaaggccct caggctgctg aacttccaga ggcagctgcg ccaggaggtg   1260gtggtgtgca tgcggaggga cacagcgctg gagacagccc tcaatgctaa ggcctacaag   1320cgcagcaagc gccagtccct gcgcgaggcc cgcatcactg agaagctgga gaagcagcag   1380aagatcgagc aggagcgcaa gcgccggcag aagcaccagg aatacctcaa tagcattctc   1440cagcatgcca aggatttcaa ggaatatcac agatccgtca caggcaaaat ccagaagctg   1500accaaggcag tggccacgta ccatgccaac acggagcggg agcagaagaa agagaacgag   1560cggatcgaga aggagcgcat gcggaggctc atggctgaag atgaggaggg gtaccgcaag   1620ctcatcgacc agaagaagga caagcgcctg gcctacctct tgcagcagac agacgagtac   1680gtggctaacc tcacggagct ggtgcggcag cacaaggctg cccaggtcgc caaggagaaa   1740aagaagaaaa agaaaaagaa gaaggcagaa aatgcagaag gacagacgcc tgccattggg   1800ccggatggcg agcctctgga cgagaccagc cagatgagcg acctcccggt gaaggtgatc   1860cacgtggaga gtgggaagat cctcacaggc acagatgccc ccaaagccgg gcagctggag   1920gcctggctcg agatgaaccc ggggtatgaa gtagctccga ggtctgatag tgaagaaagt   1980ggctcagaag aagaggaaga ggaggaggag gaagagcagc cgcaggcagc acagcctccc   2040accctgcccg tggaggagaa gaagaagatt ccagatccag acagcgatga cgtctctgag   2100gtggacgcgc ggcacatcat tgagaatgcc aagcaagatg tcgatgatga atatggcgtg   2160tcccaggccc ttgcacgtgg cctgcagtcc tactatgccg tggcccatgc tgtcactgag   2220agagtggaca agcagtcagc gcttatggtc aatggtgtcc tcaaacagta ccagatcaaa   2280ggtttggagt ggctggtgtc cctgtacaac aacaacctga acggcatcct ggccgacgag   2340atgggcctgg ggaagaccat ccagaccatc gcgctcatca cgtacctcat ggagcacaaa   2400cgcatcaatg ggcccttcct catcatcgtg cctctctcaa cgctgtccaa ctgggcgtac   2460gagtttgaca agtgggcccc ctccgtggtg aaggtgtctt acaagggatc cccagcagca   2520agacgggcct ttgtccccca gctccggagt gggaagttca acgtcttgct gacgacgtac   2580gagtacatca tcaaagacaa gcacatcctc gccaagatcc gttggaagta catgattgtg   2640gacgaaggtc accgcatgaa gaaccaccac tgcaagctga cgcaggtgct caacacgcac   2700tatgtggcac cccgccgcct gctgctgacg ggcacaccgc tgcagaacaa gcttcccgag   2760ctctgggcgc tgctcaactt cctgctgccc accatcttca agagctgcag caccttcgag   2820cagtggttta acgcaccctt tgccatgacc ggggaaaagg tggacctgaa tgaggaggaa   2880accattctca tcatccggcg tctccacaaa gtgctgcggc ccttcttgct ccgacgactc   2940aagaaggaag tcgaggccca gttgcccgaa aaggtggagt acgtcatcaa gtgcgacatg   3000tctgcgctgc agcgagtgct ctaccgccac atgcaggcca agggcgtgct gctgactgat   3060ggctccgaga aggacaagaa gggcaaaggc ggcaccaaga ccctgatgaa caccatcatg   3120cagctgcgga agatctgcaa ccacccctac atgttccagc acatcgagga gtccttttcc   3180gagcacttgg ggttcactgg cggcattgtc caagggctgg acctgtaccg agcctcgggt   3240aaatttgagc ttcttgatag aattcttccc aaactccgag caaccaacca caaagtgctg   3300ctgttctgcc aaatgacctc cctcatgacc atcatggaag attactttgc gtatcgcggc   3360tttaaatacc tcaggcttga tggaaccacg aaggcggagg accggggcat gctgctgaaa   3420accttcaacg agcccggctc tgagtacttc atcttcctgc tcagcacccg ggctgggggg   3480ctcggcctga acctccagtc ggcagacact gtgatcattt ttgacagcga ctggaatcct   3540caccaggacc tgcaagcgca ggaccgagcc caccgcatcg ggcagcagaa cgaggtgcgt   3600gtgctccgcc tctgcaccgt caacagcgtg gaggagaaga tcctagctgc agccaagtac   3660aagctcaacg tggaccagaa ggtgatccag gccggcatgt tcgaccagaa gtcctccagc   3720catgagcggc gcgccttcct gcaggccatc ctggagcacg aggagcagga tgaggaggaa   3780gacgaggtgc ccgacgacga gaccgtcaac cagatgatcg cccggcacga ggaggagttt   3840gatctgttca tgcgcatgga cctggaccgc aggcgcgagg aggcccgcaa ccccaagcgg   3900aagccgcgcc tcatggagga ggacgagctc ccctcgtgga tcatcaagga cgacgcggag   3960gtggagcggc tgacctgtga ggaggaggag gagaagatgt tcggccgtgg ctcccgccac   4020cgcaaggagg tggactacag cgactcactg acggagaagc agtggctcaa ggccatcgag   4080gagggcacgc tggaggagat cgaagaggag gtccggcaga agaaatcatc acggaagcgc   4140aagcgagaca gcgacgccgg ctcctccacc ccgaccacca gcacccgcag ccgcgacaag   4200gacgacgaga gcaagaagca gaagaagcgc gggcggccgc ctgccgagaa actctcccct   4260aacccaccca acctcaccaa gaagatgaag aagattgtgg atgccgtgat caagtacaag   4320gacagcagca gtggacgtca gctcagcgag gtcttcatcc agctgccctc gcgaaaggag   4380ctgcccgagt actacgagct catccgcaag cccgtggact tcaagaagat aaaggagcgc   4440attcgcaacc acaagtaccg cagcctcaac gacctagaga aggacgtcat gctcctgtgc   4500cagaacgcac agaccttcaa cctggagggc tccctgatct atgaagactc catcgtcttg   4560cagtcggtct tcaccagcgt gcggcagaaa atcgagaagg aggatgacag tgaaggcgag   4620gagagtgagg aggaggaaga gggcgaggag gaaggctccg aatccgaatc tcggtccgtc   4680aaagtgaaga tcaagcttgg ccggaaggag aaggcacagg accggctgaa gggcggccgg   4740cggcggccga gccgagggtc ccgagccaag ccggtcgtga gtgacgatga cagtgaggag   4800gaacaagagg aggaccgctc aggaagtggc agcgaagaag actgagcccc gacattccag   4860tctcgacccc gagcccctcg ttccagagct gagatggcat aggccttagc agtaacgggt   4920agcagcagat gtagtttcag acttggagta aaactgtata aacaaaagaa tcttccatat   4980ttatacagca gagaagctgt aggactgttt gtgactggcc ctgtcctggc atcagtagca   5040tctgtaacag cattaactgt cttaaagaga gagagagaga attccgaatt ggggaacaca   5100cgatacctgt ttttcttttc cgttgctggc agtactgttg cgccgcagtt tggagtcact   5160gtagttaagt gtggatgcat gtgcgtcacc gtccactcct cctactgtat tttattggac   5220aggtcagact cgccgggggc ccggcgaggg tatgtcagtg tcactggatg tcaaacagta   5280ataaattaaa ccaacaacaa aacgcacagc caaaaaaaaa                         5320</s400><s200><s210>14</s210><s211>5317</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 14atgtccactc cagacccacc cctgggcgga actcctcggc caggtccttc cccgggccct     60ggcccttccc ctggagccat gctgggccct agcccgggtc cctcgccggg ctccgcccac    120agcatgatgg ggcccagccc agggccgccc tcagcaggac accccatccc cacccagggg    180cctggagggt accctcagga caacatgcac cagatgcaca agcccatgga gtccatgcat    240gagaagggca tgtcggacga cccgcgctac aaccagatga aaggaatggg gatgcggtca    300gggggccatg ctgggatggg gcccccgccc agccccatgg accagcactc ccaaggttac    360ccctcgcccc tgggtggctc tgagcatgcc tctagtccag ttccagccag tggcccgtct    420tcggggcccc agatgtcttc cgggccagga ggtgccccgc tggatggtgc tgacccccag    480gccttggggc agcagaaccg gggcccaacc ccatttaacc agaaccagct gcaccagctc    540agagctcaga tcatggccta caagatgctg gccagggggc agcccctccc cgaccacctg    600cagatggcgg tgcagggcaa gcggccgatg cccgggatgc agcagcagat gccaacgcta    660cctccaccct cggtgtccgc aacaggaccc ggccctggcc ctggccctgg ccccggcccg    720ggtcccggcc cggcacctcc aaattacagc aggcctcatg gtatgggagg gcccaacatg    780cctcccccag gaccctcggg cgtgcccccc gggatgccag gccagcctcc tggagggcct    840cccaagccct ggcctgaagg acccatggcg aatgctgctg cccccacgag cacccctcag    900aagctgattc ccccgcagcc aacgggccgc ccttcccccg cgccccctgc cgtcccaccc    960gccgcctcgc ccgtgatgcc accgcagacc cagtcccccg ggcagccggc ccagcccgcg   1020cccatggtgc cactgcacca gaagcagagc cgcatcaccc ccatccagaa gccgcggggc   1080ctcgaccctg tggagatcct gcaggagcgc gagtacaggc tgcaggctcg catcgcacac   1140cgaattcagg aacttgaaaa ccttcccggg tccctggccg gggatttgcg aaccaaagcg   1200accattgagc tcaaggccct caggctgctg aacttccaga ggcagctgcg ccaggaggtg   1260gtggtgtgca tgcggaggga cacagcgctg gagacagccc tcaatgctaa ggcctacaag   1320cgcagcaagc gccagtccct gcgcgaggcc cgcatcactg agaagctgga gaagcagcag   1380aagatcgagc aggagcgcaa gcgccggcag aagcaccagg aatacctcaa tagcattctc   1440cagcatgcca aggatttcaa ggaatatcac agatccgtca caggcaaaat ccagaagctg   1500accaaggcag tggccacgta ccatgccaac acggagcggg agcagaagaa agagaacgag   1560cggatcgaga aggagcgcat gcggaggctc atggctgaag atgaggaggg gtaccgcaag   1620ctcatcgacc agaagaagga caagcgcctg gcctacctct tgcagcagac agacgagtac   1680gtggctaacc tcacggagct ggtgcggcag cacaaggctg cccaggtcgc caaggagaaa   1740aagaagaaaa agaaaaagaa gaaggcagaa aatgcagaag gacagacgcc tgccattggg   1800ccggatggcg agcctctgga cgagaccagc cagatgagcg acctcccggt gaaggtgatc   1860cacgtggaga gtgggaagat cctcacaggc acagatgccc ccaaagccgg gcagctggag   1920gcctggctcg agatgaaccc ggggtatgaa gtagctccga ggtctgatag tgaagaaagt   1980ggctcagaag aagaggaaga ggaggaggag gaagagcagc cgcaggcagc acagcctccc   2040accctgcccg tggaggagaa gaagaagatt ccagatccag acagcgatga cgtctctgag   2100gtggacgcgc ggcacatcat tgagaatgcc aagcaagatg tcgatgatga atatggcgtg   2160tcccaggccc ttgcacgtgg cctgcagtcc tactatgccg tggcccatgc tgtcactgag   2220agagtggaca agcagtcagc gcttatggtc aatggtgtcc tcaaacagta ccagatcaaa   2280ggtttggagt ggctggtgtc cctgtacaac aacaacctga acggcatcct ggccgacgag   2340atgggcctgg ggaagaccat ccagaccatc gcgctcatca cgtacctcat ggagcacaaa   2400cgcatcaatg ggcccttcct catcatcgtg cctctctcaa cgctgtccaa ctgggcgtac   2460gagtttgaca agtgggcccc ctccgtggtg aaggtgtctt acaagggatc cccagcagca   2520agacgggcct ttgtccccca gctccggagt gggaagttca acgtcttgct gacgacgtac   2580gagtacatca tcaaagacaa gcacatcctc gccaagatcc gttggaagta catgattgtg   2640gacgaaggtc accgcatgaa gaaccaccac tgcaagctga cgcaggtgct caacacgcac   2700tatgtggcac cccgccgcct gctgctgacg ggcacaccgc tgcagaacaa gcttcccgag   2760ctctgggcgc tgctcaactt cctgctgccc accatcttca agagctgcag caccttcgag   2820cagtggttta acgcaccctt tgccatgacc ggggaaaagg tggacctgaa tgaggaggaa   2880accattctca tcatccggcg tctccacaaa gtgctgcggc ccttcttgct ccgacgactc   2940aagaaggaag tcgaggccca gttgcccgaa aaggtggagt acgtcatcaa gtgcgacatg   3000tctgcgctgc agcgagtgct ctaccgccac atgcaggcca agggcgtgct gctgactgat   3060ggctccgaga aggacaagaa gggcaaaggc ggcaccaaga ccctgatgaa caccatcatg   3120cagctgcgga agatctgcaa ccacccctac atgttccagc acatcgagga gtccttttcc   3180gagcacttgg ggttcactgg cggcattgtc caagggctgg acctgtaccg agcctcgggt   3240aaatttgagc ttcttgatag aattcttccc aaactccgag caaccaacca caaagtgctg   3300ctgttctgcc aaatgacctc cctcatgacc atcatggaag attactttgc gtatcgcggc   3360tttaaatacc tcaggcttga tggaaccacg aaggcggagg accggggcat gctgctgaaa   3420accttcaacg agcccggctc tgagtacttc atcttcctgc tcagcacccg ggctgggggg   3480ctcggcctga acctccagtc ggcagacact gtgatcattt ttgacagcga ctggaatcct   3540caccaggacc tgcaagcgca ggaccgagcc caccgcatcg ggcagcagaa cgaggtgcgt   3600gtgctccgcc tctgcaccgt caacagcgtg gaggagaaga tcctagctgc agccaagtac   3660aagctcaacg tggaccagaa ggtgatccag gccggcatgt tcgaccagaa gtcctccagc   3720catgagcggc gcgccttcct gcaggccatc ctggagcacg aggagcagga tgaggaggaa   3780gacgaggtgc ccgacgacga gaccgtcaac cagatgatcg cccggcacga ggaggagttt   3840gatctgttca tgcgcatgga cctggaccgc aggcgcgagg aggcccgcaa ccccaagcgg   3900aagccgcgcc tcatggagga ggacgagctc ccctcgtgga tcatcaagga cgacgcggag   3960gtggagcggc tgacctgtga ggaggaggag gagaagatgt tcggccgtgg ctcccgccac   4020cgcaaggagg tggactacag cgactcactg acggagaagc agtggctcaa ggccatcgag   4080gagggcacgc tggaggagat cgaagaggag gtccggcaga agaaatcatc acggaagcgc   4140aagcgagaca gcgacgccgg ctcctccacc ccgaccacca gcacccgcag ccgcgacaag   4200gacgacgaga gcaagaagca gaagaagcgc gggcggccgc ctgccgagaa actctcccct   4260aacccaccca acctcaccaa gaagatgaag aagattgtgg atgccgtgat caagtacaag   4320gacagcagtg gacgtcagct cagcgaggtc ttcatccagc tgccctcgcg aaaggagctg   4380cccgagtact acgagctcat ccgcaagccc gtggacttca agaagataaa ggagcgcatt   4440cgcaaccaca agtaccgcag cctcaacgac ctagagaagg acgtcatgct cctgtgccag   4500aacgcacaga ccttcaacct ggagggctcc ctgatctatg aagactccat cgtcttgcag   4560tcggtcttca ccagcgtgcg gcagaaaatc gagaaggagg atgacagtga aggcgaggag   4620agtgaggagg aggaagaggg cgaggaggaa ggctccgaat ccgaatctcg gtccgtcaaa   4680gtgaagatca agcttggccg gaaggagaag gcacaggacc ggctgaaggg cggccggcgg   4740cggccgagcc gagggtcccg agccaagccg gtcgtgagtg acgatgacag tgaggaggaa   4800caagaggagg accgctcagg aagtggcagc gaagaagact gagccccgac attccagtct   4860cgaccccgag cccctcgttc cagagctgag atggcatagg ccttagcagt aacgggtagc   4920agcagatgta gtttcagact tggagtaaaa ctgtataaac aaaagaatct tccatattta   4980tacagcagag aagctgtagg actgtttgtg actggccctg tcctggcatc agtagcatct   5040gtaacagcat taactgtctt aaagagagag agagagaatt ccgaattggg gaacacacga   5100tacctgtttt tcttttccgt tgctggcagt actgttgcgc cgcagtttgg agtcactgta   5160gttaagtgtg gatgcatgtg cgtcaccgtc cactcctcct actgtatttt attggacagg   5220tcagactcgc cgggggcccg gcgagggtat gtcagtgtca ctggatgtca aacagtaata   5280aattaaacca acaacaaaac gcacagccaa aaaaaaa                            5317</s400><s200><s210>15</s210><s211>1679</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 15Met Ser Thr Pro Asp Pro Pro Leu Gly Gly Thr Pro Arg Pro Gly Pro1               5                   10                  15Ser Pro Gly Pro Gly Pro Ser Pro Gly Ala Met Leu Gly Pro Ser Pro            20                  25                  30Gly Pro Ser Pro Gly Ser Ala His Ser Met Met Gly Pro Ser Pro Gly        35                  40                  45Pro Pro Ser Ala Gly His Pro Ile Pro Thr Gln Gly Pro Gly Gly Tyr    50                  55                  60Pro Gln Asp Asn Met His Gln Met His Lys Pro Met Glu Ser Met His65                  70                  75                  80Glu Lys Gly Met Ser Asp Asp Pro Arg Tyr Asn Gln Met Lys Gly Met                85                  90                  95Gly Met Arg Ser Gly Gly His Ala Gly Met Gly Pro Pro Pro Ser Pro            100                 105                 110Met Asp Gln His Ser Gln Gly Tyr Pro Ser Pro Leu Gly Gly Ser Glu        115                 120                 125His Ala Ser Ser Pro Val Pro Ala Ser Gly Pro Ser Ser Gly Pro Gln    130                 135                 140Met Ser Ser Gly Pro Gly Gly Ala Pro Leu Asp Gly Ala Asp Pro Gln145                 150                 155                 160Ala Leu Gly Gln Gln Asn Arg Gly Pro Thr Pro Phe Asn Gln Asn Gln                165                 170                 175Leu His Gln Leu Arg Ala Gln Ile Met Ala Tyr Lys Met Leu Ala Arg            180                 185                 190Gly Gln Pro Leu Pro Asp His Leu Gln Met Ala Val Gln Gly Lys Arg        195                 200                 205Pro Met Pro Gly Met Gln Gln Gln Met Pro Thr Leu Pro Pro Pro Ser    210                 215                 220Val Ser Ala Thr Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro225                 230                 235                 240Gly Pro Gly Pro Ala Pro Pro Asn Tyr Ser Arg Pro His Gly Met Gly                245                 250                 255Gly Pro Asn Met Pro Pro Pro Gly Pro Ser Gly Val Pro Pro Gly Met            260                 265                 270Pro Gly Gln Pro Pro Gly Gly Pro Pro Lys Pro Trp Pro Glu Gly Pro        275                 280                 285Met Ala Asn Ala Ala Ala Pro Thr Ser Thr Pro Gln Lys Leu Ile Pro    290                 295                 300Pro Gln Pro Thr Gly Arg Pro Ser Pro Ala Pro Pro Ala Val Pro Pro305                 310                 315                 320Ala Ala Ser Pro Val Met Pro Pro Gln Thr Gln Ser Pro Gly Gln Pro                325                 330                 335Ala Gln Pro Ala Pro Met Val Pro Leu His Gln Lys Gln Ser Arg Ile            340                 345                 350Thr Pro Ile Gln Lys Pro Arg Gly Leu Asp Pro Val Glu Ile Leu Gln        355                 360                 365Glu Arg Glu Tyr Arg Leu Gln Ala Arg Ile Ala His Arg Ile Gln Glu    370                 375                 380Leu Glu Asn Leu Pro Gly Ser Leu Ala Gly Asp Leu Arg Thr Lys Ala385                 390                 395                 400Thr Ile Glu Leu Lys Ala Leu Arg Leu Leu Asn Phe Gln Arg Gln Leu                405                 410                 415Arg Gln Glu Val Val Val Cys Met Arg Arg Asp Thr Ala Leu Glu Thr            420                 425                 430Ala Leu Asn Ala Lys Ala Tyr Lys Arg Ser Lys Arg Gln Ser Leu Arg        435                 440                 445Glu Ala Arg Ile Thr Glu Lys Leu Glu Lys Gln Gln Lys Ile Glu Gln    450                 455                 460Glu Arg Lys Arg Arg Gln Lys His Gln Glu Tyr Leu Asn Ser Ile Leu465                 470                 475                 480Gln His Ala Lys Asp Phe Lys Glu Tyr His Arg Ser Val Thr Gly Lys                485                 490                 495Ile Gln Lys Leu Thr Lys Ala Val Ala Thr Tyr His Ala Asn Thr Glu            500                 505                 510Arg Glu Gln Lys Lys Glu Asn Glu Arg Ile Glu Lys Glu Arg Met Arg        515                 520                 525Arg Leu Met Ala Glu Asp Glu Glu Gly Tyr Arg Lys Leu Ile Asp Gln    530                 535                 540Lys Lys Asp Lys Arg Leu Ala Tyr Leu Leu Gln Gln Thr Asp Glu Tyr545                 550                 555                 560Val Ala Asn Leu Thr Glu Leu Val Arg Gln His Lys Ala Ala Gln Val                565                 570                 575Ala Lys Glu Lys Lys Lys Lys Lys Lys Lys Lys Lys Ala Glu Asn Ala            580                 585                 590Glu Gly Gln Thr Pro Ala Ile Gly Pro Asp Gly Glu Pro Leu Asp Glu        595                 600                 605Thr Ser Gln Met Ser Asp Leu Pro Val Lys Val Ile His Val Glu Ser    610                 615                 620Gly Lys Ile Leu Thr Gly Thr Asp Ala Pro Lys Ala Gly Gln Leu Glu625                 630                 635                 640Ala Trp Leu Glu Met Asn Pro Gly Tyr Glu Val Ala Pro Arg Ser Asp                645                 650                 655Ser Glu Glu Ser Gly Ser Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu            660                 665                 670Gln Pro Gln Ala Ala Gln Pro Pro Thr Leu Pro Val Glu Glu Lys Lys        675                 680                 685Lys Ile Pro Asp Pro Asp Ser Asp Asp Val Ser Glu Val Asp Ala Arg    690                 695                 700His Ile Ile Glu Asn Ala Lys Gln Asp Val Asp Asp Glu Tyr Gly Val705                 710                 715                 720Ser Gln Ala Leu Ala Arg Gly Leu Gln Ser Tyr Tyr Ala Val Ala His                725                 730                 735Ala Val Thr Glu Arg Val Asp Lys Gln Ser Ala Leu Met Val Asn Gly            740                 745                 750Val Leu Lys Gln Tyr Gln Ile Lys Gly Leu Glu Trp Leu Val Ser Leu        755                 760                 765Tyr Asn Asn Asn Leu Asn Gly Ile Leu Ala Asp Glu Met Gly Leu Gly    770                 775                 780Lys Thr Ile Gln Thr Ile Ala Leu Ile Thr Tyr Leu Met Glu His Lys785                 790                 795                 800Arg Ile Asn Gly Pro Phe Leu Ile Ile Val Pro Leu Ser Thr Leu Ser                805                 810                 815Asn Trp Ala Tyr Glu Phe Asp Lys Trp Ala Pro Ser Val Val Lys Val            820                 825                 830Ser Tyr Lys Gly Ser Pro Ala Ala Arg Arg Ala Phe Val Pro Gln Leu        835                 840                 845Arg Ser Gly Lys Phe Asn Val Leu Leu Thr Thr Tyr Glu Tyr Ile Ile    850                 855                 860Lys Asp Lys His Ile Leu Ala Lys Ile Arg Trp Lys Tyr Met Ile Val865                 870                 875                 880Asp Glu Gly His Arg Met Lys Asn His His Cys Lys Leu Thr Gln Val                885                 890                 895Leu Asn Thr His Tyr Val Ala Pro Arg Arg Leu Leu Leu Thr Gly Thr            900                 905                 910Pro Leu Gln Asn Lys Leu Pro Glu Leu Trp Ala Leu Leu Asn Phe Leu        915                 920                 925Leu Pro Thr Ile Phe Lys Ser Cys Ser Thr Phe Glu Gln Trp Phe Asn    930                 935                 940Ala Pro Phe Ala Met Thr Gly Glu Lys Val Asp Leu Asn Glu Glu Glu945                 950                 955                 960Thr Ile Leu Ile Ile Arg Arg Leu His Lys Val Leu Arg Pro Phe Leu                965                 970                 975Leu Arg Arg Leu Lys Lys Glu Val Glu Ala Gln Leu Pro Glu Lys Val            980                 985                 990Glu Tyr Val Ile Lys Cys Asp Met  Ser Ala Leu Gln Arg  Val Leu Tyr        995                 1000                 1005Arg His  Met Gln Ala Lys Gly  Val Leu Leu Thr Asp  Gly Ser Glu    1010                 1015                 1020Lys Asp  Lys Lys Gly Lys Gly  Gly Thr Lys Thr Leu  Met Asn Thr    1025                 1030                 1035Ile Met  Gln Leu Arg Lys Ile  Cys Asn His Pro Tyr  Met Phe Gln    1040                 1045                 1050His Ile  Glu Glu Ser Phe Ser  Glu His Leu Gly Phe  Thr Gly Gly    1055                 1060                 1065Ile Val  Gln Gly Leu Asp Leu  Tyr Arg Ala Ser Gly  Lys Phe Glu    1070                 1075                 1080Leu Leu  Asp Arg Ile Leu Pro  Lys Leu Arg Ala Thr  Asn His Lys    1085                 1090                 1095Val Leu  Leu Phe Cys Gln Met  Thr Ser Leu Met Thr  Ile Met Glu    1100                 1105                 1110Asp Tyr  Phe Ala Tyr Arg Gly  Phe Lys Tyr Leu Arg  Leu Asp Gly    1115                 1120                 1125Thr Thr  Lys Ala Glu Asp Arg  Gly Met Leu Leu Lys  Thr Phe Asn    1130                 1135                 1140Glu Pro  Gly Ser Glu Tyr Phe  Ile Phe Leu Leu Ser  Thr Arg Ala    1145                 1150                 1155Gly Gly  Leu Gly Leu Asn Leu  Gln Ser Ala Asp Thr  Val Ile Ile    1160                 1165                 1170Phe Asp  Ser Asp Trp Asn Pro  His Gln Asp Leu Gln  Ala Gln Asp    1175                 1180                 1185Arg Ala  His Arg Ile Gly Gln  Gln Asn Glu Val Arg  Val Leu Arg    1190                 1195                 1200Leu Cys  Thr Val Asn Ser Val  Glu Glu Lys Ile Leu  Ala Ala Ala    1205                 1210                 1215Lys Tyr  Lys Leu Asn Val Asp  Gln Lys Val Ile Gln  Ala Gly Met    1220                 1225                 1230Phe Asp  Gln Lys Ser Ser Ser  His Glu Arg Arg Ala  Phe Leu Gln    1235                 1240                 1245Ala Ile  Leu Glu His Glu Glu  Gln Asp Glu Ser Arg  His Cys Ser    1250                 1255                 1260Thr Gly  Ser Gly Ser Ala Ser  Phe Ala His Thr Ala  Pro Pro Pro    1265                 1270                 1275Ala Gly  Val Asn Pro Asp Leu  Glu Glu Pro Pro Leu  Lys Glu Glu    1280                 1285                 1290Asp Glu  Val Pro Asp Asp Glu  Thr Val Asn Gln Met  Ile Ala Arg    1295                 1300                 1305His Glu  Glu Glu Phe Asp Leu  Phe Met Arg Met Asp  Leu Asp Arg    1310                 1315                 1320Arg Arg  Glu Glu Ala Arg Asn  Pro Lys Arg Lys Pro  Arg Leu Met    1325                 1330                 1335Glu Glu  Asp Glu Leu Pro Ser  Trp Ile Ile Lys Asp  Asp Ala Glu    1340                 1345                 1350Val Glu  Arg Leu Thr Cys Glu  Glu Glu Glu Glu Lys  Met Phe Gly    1355                 1360                 1365Arg Gly  Ser Arg His Arg Lys  Glu Val Asp Tyr Ser  Asp Ser Leu    1370                 1375                 1380Thr Glu  Lys Gln Trp Leu Lys  Lys Ile Thr Gly Lys  Asp Ile His    1385                 1390                 1395Asp Thr  Ala Ser Ser Val Ala  Arg Gly Leu Gln Phe  Gln Arg Gly    1400                 1405                 1410Leu Gln  Phe Cys Thr Arg Ala  Ser Lys Ala Ile Glu  Glu Gly Thr    1415                 1420                 1425Leu Glu  Glu Ile Glu Glu Glu  Val Arg Gln Lys Lys  Ser Ser Arg    1430                 1435                 1440Lys Arg  Lys Arg Asp Ser Asp  Ala Gly Ser Ser Thr  Pro Thr Thr    1445                 1450                 1455Ser Thr  Arg Ser Arg Asp Lys  Asp Asp Glu Ser Lys  Lys Gln Lys    1460                 1465                 1470Lys Arg  Gly Arg Pro Pro Ala  Glu Lys Leu Ser Pro  Asn Pro Pro    1475                 1480                 1485Asn Leu  Thr Lys Lys Met Lys  Lys Ile Val Asp Ala  Val Ile Lys    1490                 1495                 1500Tyr Lys  Asp Ser Ser Ser Gly  Arg Gln Leu Ser Glu  Val Phe Ile    1505                 1510                 1515Gln Leu  Pro Ser Arg Lys Glu  Leu Pro Glu Tyr Tyr  Glu Leu Ile    1520                 1525                 1530Arg Lys  Pro Val Asp Phe Lys  Lys Ile Lys Glu Arg  Ile Arg Asn    1535                 1540                 1545His Lys  Tyr Arg Ser Leu Asn  Asp Leu Glu Lys Asp  Val Met Leu    1550                 1555                 1560Leu Cys  Gln Asn Ala Gln Thr  Phe Asn Leu Glu Gly  Ser Leu Ile    1565                 1570                 1575Tyr Glu  Asp Ser Ile Val Leu  Gln Ser Val Phe Thr  Ser Val Arg    1580                 1585                 1590Gln Lys  Ile Glu Lys Glu Asp  Asp Ser Glu Gly Glu  Glu Ser Glu    1595                 1600                 1605Glu Glu  Glu Glu Gly Glu Glu  Glu Gly Ser Glu Ser  Glu Ser Arg    1610                 1615                 1620Ser Val  Lys Val Lys Ile Lys  Leu Gly Arg Lys Glu  Lys Ala Gln    1625                 1630                 1635Asp Arg  Leu Lys Gly Gly Arg  Arg Arg Pro Ser Arg  Gly Ser Arg    1640                 1645                 1650Ala Lys  Pro Val Val Ser Asp  Asp Asp Ser Glu Glu  Glu Gln Glu    1655                 1660                 1665Glu Asp  Arg Ser Gly Ser Gly  Ser Glu Glu Asp    1670                 1675</s400><s200><s210>16</s210><s211>1647</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 16Met Ser Thr Pro Asp Pro Pro Leu Gly Gly Thr Pro Arg Pro Gly Pro1               5                   10                  15Ser Pro Gly Pro Gly Pro Ser Pro Gly Ala Met Leu Gly Pro Ser Pro            20                  25                  30Gly Pro Ser Pro Gly Ser Ala His Ser Met Met Gly Pro Ser Pro Gly        35                  40                  45Pro Pro Ser Ala Gly His Pro Ile Pro Thr Gln Gly Pro Gly Gly Tyr    50                  55                  60Pro Gln Asp Asn Met His Gln Met His Lys Pro Met Glu Ser Met His65                  70                  75                  80Glu Lys Gly Met Ser Asp Asp Pro Arg Tyr Asn Gln Met Lys Gly Met                85                  90                  95Gly Met Arg Ser Gly Gly His Ala Gly Met Gly Pro Pro Pro Ser Pro            100                 105                 110Met Asp Gln His Ser Gln Gly Tyr Pro Ser Pro Leu Gly Gly Ser Glu        115                 120                 125His Ala Ser Ser Pro Val Pro Ala Ser Gly Pro Ser Ser Gly Pro Gln    130                 135                 140Met Ser Ser Gly Pro Gly Gly Ala Pro Leu Asp Gly Ala Asp Pro Gln145                 150                 155                 160Ala Leu Gly Gln Gln Asn Arg Gly Pro Thr Pro Phe Asn Gln Asn Gln                165                 170                 175Leu His Gln Leu Arg Ala Gln Ile Met Ala Tyr Lys Met Leu Ala Arg            180                 185                 190Gly Gln Pro Leu Pro Asp His Leu Gln Met Ala Val Gln Gly Lys Arg        195                 200                 205Pro Met Pro Gly Met Gln Gln Gln Met Pro Thr Leu Pro Pro Pro Ser    210                 215                 220Val Ser Ala Thr Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro225                 230                 235                 240Gly Pro Gly Pro Ala Pro Pro Asn Tyr Ser Arg Pro His Gly Met Gly                245                 250                 255Gly Pro Asn Met Pro Pro Pro Gly Pro Ser Gly Val Pro Pro Gly Met            260                 265                 270Pro Gly Gln Pro Pro Gly Gly Pro Pro Lys Pro Trp Pro Glu Gly Pro        275                 280                 285Met Ala Asn Ala Ala Ala Pro Thr Ser Thr Pro Gln Lys Leu Ile Pro    290                 295                 300Pro Gln Pro Thr Gly Arg Pro Ser Pro Ala Pro Pro Ala Val Pro Pro305                 310                 315                 320Ala Ala Ser Pro Val Met Pro Pro Gln Thr Gln Ser Pro Gly Gln Pro                325                 330                 335Ala Gln Pro Ala Pro Met Val Pro Leu His Gln Lys Gln Ser Arg Ile            340                 345                 350Thr Pro Ile Gln Lys Pro Arg Gly Leu Asp Pro Val Glu Ile Leu Gln        355                 360                 365Glu Arg Glu Tyr Arg Leu Gln Ala Arg Ile Ala His Arg Ile Gln Glu    370                 375                 380Leu Glu Asn Leu Pro Gly Ser Leu Ala Gly Asp Leu Arg Thr Lys Ala385                 390                 395                 400Thr Ile Glu Leu Lys Ala Leu Arg Leu Leu Asn Phe Gln Arg Gln Leu                405                 410                 415Arg Gln Glu Val Val Val Cys Met Arg Arg Asp Thr Ala Leu Glu Thr            420                 425                 430Ala Leu Asn Ala Lys Ala Tyr Lys Arg Ser Lys Arg Gln Ser Leu Arg        435                 440                 445Glu Ala Arg Ile Thr Glu Lys Leu Glu Lys Gln Gln Lys Ile Glu Gln    450                 455                 460Glu Arg Lys Arg Arg Gln Lys His Gln Glu Tyr Leu Asn Ser Ile Leu465                 470                 475                 480Gln His Ala Lys Asp Phe Lys Glu Tyr His Arg Ser Val Thr Gly Lys                485                 490                 495Ile Gln Lys Leu Thr Lys Ala Val Ala Thr Tyr His Ala Asn Thr Glu            500                 505                 510Arg Glu Gln Lys Lys Glu Asn Glu Arg Ile Glu Lys Glu Arg Met Arg        515                 520                 525Arg Leu Met Ala Glu Asp Glu Glu Gly Tyr Arg Lys Leu Ile Asp Gln    530                 535                 540Lys Lys Asp Lys Arg Leu Ala Tyr Leu Leu Gln Gln Thr Asp Glu Tyr545                 550                 555                 560Val Ala Asn Leu Thr Glu Leu Val Arg Gln His Lys Ala Ala Gln Val                565                 570                 575Ala Lys Glu Lys Lys Lys Lys Lys Lys Lys Lys Lys Ala Glu Asn Ala            580                 585                 590Glu Gly Gln Thr Pro Ala Ile Gly Pro Asp Gly Glu Pro Leu Asp Glu        595                 600                 605Thr Ser Gln Met Ser Asp Leu Pro Val Lys Val Ile His Val Glu Ser    610                 615                 620Gly Lys Ile Leu Thr Gly Thr Asp Ala Pro Lys Ala Gly Gln Leu Glu625                 630                 635                 640Ala Trp Leu Glu Met Asn Pro Gly Tyr Glu Val Ala Pro Arg Ser Asp                645                 650                 655Ser Glu Glu Ser Gly Ser Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu            660                 665                 670Gln Pro Gln Ala Ala Gln Pro Pro Thr Leu Pro Val Glu Glu Lys Lys        675                 680                 685Lys Ile Pro Asp Pro Asp Ser Asp Asp Val Ser Glu Val Asp Ala Arg    690                 695                 700His Ile Ile Glu Asn Ala Lys Gln Asp Val Asp Asp Glu Tyr Gly Val705                 710                 715                 720Ser Gln Ala Leu Ala Arg Gly Leu Gln Ser Tyr Tyr Ala Val Ala His                725                 730                 735Ala Val Thr Glu Arg Val Asp Lys Gln Ser Ala Leu Met Val Asn Gly            740                 745                 750Val Leu Lys Gln Tyr Gln Ile Lys Gly Leu Glu Trp Leu Val Ser Leu        755                 760                 765Tyr Asn Asn Asn Leu Asn Gly Ile Leu Ala Asp Glu Met Gly Leu Gly    770                 775                 780Lys Thr Ile Gln Thr Ile Ala Leu Ile Thr Tyr Leu Met Glu His Lys785                 790                 795                 800Arg Ile Asn Gly Pro Phe Leu Ile Ile Val Pro Leu Ser Thr Leu Ser                805                 810                 815Asn Trp Ala Tyr Glu Phe Asp Lys Trp Ala Pro Ser Val Val Lys Val            820                 825                 830Ser Tyr Lys Gly Ser Pro Ala Ala Arg Arg Ala Phe Val Pro Gln Leu        835                 840                 845Arg Ser Gly Lys Phe Asn Val Leu Leu Thr Thr Tyr Glu Tyr Ile Ile    850                 855                 860Lys Asp Lys His Ile Leu Ala Lys Ile Arg Trp Lys Tyr Met Ile Val865                 870                 875                 880Asp Glu Gly His Arg Met Lys Asn His His Cys Lys Leu Thr Gln Val                885                 890                 895Leu Asn Thr His Tyr Val Ala Pro Arg Arg Leu Leu Leu Thr Gly Thr            900                 905                 910Pro Leu Gln Asn Lys Leu Pro Glu Leu Trp Ala Leu Leu Asn Phe Leu        915                 920                 925Leu Pro Thr Ile Phe Lys Ser Cys Ser Thr Phe Glu Gln Trp Phe Asn    930                 935                 940Ala Pro Phe Ala Met Thr Gly Glu Lys Val Asp Leu Asn Glu Glu Glu945                 950                 955                 960Thr Ile Leu Ile Ile Arg Arg Leu His Lys Val Leu Arg Pro Phe Leu                965                 970                 975Leu Arg Arg Leu Lys Lys Glu Val Glu Ala Gln Leu Pro Glu Lys Val            980                 985                 990Glu Tyr Val Ile Lys Cys Asp Met  Ser Ala Leu Gln Arg  Val Leu Tyr        995                 1000                 1005Arg His  Met Gln Ala Lys Gly  Val Leu Leu Thr Asp  Gly Ser Glu    1010                 1015                 1020Lys Asp  Lys Lys Gly Lys Gly  Gly Thr Lys Thr Leu  Met Asn Thr    1025                 1030                 1035Ile Met  Gln Leu Arg Lys Ile  Cys Asn His Pro Tyr  Met Phe Gln    1040                 1045                 1050His Ile  Glu Glu Ser Phe Ser  Glu His Leu Gly Phe  Thr Gly Gly    1055                 1060                 1065Ile Val  Gln Gly Leu Asp Leu  Tyr Arg Ala Ser Gly  Lys Phe Glu    1070                 1075                 1080Leu Leu  Asp Arg Ile Leu Pro  Lys Leu Arg Ala Thr  Asn His Lys    1085                 1090                 1095Val Leu  Leu Phe Cys Gln Met  Thr Ser Leu Met Thr  Ile Met Glu    1100                 1105                 1110Asp Tyr  Phe Ala Tyr Arg Gly  Phe Lys Tyr Leu Arg  Leu Asp Gly    1115                 1120                 1125Thr Thr  Lys Ala Glu Asp Arg  Gly Met Leu Leu Lys  Thr Phe Asn    1130                 1135                 1140Glu Pro  Gly Ser Glu Tyr Phe  Ile Phe Leu Leu Ser  Thr Arg Ala    1145                 1150                 1155Gly Gly  Leu Gly Leu Asn Leu  Gln Ser Ala Asp Thr  Val Ile Ile    1160                 1165                 1170Phe Asp  Ser Asp Trp Asn Pro  His Gln Asp Leu Gln  Ala Gln Asp    1175                 1180                 1185Arg Ala  His Arg Ile Gly Gln  Gln Asn Glu Val Arg  Val Leu Arg    1190                 1195                 1200Leu Cys  Thr Val Asn Ser Val  Glu Glu Lys Ile Leu  Ala Ala Ala    1205                 1210                 1215Lys Tyr  Lys Leu Asn Val Asp  Gln Lys Val Ile Gln  Ala Gly Met    1220                 1225                 1230Phe Asp  Gln Lys Ser Ser Ser  His Glu Arg Arg Ala  Phe Leu Gln    1235                 1240                 1245Ala Ile  Leu Glu His Glu Glu  Gln Asp Glu Ser Arg  His Cys Ser    1250                 1255                 1260Thr Gly  Ser Gly Ser Ala Ser  Phe Ala His Thr Ala  Pro Pro Pro    1265                 1270                 1275Ala Gly  Val Asn Pro Asp Leu  Glu Glu Pro Pro Leu  Lys Glu Glu    1280                 1285                 1290Asp Glu  Val Pro Asp Asp Glu  Thr Val Asn Gln Met  Ile Ala Arg    1295                 1300                 1305His Glu  Glu Glu Phe Asp Leu  Phe Met Arg Met Asp  Leu Asp Arg    1310                 1315                 1320Arg Arg  Glu Glu Ala Arg Asn  Pro Lys Arg Lys Pro  Arg Leu Met    1325                 1330                 1335Glu Glu  Asp Glu Leu Pro Ser  Trp Ile Ile Lys Asp  Asp Ala Glu    1340                 1345                 1350Val Glu  Arg Leu Thr Cys Glu  Glu Glu Glu Glu Lys  Met Phe Gly    1355                 1360                 1365Arg Gly  Ser Arg His Arg Lys  Glu Val Asp Tyr Ser  Asp Ser Leu    1370                 1375                 1380Thr Glu  Lys Gln Trp Leu Lys  Ala Ile Glu Glu Gly  Thr Leu Glu    1385                 1390                 1395Glu Ile  Glu Glu Glu Val Arg  Gln Lys Lys Ser Ser  Arg Lys Arg    1400                 1405                 1410Lys Arg  Asp Ser Asp Ala Gly  Ser Ser Thr Pro Thr  Thr Ser Thr    1415                 1420                 1425Arg Ser  Arg Asp Lys Asp Asp  Glu Ser Lys Lys Gln  Lys Lys Arg    1430                 1435                 1440Gly Arg  Pro Pro Ala Glu Lys  Leu Ser Pro Asn Pro  Pro Asn Leu    1445                 1450                 1455Thr Lys  Lys Met Lys Lys Ile  Val Asp Ala Val Ile  Lys Tyr Lys    1460                 1465                 1470Asp Ser  Ser Ser Gly Arg Gln  Leu Ser Glu Val Phe  Ile Gln Leu    1475                 1480                 1485Pro Ser  Arg Lys Glu Leu Pro  Glu Tyr Tyr Glu Leu  Ile Arg Lys    1490                 1495                 1500Pro Val  Asp Phe Lys Lys Ile  Lys Glu Arg Ile Arg  Asn His Lys    1505                 1510                 1515Tyr Arg  Ser Leu Asn Asp Leu  Glu Lys Asp Val Met  Leu Leu Cys    1520                 1525                 1530Gln Asn  Ala Gln Thr Phe Asn  Leu Glu Gly Ser Leu  Ile Tyr Glu    1535                 1540                 1545Asp Ser  Ile Val Leu Gln Ser  Val Phe Thr Ser Val  Arg Gln Lys    1550                 1555                 1560Ile Glu  Lys Glu Asp Asp Ser  Glu Gly Glu Glu Ser  Glu Glu Glu    1565                 1570                 1575Glu Glu  Gly Glu Glu Glu Gly  Ser Glu Ser Glu Ser  Arg Ser Val    1580                 1585                 1590Lys Val  Lys Ile Lys Leu Gly  Arg Lys Glu Lys Ala  Gln Asp Arg    1595                 1600                 1605Leu Lys  Gly Gly Arg Arg Arg  Pro Ser Arg Gly Ser  Arg Ala Lys    1610                 1615                 1620Pro Val  Val Ser Asp Asp Asp  Ser Glu Glu Glu Gln  Glu Glu Asp    1625                 1630                 1635Arg Ser  Gly Ser Gly Ser Glu  Glu Asp    1640                 1645</s400><s200><s210>17</s210><s211>1617</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 17Met Ser Thr Pro Asp Pro Pro Leu Gly Gly Thr Pro Arg Pro Gly Pro1               5                   10                  15Ser Pro Gly Pro Gly Pro Ser Pro Gly Ala Met Leu Gly Pro Ser Pro            20                  25                  30Gly Pro Ser Pro Gly Ser Ala His Ser Met Met Gly Pro Ser Pro Gly        35                  40                  45Pro Pro Ser Ala Gly His Pro Ile Pro Thr Gln Gly Pro Gly Gly Tyr    50                  55                  60Pro Gln Asp Asn Met His Gln Met His Lys Pro Met Glu Ser Met His65                  70                  75                  80Glu Lys Gly Met Ser Asp Asp Pro Arg Tyr Asn Gln Met Lys Gly Met                85                  90                  95Gly Met Arg Ser Gly Gly His Ala Gly Met Gly Pro Pro Pro Ser Pro            100                 105                 110Met Asp Gln His Ser Gln Gly Tyr Pro Ser Pro Leu Gly Gly Ser Glu        115                 120                 125His Ala Ser Ser Pro Val Pro Ala Ser Gly Pro Ser Ser Gly Pro Gln    130                 135                 140Met Ser Ser Gly Pro Gly Gly Ala Pro Leu Asp Gly Ala Asp Pro Gln145                 150                 155                 160Ala Leu Gly Gln Gln Asn Arg Gly Pro Thr Pro Phe Asn Gln Asn Gln                165                 170                 175Leu His Gln Leu Arg Ala Gln Ile Met Ala Tyr Lys Met Leu Ala Arg            180                 185                 190Gly Gln Pro Leu Pro Asp His Leu Gln Met Ala Val Gln Gly Lys Arg        195                 200                 205Pro Met Pro Gly Met Gln Gln Gln Met Pro Thr Leu Pro Pro Pro Ser    210                 215                 220Val Ser Ala Thr Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro225                 230                 235                 240Gly Pro Gly Pro Ala Pro Pro Asn Tyr Ser Arg Pro His Gly Met Gly                245                 250                 255Gly Pro Asn Met Pro Pro Pro Gly Pro Ser Gly Val Pro Pro Gly Met            260                 265                 270Pro Gly Gln Pro Pro Gly Gly Pro Pro Lys Pro Trp Pro Glu Gly Pro        275                 280                 285Met Ala Asn Ala Ala Ala Pro Thr Ser Thr Pro Gln Lys Leu Ile Pro    290                 295                 300Pro Gln Pro Thr Gly Arg Pro Ser Pro Ala Pro Pro Ala Val Pro Pro305                 310                 315                 320Ala Ala Ser Pro Val Met Pro Pro Gln Thr Gln Ser Pro Gly Gln Pro                325                 330                 335Ala Gln Pro Ala Pro Met Val Pro Leu His Gln Lys Gln Ser Arg Ile            340                 345                 350Thr Pro Ile Gln Lys Pro Arg Gly Leu Asp Pro Val Glu Ile Leu Gln        355                 360                 365Glu Arg Glu Tyr Arg Leu Gln Ala Arg Ile Ala His Arg Ile Gln Glu    370                 375                 380Leu Glu Asn Leu Pro Gly Ser Leu Ala Gly Asp Leu Arg Thr Lys Ala385                 390                 395                 400Thr Ile Glu Leu Lys Ala Leu Arg Leu Leu Asn Phe Gln Arg Gln Leu                405                 410                 415Arg Gln Glu Val Val Val Cys Met Arg Arg Asp Thr Ala Leu Glu Thr            420                 425                 430Ala Leu Asn Ala Lys Ala Tyr Lys Arg Ser Lys Arg Gln Ser Leu Arg        435                 440                 445Glu Ala Arg Ile Thr Glu Lys Leu Glu Lys Gln Gln Lys Ile Glu Gln    450                 455                 460Glu Arg Lys Arg Arg Gln Lys His Gln Glu Tyr Leu Asn Ser Ile Leu465                 470                 475                 480Gln His Ala Lys Asp Phe Lys Glu Tyr His Arg Ser Val Thr Gly Lys                485                 490                 495Ile Gln Lys Leu Thr Lys Ala Val Ala Thr Tyr His Ala Asn Thr Glu            500                 505                 510Arg Glu Gln Lys Lys Glu Asn Glu Arg Ile Glu Lys Glu Arg Met Arg        515                 520                 525Arg Leu Met Ala Glu Asp Glu Glu Gly Tyr Arg Lys Leu Ile Asp Gln    530                 535                 540Lys Lys Asp Lys Arg Leu Ala Tyr Leu Leu Gln Gln Thr Asp Glu Tyr545                 550                 555                 560Val Ala Asn Leu Thr Glu Leu Val Arg Gln His Lys Ala Ala Gln Val                565                 570                 575Ala Lys Glu Lys Lys Lys Lys Lys Lys Lys Lys Lys Ala Glu Asn Ala            580                 585                 590Glu Gly Gln Thr Pro Ala Ile Gly Pro Asp Gly Glu Pro Leu Asp Glu        595                 600                 605Thr Ser Gln Met Ser Asp Leu Pro Val Lys Val Ile His Val Glu Ser    610                 615                 620Gly Lys Ile Leu Thr Gly Thr Asp Ala Pro Lys Ala Gly Gln Leu Glu625                 630                 635                 640Ala Trp Leu Glu Met Asn Pro Gly Tyr Glu Val Ala Pro Arg Ser Asp                645                 650                 655Ser Glu Glu Ser Gly Ser Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu            660                 665                 670Gln Pro Gln Ala Ala Gln Pro Pro Thr Leu Pro Val Glu Glu Lys Lys        675                 680                 685Lys Ile Pro Asp Pro Asp Ser Asp Asp Val Ser Glu Val Asp Ala Arg    690                 695                 700His Ile Ile Glu Asn Ala Lys Gln Asp Val Asp Asp Glu Tyr Gly Val705                 710                 715                 720Ser Gln Ala Leu Ala Arg Gly Leu Gln Ser Tyr Tyr Ala Val Ala His                725                 730                 735Ala Val Thr Glu Arg Val Asp Lys Gln Ser Ala Leu Met Val Asn Gly            740                 745                 750Val Leu Lys Gln Tyr Gln Ile Lys Gly Leu Glu Trp Leu Val Ser Leu        755                 760                 765Tyr Asn Asn Asn Leu Asn Gly Ile Leu Ala Asp Glu Met Gly Leu Gly    770                 775                 780Lys Thr Ile Gln Thr Ile Ala Leu Ile Thr Tyr Leu Met Glu His Lys785                 790                 795                 800Arg Ile Asn Gly Pro Phe Leu Ile Ile Val Pro Leu Ser Thr Leu Ser                805                 810                 815Asn Trp Ala Tyr Glu Phe Asp Lys Trp Ala Pro Ser Val Val Lys Val            820                 825                 830Ser Tyr Lys Gly Ser Pro Ala Ala Arg Arg Ala Phe Val Pro Gln Leu        835                 840                 845Arg Ser Gly Lys Phe Asn Val Leu Leu Thr Thr Tyr Glu Tyr Ile Ile    850                 855                 860Lys Asp Lys His Ile Leu Ala Lys Ile Arg Trp Lys Tyr Met Ile Val865                 870                 875                 880Asp Glu Gly His Arg Met Lys Asn His His Cys Lys Leu Thr Gln Val                885                 890                 895Leu Asn Thr His Tyr Val Ala Pro Arg Arg Leu Leu Leu Thr Gly Thr            900                 905                 910Pro Leu Gln Asn Lys Leu Pro Glu Leu Trp Ala Leu Leu Asn Phe Leu        915                 920                 925Leu Pro Thr Ile Phe Lys Ser Cys Ser Thr Phe Glu Gln Trp Phe Asn    930                 935                 940Ala Pro Phe Ala Met Thr Gly Glu Lys Val Asp Leu Asn Glu Glu Glu945                 950                 955                 960Thr Ile Leu Ile Ile Arg Arg Leu His Lys Val Leu Arg Pro Phe Leu                965                 970                 975Leu Arg Arg Leu Lys Lys Glu Val Glu Ala Gln Leu Pro Glu Lys Val            980                 985                 990Glu Tyr Val Ile Lys Cys Asp Met  Ser Ala Leu Gln Arg  Val Leu Tyr        995                 1000                 1005Arg His  Met Gln Ala Lys Gly  Val Leu Leu Thr Asp  Gly Ser Glu    1010                 1015                 1020Lys Asp  Lys Lys Gly Lys Gly  Gly Thr Lys Thr Leu  Met Asn Thr    1025                 1030                 1035Ile Met  Gln Leu Arg Lys Ile  Cys Asn His Pro Tyr  Met Phe Gln    1040                 1045                 1050His Ile  Glu Glu Ser Phe Ser  Glu His Leu Gly Phe  Thr Gly Gly    1055                 1060                 1065Ile Val  Gln Gly Leu Asp Leu  Tyr Arg Ala Ser Gly  Lys Phe Glu    1070                 1075                 1080Leu Leu  Asp Arg Ile Leu Pro  Lys Leu Arg Ala Thr  Asn His Lys    1085                 1090                 1095Val Leu  Leu Phe Cys Gln Met  Thr Ser Leu Met Thr  Ile Met Glu    1100                 1105                 1110Asp Tyr  Phe Ala Tyr Arg Gly  Phe Lys Tyr Leu Arg  Leu Asp Gly    1115                 1120                 1125Thr Thr  Lys Ala Glu Asp Arg  Gly Met Leu Leu Lys  Thr Phe Asn    1130                 1135                 1140Glu Pro  Gly Ser Glu Tyr Phe  Ile Phe Leu Leu Ser  Thr Arg Ala    1145                 1150                 1155Gly Gly  Leu Gly Leu Asn Leu  Gln Ser Ala Asp Thr  Val Ile Ile    1160                 1165                 1170Phe Asp  Ser Asp Trp Asn Pro  His Gln Asp Leu Gln  Ala Gln Asp    1175                 1180                 1185Arg Ala  His Arg Ile Gly Gln  Gln Asn Glu Val Arg  Val Leu Arg    1190                 1195                 1200Leu Cys  Thr Val Asn Ser Val  Glu Glu Lys Ile Leu  Ala Ala Ala    1205                 1210                 1215Lys Tyr  Lys Leu Asn Val Asp  Gln Lys Val Ile Gln  Ala Gly Met    1220                 1225                 1230Phe Asp  Gln Lys Ser Ser Ser  His Glu Arg Arg Ala  Phe Leu Gln    1235                 1240                 1245Ala Ile  Leu Glu His Glu Glu  Gln Asp Glu Glu Glu  Asp Glu Val    1250                 1255                 1260Pro Asp  Asp Glu Thr Val Asn  Gln Met Ile Ala Arg  His Glu Glu    1265                 1270                 1275Glu Phe  Asp Leu Phe Met Arg  Met Asp Leu Asp Arg  Arg Arg Glu    1280                 1285                 1290Glu Ala  Arg Asn Pro Lys Arg  Lys Pro Arg Leu Met  Glu Glu Asp    1295                 1300                 1305Glu Leu  Pro Ser Trp Ile Ile  Lys Asp Asp Ala Glu  Val Glu Arg    1310                 1315                 1320Leu Thr  Cys Glu Glu Glu Glu  Glu Lys Met Phe Gly  Arg Gly Ser    1325                 1330                 1335Arg His  Arg Lys Glu Val Asp  Tyr Ser Asp Ser Leu  Thr Glu Lys    1340                 1345                 1350Gln Trp  Leu Lys Thr Leu Lys  Ala Ile Glu Glu Gly  Thr Leu Glu    1355                 1360                 1365Glu Ile  Glu Glu Glu Val Arg  Gln Lys Lys Ser Ser  Arg Lys Arg    1370                 1375                 1380Lys Arg  Asp Ser Asp Ala Gly  Ser Ser Thr Pro Thr  Thr Ser Thr    1385                 1390                 1395Arg Ser  Arg Asp Lys Asp Asp  Glu Ser Lys Lys Gln  Lys Lys Arg    1400                 1405                 1410Gly Arg  Pro Pro Ala Glu Lys  Leu Ser Pro Asn Pro  Pro Asn Leu    1415                 1420                 1425Thr Lys  Lys Met Lys Lys Ile  Val Asp Ala Val Ile  Lys Tyr Lys    1430                 1435                 1440Asp Ser  Ser Ser Gly Arg Gln  Leu Ser Glu Val Phe  Ile Gln Leu    1445                 1450                 1455Pro Ser  Arg Lys Glu Leu Pro  Glu Tyr Tyr Glu Leu  Ile Arg Lys    1460                 1465                 1470Pro Val  Asp Phe Lys Lys Ile  Lys Glu Arg Ile Arg  Asn His Lys    1475                 1480                 1485Tyr Arg  Ser Leu Asn Asp Leu  Glu Lys Asp Val Met  Leu Leu Cys    1490                 1495                 1500Gln Asn  Ala Gln Thr Phe Asn  Leu Glu Gly Ser Leu  Ile Tyr Glu    1505                 1510                 1515Asp Ser  Ile Val Leu Gln Ser  Val Phe Thr Ser Val  Arg Gln Lys    1520                 1525                 1530Ile Glu  Lys Glu Asp Asp Ser  Glu Gly Glu Glu Ser  Glu Glu Glu    1535                 1540                 1545Glu Glu  Gly Glu Glu Glu Gly  Ser Glu Ser Glu Ser  Arg Ser Val    1550                 1555                 1560Lys Val  Lys Ile Lys Leu Gly  Arg Lys Glu Lys Ala  Gln Asp Arg    1565                 1570                 1575Leu Lys  Gly Gly Arg Arg Arg  Pro Ser Arg Gly Ser  Arg Ala Lys    1580                 1585                 1590Pro Val  Val Ser Asp Asp Asp  Ser Glu Glu Glu Gln  Glu Glu Asp    1595                 1600                 1605Arg Ser  Gly Ser Gly Ser Glu  Glu Asp    1610                 1615</s400><s200><s210>18</s210><s211>1616</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 18Met Ser Thr Pro Asp Pro Pro Leu Gly Gly Thr Pro Arg Pro Gly Pro1               5                   10                  15Ser Pro Gly Pro Gly Pro Ser Pro Gly Ala Met Leu Gly Pro Ser Pro            20                  25                  30Gly Pro Ser Pro Gly Ser Ala His Ser Met Met Gly Pro Ser Pro Gly        35                  40                  45Pro Pro Ser Ala Gly His Pro Ile Pro Thr Gln Gly Pro Gly Gly Tyr    50                  55                  60Pro Gln Asp Asn Met His Gln Met His Lys Pro Met Glu Ser Met His65                  70                  75                  80Glu Lys Gly Met Ser Asp Asp Pro Arg Tyr Asn Gln Met Lys Gly Met                85                  90                  95Gly Met Arg Ser Gly Gly His Ala Gly Met Gly Pro Pro Pro Ser Pro            100                 105                 110Met Asp Gln His Ser Gln Gly Tyr Pro Ser Pro Leu Gly Gly Ser Glu        115                 120                 125His Ala Ser Ser Pro Val Pro Ala Ser Gly Pro Ser Ser Gly Pro Gln    130                 135                 140Met Ser Ser Gly Pro Gly Gly Ala Pro Leu Asp Gly Ala Asp Pro Gln145                 150                 155                 160Ala Leu Gly Gln Gln Asn Arg Gly Pro Thr Pro Phe Asn Gln Asn Gln                165                 170                 175Leu His Gln Leu Arg Ala Gln Ile Met Ala Tyr Lys Met Leu Ala Arg            180                 185                 190Gly Gln Pro Leu Pro Asp His Leu Gln Met Ala Val Gln Gly Lys Arg        195                 200                 205Pro Met Pro Gly Met Gln Gln Gln Met Pro Thr Leu Pro Pro Pro Ser    210                 215                 220Val Ser Ala Thr Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro225                 230                 235                 240Gly Pro Gly Pro Ala Pro Pro Asn Tyr Ser Arg Pro His Gly Met Gly                245                 250                 255Gly Pro Asn Met Pro Pro Pro Gly Pro Ser Gly Val Pro Pro Gly Met            260                 265                 270Pro Gly Gln Pro Pro Gly Gly Pro Pro Lys Pro Trp Pro Glu Gly Pro        275                 280                 285Met Ala Asn Ala Ala Ala Pro Thr Ser Thr Pro Gln Lys Leu Ile Pro    290                 295                 300Pro Gln Pro Thr Gly Arg Pro Ser Pro Ala Pro Pro Ala Val Pro Pro305                 310                 315                 320Ala Ala Ser Pro Val Met Pro Pro Gln Thr Gln Ser Pro Gly Gln Pro                325                 330                 335Ala Gln Pro Ala Pro Met Val Pro Leu His Gln Lys Gln Ser Arg Ile            340                 345                 350Thr Pro Ile Gln Lys Pro Arg Gly Leu Asp Pro Val Glu Ile Leu Gln        355                 360                 365Glu Arg Glu Tyr Arg Leu Gln Ala Arg Ile Ala His Arg Ile Gln Glu    370                 375                 380Leu Glu Asn Leu Pro Gly Ser Leu Ala Gly Asp Leu Arg Thr Lys Ala385                 390                 395                 400Thr Ile Glu Leu Lys Ala Leu Arg Leu Leu Asn Phe Gln Arg Gln Leu                405                 410                 415Arg Gln Glu Val Val Val Cys Met Arg Arg Asp Thr Ala Leu Glu Thr            420                 425                 430Ala Leu Asn Ala Lys Ala Tyr Lys Arg Ser Lys Arg Gln Ser Leu Arg        435                 440                 445Glu Ala Arg Ile Thr Glu Lys Leu Glu Lys Gln Gln Lys Ile Glu Gln    450                 455                 460Glu Arg Lys Arg Arg Gln Lys His Gln Glu Tyr Leu Asn Ser Ile Leu465                 470                 475                 480Gln His Ala Lys Asp Phe Lys Glu Tyr His Arg Ser Val Thr Gly Lys                485                 490                 495Ile Gln Lys Leu Thr Lys Ala Val Ala Thr Tyr His Ala Asn Thr Glu            500                 505                 510Arg Glu Gln Lys Lys Glu Asn Glu Arg Ile Glu Lys Glu Arg Met Arg        515                 520                 525Arg Leu Met Ala Glu Asp Glu Glu Gly Tyr Arg Lys Leu Ile Asp Gln    530                 535                 540Lys Lys Asp Lys Arg Leu Ala Tyr Leu Leu Gln Gln Thr Asp Glu Tyr545                 550                 555                 560Val Ala Asn Leu Thr Glu Leu Val Arg Gln His Lys Ala Ala Gln Val                565                 570                 575Ala Lys Glu Lys Lys Lys Lys Lys Lys Lys Lys Lys Ala Glu Asn Ala            580                 585                 590Glu Gly Gln Thr Pro Ala Ile Gly Pro Asp Gly Glu Pro Leu Asp Glu        595                 600                 605Thr Ser Gln Met Ser Asp Leu Pro Val Lys Val Ile His Val Glu Ser    610                 615                 620Gly Lys Ile Leu Thr Gly Thr Asp Ala Pro Lys Ala Gly Gln Leu Glu625                 630                 635                 640Ala Trp Leu Glu Met Asn Pro Gly Tyr Glu Val Ala Pro Arg Ser Asp                645                 650                 655Ser Glu Glu Ser Gly Ser Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu            660                 665                 670Gln Pro Gln Ala Ala Gln Pro Pro Thr Leu Pro Val Glu Glu Lys Lys        675                 680                 685Lys Ile Pro Asp Pro Asp Ser Asp Asp Val Ser Glu Val Asp Ala Arg    690                 695                 700His Ile Ile Glu Asn Ala Lys Gln Asp Val Asp Asp Glu Tyr Gly Val705                 710                 715                 720Ser Gln Ala Leu Ala Arg Gly Leu Gln Ser Tyr Tyr Ala Val Ala His                725                 730                 735Ala Val Thr Glu Arg Val Asp Lys Gln Ser Ala Leu Met Val Asn Gly            740                 745                 750Val Leu Lys Gln Tyr Gln Ile Lys Gly Leu Glu Trp Leu Val Ser Leu        755                 760                 765Tyr Asn Asn Asn Leu Asn Gly Ile Leu Ala Asp Glu Met Gly Leu Gly    770                 775                 780Lys Thr Ile Gln Thr Ile Ala Leu Ile Thr Tyr Leu Met Glu His Lys785                 790                 795                 800Arg Ile Asn Gly Pro Phe Leu Ile Ile Val Pro Leu Ser Thr Leu Ser                805                 810                 815Asn Trp Ala Tyr Glu Phe Asp Lys Trp Ala Pro Ser Val Val Lys Val            820                 825                 830Ser Tyr Lys Gly Ser Pro Ala Ala Arg Arg Ala Phe Val Pro Gln Leu        835                 840                 845Arg Ser Gly Lys Phe Asn Val Leu Leu Thr Thr Tyr Glu Tyr Ile Ile    850                 855                 860Lys Asp Lys His Ile Leu Ala Lys Ile Arg Trp Lys Tyr Met Ile Val865                 870                 875                 880Asp Glu Gly His Arg Met Lys Asn His His Cys Lys Leu Thr Gln Val                885                 890                 895Leu Asn Thr His Tyr Val Ala Pro Arg Arg Leu Leu Leu Thr Gly Thr            900                 905                 910Pro Leu Gln Asn Lys Leu Pro Glu Leu Trp Ala Leu Leu Asn Phe Leu        915                 920                 925Leu Pro Thr Ile Phe Lys Ser Cys Ser Thr Phe Glu Gln Trp Phe Asn    930                 935                 940Ala Pro Phe Ala Met Thr Gly Glu Lys Val Asp Leu Asn Glu Glu Glu945                 950                 955                 960Thr Ile Leu Ile Ile Arg Arg Leu His Lys Val Leu Arg Pro Phe Leu                965                 970                 975Leu Arg Arg Leu Lys Lys Glu Val Glu Ala Gln Leu Pro Glu Lys Val            980                 985                 990Glu Tyr Val Ile Lys Cys Asp Met  Ser Ala Leu Gln Arg  Val Leu Tyr        995                 1000                 1005Arg His  Met Gln Ala Lys Gly  Val Leu Leu Thr Asp  Gly Ser Glu    1010                 1015                 1020Lys Asp  Lys Lys Gly Lys Gly  Gly Thr Lys Thr Leu  Met Asn Thr    1025                 1030                 1035Ile Met  Gln Leu Arg Lys Ile  Cys Asn His Pro Tyr  Met Phe Gln    1040                 1045                 1050His Ile  Glu Glu Ser Phe Ser  Glu His Leu Gly Phe  Thr Gly Gly    1055                 1060                 1065Ile Val  Gln Gly Leu Asp Leu  Tyr Arg Ala Ser Gly  Lys Phe Glu    1070                 1075                 1080Leu Leu  Asp Arg Ile Leu Pro  Lys Leu Arg Ala Thr  Asn His Lys    1085                 1090                 1095Val Leu  Leu Phe Cys Gln Met  Thr Ser Leu Met Thr  Ile Met Glu    1100                 1105                 1110Asp Tyr  Phe Ala Tyr Arg Gly  Phe Lys Tyr Leu Arg  Leu Asp Gly    1115                 1120                 1125Thr Thr  Lys Ala Glu Asp Arg  Gly Met Leu Leu Lys  Thr Phe Asn    1130                 1135                 1140Glu Pro  Gly Ser Glu Tyr Phe  Ile Phe Leu Leu Ser  Thr Arg Ala    1145                 1150                 1155Gly Gly  Leu Gly Leu Asn Leu  Gln Ser Ala Asp Thr  Val Ile Ile    1160                 1165                 1170Phe Asp  Ser Asp Trp Asn Pro  His Gln Asp Leu Gln  Ala Gln Asp    1175                 1180                 1185Arg Ala  His Arg Ile Gly Gln  Gln Asn Glu Val Arg  Val Leu Arg    1190                 1195                 1200Leu Cys  Thr Val Asn Ser Val  Glu Glu Lys Ile Leu  Ala Ala Ala    1205                 1210                 1215Lys Tyr  Lys Leu Asn Val Asp  Gln Lys Val Ile Gln  Ala Gly Met    1220                 1225                 1230Phe Asp  Gln Lys Ser Ser Ser  His Glu Arg Arg Ala  Phe Leu Gln    1235                 1240                 1245Ala Ile  Leu Glu His Glu Glu  Gln Asp Glu Glu Glu  Asp Glu Val    1250                 1255                 1260Pro Asp  Asp Glu Thr Val Asn  Gln Met Ile Ala Arg  His Glu Glu    1265                 1270                 1275Glu Phe  Asp Leu Phe Met Arg  Met Asp Leu Asp Arg  Arg Arg Glu    1280                 1285                 1290Glu Ala  Arg Asn Pro Lys Arg  Lys Pro Arg Leu Met  Glu Glu Asp    1295                 1300                 1305Glu Leu  Pro Ser Trp Ile Ile  Lys Asp Asp Ala Glu  Val Glu Arg    1310                 1315                 1320Leu Thr  Cys Glu Glu Glu Glu  Glu Lys Met Phe Gly  Arg Gly Ser    1325                 1330                 1335Arg His  Arg Lys Glu Val Asp  Tyr Ser Asp Ser Leu  Thr Glu Lys    1340                 1345                 1350Gln Trp  Leu Lys Thr Leu Lys  Ala Ile Glu Glu Gly  Thr Leu Glu    1355                 1360                 1365Glu Ile  Glu Glu Glu Val Arg  Gln Lys Lys Ser Ser  Arg Lys Arg    1370                 1375                 1380Lys Arg  Asp Ser Asp Ala Gly  Ser Ser Thr Pro Thr  Thr Ser Thr    1385                 1390                 1395Arg Ser  Arg Asp Lys Asp Asp  Glu Ser Lys Lys Gln  Lys Lys Arg    1400                 1405                 1410Gly Arg  Pro Pro Ala Glu Lys  Leu Ser Pro Asn Pro  Pro Asn Leu    1415                 1420                 1425Thr Lys  Lys Met Lys Lys Ile  Val Asp Ala Val Ile  Lys Tyr Lys    1430                 1435                 1440Asp Ser  Ser Gly Arg Gln Leu  Ser Glu Val Phe Ile  Gln Leu Pro    1445                 1450                 1455Ser Arg  Lys Glu Leu Pro Glu  Tyr Tyr Glu Leu Ile  Arg Lys Pro    1460                 1465                 1470Val Asp  Phe Lys Lys Ile Lys  Glu Arg Ile Arg Asn  His Lys Tyr    1475                 1480                 1485Arg Ser  Leu Asn Asp Leu Glu  Lys Asp Val Met Leu  Leu Cys Gln    1490                 1495                 1500Asn Ala  Gln Thr Phe Asn Leu  Glu Gly Ser Leu Ile  Tyr Glu Asp    1505                 1510                 1515Ser Ile  Val Leu Gln Ser Val  Phe Thr Ser Val Arg  Gln Lys Ile    1520                 1525                 1530Glu Lys  Glu Asp Asp Ser Glu  Gly Glu Glu Ser Glu  Glu Glu Glu    1535                 1540                 1545Glu Gly  Glu Glu Glu Gly Ser  Glu Ser Glu Ser Arg  Ser Val Lys    1550                 1555                 1560Val Lys  Ile Lys Leu Gly Arg  Lys Glu Lys Ala Gln  Asp Arg Leu    1565                 1570                 1575Lys Gly  Gly Arg Arg Arg Pro  Ser Arg Gly Ser Arg  Ala Lys Pro    1580                 1585                 1590Val Val  Ser Asp Asp Asp Ser  Glu Glu Glu Gln Glu  Glu Asp Arg    1595                 1600                 1605Ser Gly  Ser Gly Ser Glu Glu  Asp    1610                 1615</s400><s200><s210>19</s210><s211>1614</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 19Met Ser Thr Pro Asp Pro Pro Leu Gly Gly Thr Pro Arg Pro Gly Pro1               5                   10                  15Ser Pro Gly Pro Gly Pro Ser Pro Gly Ala Met Leu Gly Pro Ser Pro            20                  25                  30Gly Pro Ser Pro Gly Ser Ala His Ser Met Met Gly Pro Ser Pro Gly        35                  40                  45Pro Pro Ser Ala Gly His Pro Ile Pro Thr Gln Gly Pro Gly Gly Tyr    50                  55                  60Pro Gln Asp Asn Met His Gln Met His Lys Pro Met Glu Ser Met His65                  70                  75                  80Glu Lys Gly Met Ser Asp Asp Pro Arg Tyr Asn Gln Met Lys Gly Met                85                  90                  95Gly Met Arg Ser Gly Gly His Ala Gly Met Gly Pro Pro Pro Ser Pro            100                 105                 110Met Asp Gln His Ser Gln Gly Tyr Pro Ser Pro Leu Gly Gly Ser Glu        115                 120                 125His Ala Ser Ser Pro Val Pro Ala Ser Gly Pro Ser Ser Gly Pro Gln    130                 135                 140Met Ser Ser Gly Pro Gly Gly Ala Pro Leu Asp Gly Ala Asp Pro Gln145                 150                 155                 160Ala Leu Gly Gln Gln Asn Arg Gly Pro Thr Pro Phe Asn Gln Asn Gln                165                 170                 175Leu His Gln Leu Arg Ala Gln Ile Met Ala Tyr Lys Met Leu Ala Arg            180                 185                 190Gly Gln Pro Leu Pro Asp His Leu Gln Met Ala Val Gln Gly Lys Arg        195                 200                 205Pro Met Pro Gly Met Gln Gln Gln Met Pro Thr Leu Pro Pro Pro Ser    210                 215                 220Val Ser Ala Thr Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro225                 230                 235                 240Gly Pro Gly Pro Ala Pro Pro Asn Tyr Ser Arg Pro His Gly Met Gly                245                 250                 255Gly Pro Asn Met Pro Pro Pro Gly Pro Ser Gly Val Pro Pro Gly Met            260                 265                 270Pro Gly Gln Pro Pro Gly Gly Pro Pro Lys Pro Trp Pro Glu Gly Pro        275                 280                 285Met Ala Asn Ala Ala Ala Pro Thr Ser Thr Pro Gln Lys Leu Ile Pro    290                 295                 300Pro Gln Pro Thr Gly Arg Pro Ser Pro Ala Pro Pro Ala Val Pro Pro305                 310                 315                 320Ala Ala Ser Pro Val Met Pro Pro Gln Thr Gln Ser Pro Gly Gln Pro                325                 330                 335Ala Gln Pro Ala Pro Met Val Pro Leu His Gln Lys Gln Ser Arg Ile            340                 345                 350Thr Pro Ile Gln Lys Pro Arg Gly Leu Asp Pro Val Glu Ile Leu Gln        355                 360                 365Glu Arg Glu Tyr Arg Leu Gln Ala Arg Ile Ala His Arg Ile Gln Glu    370                 375                 380Leu Glu Asn Leu Pro Gly Ser Leu Ala Gly Asp Leu Arg Thr Lys Ala385                 390                 395                 400Thr Ile Glu Leu Lys Ala Leu Arg Leu Leu Asn Phe Gln Arg Gln Leu                405                 410                 415Arg Gln Glu Val Val Val Cys Met Arg Arg Asp Thr Ala Leu Glu Thr            420                 425                 430Ala Leu Asn Ala Lys Ala Tyr Lys Arg Ser Lys Arg Gln Ser Leu Arg        435                 440                 445Glu Ala Arg Ile Thr Glu Lys Leu Glu Lys Gln Gln Lys Ile Glu Gln    450                 455                 460Glu Arg Lys Arg Arg Gln Lys His Gln Glu Tyr Leu Asn Ser Ile Leu465                 470                 475                 480Gln His Ala Lys Asp Phe Lys Glu Tyr His Arg Ser Val Thr Gly Lys                485                 490                 495Ile Gln Lys Leu Thr Lys Ala Val Ala Thr Tyr His Ala Asn Thr Glu            500                 505                 510Arg Glu Gln Lys Lys Glu Asn Glu Arg Ile Glu Lys Glu Arg Met Arg        515                 520                 525Arg Leu Met Ala Glu Asp Glu Glu Gly Tyr Arg Lys Leu Ile Asp Gln    530                 535                 540Lys Lys Asp Lys Arg Leu Ala Tyr Leu Leu Gln Gln Thr Asp Glu Tyr545                 550                 555                 560Val Ala Asn Leu Thr Glu Leu Val Arg Gln His Lys Ala Ala Gln Val                565                 570                 575Ala Lys Glu Lys Lys Lys Lys Lys Lys Lys Lys Lys Ala Glu Asn Ala            580                 585                 590Glu Gly Gln Thr Pro Ala Ile Gly Pro Asp Gly Glu Pro Leu Asp Glu        595                 600                 605Thr Ser Gln Met Ser Asp Leu Pro Val Lys Val Ile His Val Glu Ser    610                 615                 620Gly Lys Ile Leu Thr Gly Thr Asp Ala Pro Lys Ala Gly Gln Leu Glu625                 630                 635                 640Ala Trp Leu Glu Met Asn Pro Gly Tyr Glu Val Ala Pro Arg Ser Asp                645                 650                 655Ser Glu Glu Ser Gly Ser Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu            660                 665                 670Gln Pro Gln Ala Ala Gln Pro Pro Thr Leu Pro Val Glu Glu Lys Lys        675                 680                 685Lys Ile Pro Asp Pro Asp Ser Asp Asp Val Ser Glu Val Asp Ala Arg    690                 695                 700His Ile Ile Glu Asn Ala Lys Gln Asp Val Asp Asp Glu Tyr Gly Val705                 710                 715                 720Ser Gln Ala Leu Ala Arg Gly Leu Gln Ser Tyr Tyr Ala Val Ala His                725                 730                 735Ala Val Thr Glu Arg Val Asp Lys Gln Ser Ala Leu Met Val Asn Gly            740                 745                 750Val Leu Lys Gln Tyr Gln Ile Lys Gly Leu Glu Trp Leu Val Ser Leu        755                 760                 765Tyr Asn Asn Asn Leu Asn Gly Ile Leu Ala Asp Glu Met Gly Leu Gly    770                 775                 780Lys Thr Ile Gln Thr Ile Ala Leu Ile Thr Tyr Leu Met Glu His Lys785                 790                 795                 800Arg Ile Asn Gly Pro Phe Leu Ile Ile Val Pro Leu Ser Thr Leu Ser                805                 810                 815Asn Trp Ala Tyr Glu Phe Asp Lys Trp Ala Pro Ser Val Val Lys Val            820                 825                 830Ser Tyr Lys Gly Ser Pro Ala Ala Arg Arg Ala Phe Val Pro Gln Leu        835                 840                 845Arg Ser Gly Lys Phe Asn Val Leu Leu Thr Thr Tyr Glu Tyr Ile Ile    850                 855                 860Lys Asp Lys His Ile Leu Ala Lys Ile Arg Trp Lys Tyr Met Ile Val865                 870                 875                 880Asp Glu Gly His Arg Met Lys Asn His His Cys Lys Leu Thr Gln Val                885                 890                 895Leu Asn Thr His Tyr Val Ala Pro Arg Arg Leu Leu Leu Thr Gly Thr            900                 905                 910Pro Leu Gln Asn Lys Leu Pro Glu Leu Trp Ala Leu Leu Asn Phe Leu        915                 920                 925Leu Pro Thr Ile Phe Lys Ser Cys Ser Thr Phe Glu Gln Trp Phe Asn    930                 935                 940Ala Pro Phe Ala Met Thr Gly Glu Lys Val Asp Leu Asn Glu Glu Glu945                 950                 955                 960Thr Ile Leu Ile Ile Arg Arg Leu His Lys Val Leu Arg Pro Phe Leu                965                 970                 975Leu Arg Arg Leu Lys Lys Glu Val Glu Ala Gln Leu Pro Glu Lys Val            980                 985                 990Glu Tyr Val Ile Lys Cys Asp Met  Ser Ala Leu Gln Arg  Val Leu Tyr        995                 1000                 1005Arg His  Met Gln Ala Lys Gly  Val Leu Leu Thr Asp  Gly Ser Glu    1010                 1015                 1020Lys Asp  Lys Lys Gly Lys Gly  Gly Thr Lys Thr Leu  Met Asn Thr    1025                 1030                 1035Ile Met  Gln Leu Arg Lys Ile  Cys Asn His Pro Tyr  Met Phe Gln    1040                 1045                 1050His Ile  Glu Glu Ser Phe Ser  Glu His Leu Gly Phe  Thr Gly Gly    1055                 1060                 1065Ile Val  Gln Gly Leu Asp Leu  Tyr Arg Ala Ser Gly  Lys Phe Glu    1070                 1075                 1080Leu Leu  Asp Arg Ile Leu Pro  Lys Leu Arg Ala Thr  Asn His Lys    1085                 1090                 1095Val Leu  Leu Phe Cys Gln Met  Thr Ser Leu Met Thr  Ile Met Glu    1100                 1105                 1110Asp Tyr  Phe Ala Tyr Arg Gly  Phe Lys Tyr Leu Arg  Leu Asp Gly    1115                 1120                 1125Thr Thr  Lys Ala Glu Asp Arg  Gly Met Leu Leu Lys  Thr Phe Asn    1130                 1135                 1140Glu Pro  Gly Ser Glu Tyr Phe  Ile Phe Leu Leu Ser  Thr Arg Ala    1145                 1150                 1155Gly Gly  Leu Gly Leu Asn Leu  Gln Ser Ala Asp Thr  Val Ile Ile    1160                 1165                 1170Phe Asp  Ser Asp Trp Asn Pro  His Gln Asp Leu Gln  Ala Gln Asp    1175                 1180                 1185Arg Ala  His Arg Ile Gly Gln  Gln Asn Glu Val Arg  Val Leu Arg    1190                 1195                 1200Leu Cys  Thr Val Asn Ser Val  Glu Glu Lys Ile Leu  Ala Ala Ala    1205                 1210                 1215Lys Tyr  Lys Leu Asn Val Asp  Gln Lys Val Ile Gln  Ala Gly Met    1220                 1225                 1230Phe Asp  Gln Lys Ser Ser Ser  His Glu Arg Arg Ala  Phe Leu Gln    1235                 1240                 1245Ala Ile  Leu Glu His Glu Glu  Gln Asp Glu Glu Glu  Asp Glu Val    1250                 1255                 1260Pro Asp  Asp Glu Thr Val Asn  Gln Met Ile Ala Arg  His Glu Glu    1265                 1270                 1275Glu Phe  Asp Leu Phe Met Arg  Met Asp Leu Asp Arg  Arg Arg Glu    1280                 1285                 1290Glu Ala  Arg Asn Pro Lys Arg  Lys Pro Arg Leu Met  Glu Glu Asp    1295                 1300                 1305Glu Leu  Pro Ser Trp Ile Ile  Lys Asp Asp Ala Glu  Val Glu Arg    1310                 1315                 1320Leu Thr  Cys Glu Glu Glu Glu  Glu Lys Met Phe Gly  Arg Gly Ser    1325                 1330                 1335Arg His  Arg Lys Glu Val Asp  Tyr Ser Asp Ser Leu  Thr Glu Lys    1340                 1345                 1350Gln Trp  Leu Lys Ala Ile Glu  Glu Gly Thr Leu Glu  Glu Ile Glu    1355                 1360                 1365Glu Glu  Val Arg Gln Lys Lys  Ser Ser Arg Lys Arg  Lys Arg Asp    1370                 1375                 1380Ser Asp  Ala Gly Ser Ser Thr  Pro Thr Thr Ser Thr  Arg Ser Arg    1385                 1390                 1395Asp Lys  Asp Asp Glu Ser Lys  Lys Gln Lys Lys Arg  Gly Arg Pro    1400                 1405                 1410Pro Ala  Glu Lys Leu Ser Pro  Asn Pro Pro Asn Leu  Thr Lys Lys    1415                 1420                 1425Met Lys  Lys Ile Val Asp Ala  Val Ile Lys Tyr Lys  Asp Ser Ser    1430                 1435                 1440Ser Gly  Arg Gln Leu Ser Glu  Val Phe Ile Gln Leu  Pro Ser Arg    1445                 1450                 1455Lys Glu  Leu Pro Glu Tyr Tyr  Glu Leu Ile Arg Lys  Pro Val Asp    1460                 1465                 1470Phe Lys  Lys Ile Lys Glu Arg  Ile Arg Asn His Lys  Tyr Arg Ser    1475                 1480                 1485Leu Asn  Asp Leu Glu Lys Asp  Val Met Leu Leu Cys  Gln Asn Ala    1490                 1495                 1500Gln Thr  Phe Asn Leu Glu Gly  Ser Leu Ile Tyr Glu  Asp Ser Ile    1505                 1510                 1515Val Leu  Gln Ser Val Phe Thr  Ser Val Arg Gln Lys  Ile Glu Lys    1520                 1525                 1530Glu Asp  Asp Ser Glu Gly Glu  Glu Ser Glu Glu Glu  Glu Glu Gly    1535                 1540                 1545Glu Glu  Glu Gly Ser Glu Ser  Glu Ser Arg Ser Val  Lys Val Lys    1550                 1555                 1560Ile Lys  Leu Gly Arg Lys Glu  Lys Ala Gln Asp Arg  Leu Lys Gly    1565                 1570                 1575Gly Arg  Arg Arg Pro Ser Arg  Gly Ser Arg Ala Lys  Pro Val Val    1580                 1585                 1590Ser Asp  Asp Asp Ser Glu Glu  Glu Gln Glu Glu Asp  Arg Ser Gly    1595                 1600                 1605Ser Gly  Ser Glu Glu Asp    1610</s400><s200><s210>20</s210><s211>1613</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 20Met Ser Thr Pro Asp Pro Pro Leu Gly Gly Thr Pro Arg Pro Gly Pro1               5                   10                  15Ser Pro Gly Pro Gly Pro Ser Pro Gly Ala Met Leu Gly Pro Ser Pro            20                  25                  30Gly Pro Ser Pro Gly Ser Ala His Ser Met Met Gly Pro Ser Pro Gly        35                  40                  45Pro Pro Ser Ala Gly His Pro Ile Pro Thr Gln Gly Pro Gly Gly Tyr    50                  55                  60Pro Gln Asp Asn Met His Gln Met His Lys Pro Met Glu Ser Met His65                  70                  75                  80Glu Lys Gly Met Ser Asp Asp Pro Arg Tyr Asn Gln Met Lys Gly Met                85                  90                  95Gly Met Arg Ser Gly Gly His Ala Gly Met Gly Pro Pro Pro Ser Pro            100                 105                 110Met Asp Gln His Ser Gln Gly Tyr Pro Ser Pro Leu Gly Gly Ser Glu        115                 120                 125His Ala Ser Ser Pro Val Pro Ala Ser Gly Pro Ser Ser Gly Pro Gln    130                 135                 140Met Ser Ser Gly Pro Gly Gly Ala Pro Leu Asp Gly Ala Asp Pro Gln145                 150                 155                 160Ala Leu Gly Gln Gln Asn Arg Gly Pro Thr Pro Phe Asn Gln Asn Gln                165                 170                 175Leu His Gln Leu Arg Ala Gln Ile Met Ala Tyr Lys Met Leu Ala Arg            180                 185                 190Gly Gln Pro Leu Pro Asp His Leu Gln Met Ala Val Gln Gly Lys Arg        195                 200                 205Pro Met Pro Gly Met Gln Gln Gln Met Pro Thr Leu Pro Pro Pro Ser    210                 215                 220Val Ser Ala Thr Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro225                 230                 235                 240Gly Pro Gly Pro Ala Pro Pro Asn Tyr Ser Arg Pro His Gly Met Gly                245                 250                 255Gly Pro Asn Met Pro Pro Pro Gly Pro Ser Gly Val Pro Pro Gly Met            260                 265                 270Pro Gly Gln Pro Pro Gly Gly Pro Pro Lys Pro Trp Pro Glu Gly Pro        275                 280                 285Met Ala Asn Ala Ala Ala Pro Thr Ser Thr Pro Gln Lys Leu Ile Pro    290                 295                 300Pro Gln Pro Thr Gly Arg Pro Ser Pro Ala Pro Pro Ala Val Pro Pro305                 310                 315                 320Ala Ala Ser Pro Val Met Pro Pro Gln Thr Gln Ser Pro Gly Gln Pro                325                 330                 335Ala Gln Pro Ala Pro Met Val Pro Leu His Gln Lys Gln Ser Arg Ile            340                 345                 350Thr Pro Ile Gln Lys Pro Arg Gly Leu Asp Pro Val Glu Ile Leu Gln        355                 360                 365Glu Arg Glu Tyr Arg Leu Gln Ala Arg Ile Ala His Arg Ile Gln Glu    370                 375                 380Leu Glu Asn Leu Pro Gly Ser Leu Ala Gly Asp Leu Arg Thr Lys Ala385                 390                 395                 400Thr Ile Glu Leu Lys Ala Leu Arg Leu Leu Asn Phe Gln Arg Gln Leu                405                 410                 415Arg Gln Glu Val Val Val Cys Met Arg Arg Asp Thr Ala Leu Glu Thr            420                 425                 430Ala Leu Asn Ala Lys Ala Tyr Lys Arg Ser Lys Arg Gln Ser Leu Arg        435                 440                 445Glu Ala Arg Ile Thr Glu Lys Leu Glu Lys Gln Gln Lys Ile Glu Gln    450                 455                 460Glu Arg Lys Arg Arg Gln Lys His Gln Glu Tyr Leu Asn Ser Ile Leu465                 470                 475                 480Gln His Ala Lys Asp Phe Lys Glu Tyr His Arg Ser Val Thr Gly Lys                485                 490                 495Ile Gln Lys Leu Thr Lys Ala Val Ala Thr Tyr His Ala Asn Thr Glu            500                 505                 510Arg Glu Gln Lys Lys Glu Asn Glu Arg Ile Glu Lys Glu Arg Met Arg        515                 520                 525Arg Leu Met Ala Glu Asp Glu Glu Gly Tyr Arg Lys Leu Ile Asp Gln    530                 535                 540Lys Lys Asp Lys Arg Leu Ala Tyr Leu Leu Gln Gln Thr Asp Glu Tyr545                 550                 555                 560Val Ala Asn Leu Thr Glu Leu Val Arg Gln His Lys Ala Ala Gln Val                565                 570                 575Ala Lys Glu Lys Lys Lys Lys Lys Lys Lys Lys Lys Ala Glu Asn Ala            580                 585                 590Glu Gly Gln Thr Pro Ala Ile Gly Pro Asp Gly Glu Pro Leu Asp Glu        595                 600                 605Thr Ser Gln Met Ser Asp Leu Pro Val Lys Val Ile His Val Glu Ser    610                 615                 620Gly Lys Ile Leu Thr Gly Thr Asp Ala Pro Lys Ala Gly Gln Leu Glu625                 630                 635                 640Ala Trp Leu Glu Met Asn Pro Gly Tyr Glu Val Ala Pro Arg Ser Asp                645                 650                 655Ser Glu Glu Ser Gly Ser Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu            660                 665                 670Gln Pro Gln Ala Ala Gln Pro Pro Thr Leu Pro Val Glu Glu Lys Lys        675                 680                 685Lys Ile Pro Asp Pro Asp Ser Asp Asp Val Ser Glu Val Asp Ala Arg    690                 695                 700His Ile Ile Glu Asn Ala Lys Gln Asp Val Asp Asp Glu Tyr Gly Val705                 710                 715                 720Ser Gln Ala Leu Ala Arg Gly Leu Gln Ser Tyr Tyr Ala Val Ala His                725                 730                 735Ala Val Thr Glu Arg Val Asp Lys Gln Ser Ala Leu Met Val Asn Gly            740                 745                 750Val Leu Lys Gln Tyr Gln Ile Lys Gly Leu Glu Trp Leu Val Ser Leu        755                 760                 765Tyr Asn Asn Asn Leu Asn Gly Ile Leu Ala Asp Glu Met Gly Leu Gly    770                 775                 780Lys Thr Ile Gln Thr Ile Ala Leu Ile Thr Tyr Leu Met Glu His Lys785                 790                 795                 800Arg Ile Asn Gly Pro Phe Leu Ile Ile Val Pro Leu Ser Thr Leu Ser                805                 810                 815Asn Trp Ala Tyr Glu Phe Asp Lys Trp Ala Pro Ser Val Val Lys Val            820                 825                 830Ser Tyr Lys Gly Ser Pro Ala Ala Arg Arg Ala Phe Val Pro Gln Leu        835                 840                 845Arg Ser Gly Lys Phe Asn Val Leu Leu Thr Thr Tyr Glu Tyr Ile Ile    850                 855                 860Lys Asp Lys His Ile Leu Ala Lys Ile Arg Trp Lys Tyr Met Ile Val865                 870                 875                 880Asp Glu Gly His Arg Met Lys Asn His His Cys Lys Leu Thr Gln Val                885                 890                 895Leu Asn Thr His Tyr Val Ala Pro Arg Arg Leu Leu Leu Thr Gly Thr            900                 905                 910Pro Leu Gln Asn Lys Leu Pro Glu Leu Trp Ala Leu Leu Asn Phe Leu        915                 920                 925Leu Pro Thr Ile Phe Lys Ser Cys Ser Thr Phe Glu Gln Trp Phe Asn    930                 935                 940Ala Pro Phe Ala Met Thr Gly Glu Lys Val Asp Leu Asn Glu Glu Glu945                 950                 955                 960Thr Ile Leu Ile Ile Arg Arg Leu His Lys Val Leu Arg Pro Phe Leu                965                 970                 975Leu Arg Arg Leu Lys Lys Glu Val Glu Ala Gln Leu Pro Glu Lys Val            980                 985                 990Glu Tyr Val Ile Lys Cys Asp Met  Ser Ala Leu Gln Arg  Val Leu Tyr        995                 1000                 1005Arg His  Met Gln Ala Lys Gly  Val Leu Leu Thr Asp  Gly Ser Glu    1010                 1015                 1020Lys Asp  Lys Lys Gly Lys Gly  Gly Thr Lys Thr Leu  Met Asn Thr    1025                 1030                 1035Ile Met  Gln Leu Arg Lys Ile  Cys Asn His Pro Tyr  Met Phe Gln    1040                 1045                 1050His Ile  Glu Glu Ser Phe Ser  Glu His Leu Gly Phe  Thr Gly Gly    1055                 1060                 1065Ile Val  Gln Gly Leu Asp Leu  Tyr Arg Ala Ser Gly  Lys Phe Glu    1070                 1075                 1080Leu Leu  Asp Arg Ile Leu Pro  Lys Leu Arg Ala Thr  Asn His Lys    1085                 1090                 1095Val Leu  Leu Phe Cys Gln Met  Thr Ser Leu Met Thr  Ile Met Glu    1100                 1105                 1110Asp Tyr  Phe Ala Tyr Arg Gly  Phe Lys Tyr Leu Arg  Leu Asp Gly    1115                 1120                 1125Thr Thr  Lys Ala Glu Asp Arg  Gly Met Leu Leu Lys  Thr Phe Asn    1130                 1135                 1140Glu Pro  Gly Ser Glu Tyr Phe  Ile Phe Leu Leu Ser  Thr Arg Ala    1145                 1150                 1155Gly Gly  Leu Gly Leu Asn Leu  Gln Ser Ala Asp Thr  Val Ile Ile    1160                 1165                 1170Phe Asp  Ser Asp Trp Asn Pro  His Gln Asp Leu Gln  Ala Gln Asp    1175                 1180                 1185Arg Ala  His Arg Ile Gly Gln  Gln Asn Glu Val Arg  Val Leu Arg    1190                 1195                 1200Leu Cys  Thr Val Asn Ser Val  Glu Glu Lys Ile Leu  Ala Ala Ala    1205                 1210                 1215Lys Tyr  Lys Leu Asn Val Asp  Gln Lys Val Ile Gln  Ala Gly Met    1220                 1225                 1230Phe Asp  Gln Lys Ser Ser Ser  His Glu Arg Arg Ala  Phe Leu Gln    1235                 1240                 1245Ala Ile  Leu Glu His Glu Glu  Gln Asp Glu Glu Glu  Asp Glu Val    1250                 1255                 1260Pro Asp  Asp Glu Thr Val Asn  Gln Met Ile Ala Arg  His Glu Glu    1265                 1270                 1275Glu Phe  Asp Leu Phe Met Arg  Met Asp Leu Asp Arg  Arg Arg Glu    1280                 1285                 1290Glu Ala  Arg Asn Pro Lys Arg  Lys Pro Arg Leu Met  Glu Glu Asp    1295                 1300                 1305Glu Leu  Pro Ser Trp Ile Ile  Lys Asp Asp Ala Glu  Val Glu Arg    1310                 1315                 1320Leu Thr  Cys Glu Glu Glu Glu  Glu Lys Met Phe Gly  Arg Gly Ser    1325                 1330                 1335Arg His  Arg Lys Glu Val Asp  Tyr Ser Asp Ser Leu  Thr Glu Lys    1340                 1345                 1350Gln Trp  Leu Lys Ala Ile Glu  Glu Gly Thr Leu Glu  Glu Ile Glu    1355                 1360                 1365Glu Glu  Val Arg Gln Lys Lys  Ser Ser Arg Lys Arg  Lys Arg Asp    1370                 1375                 1380Ser Asp  Ala Gly Ser Ser Thr  Pro Thr Thr Ser Thr  Arg Ser Arg    1385                 1390                 1395Asp Lys  Asp Asp Glu Ser Lys  Lys Gln Lys Lys Arg  Gly Arg Pro    1400                 1405                 1410Pro Ala  Glu Lys Leu Ser Pro  Asn Pro Pro Asn Leu  Thr Lys Lys    1415                 1420                 1425Met Lys  Lys Ile Val Asp Ala  Val Ile Lys Tyr Lys  Asp Ser Ser    1430                 1435                 1440Gly Arg  Gln Leu Ser Glu Val  Phe Ile Gln Leu Pro  Ser Arg Lys    1445                 1450                 1455Glu Leu  Pro Glu Tyr Tyr Glu  Leu Ile Arg Lys Pro  Val Asp Phe    1460                 1465                 1470Lys Lys  Ile Lys Glu Arg Ile  Arg Asn His Lys Tyr  Arg Ser Leu    1475                 1480                 1485Asn Asp  Leu Glu Lys Asp Val  Met Leu Leu Cys Gln  Asn Ala Gln    1490                 1495                 1500Thr Phe  Asn Leu Glu Gly Ser  Leu Ile Tyr Glu Asp  Ser Ile Val    1505                 1510                 1515Leu Gln  Ser Val Phe Thr Ser  Val Arg Gln Lys Ile  Glu Lys Glu    1520                 1525                 1530Asp Asp  Ser Glu Gly Glu Glu  Ser Glu Glu Glu Glu  Glu Gly Glu    1535                 1540                 1545Glu Glu  Gly Ser Glu Ser Glu  Ser Arg Ser Val Lys  Val Lys Ile    1550                 1555                 1560Lys Leu  Gly Arg Lys Glu Lys  Ala Gln Asp Arg Leu  Lys Gly Gly    1565                 1570                 1575Arg Arg  Arg Pro Ser Arg Gly  Ser Arg Ala Lys Pro  Val Val Ser    1580                 1585                 1590Asp Asp  Asp Ser Glu Glu Glu  Gln Glu Glu Asp Arg  Ser Gly Ser    1595                 1600                 1605Gly Ser  Glu Glu Asp    1610</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000850A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000850</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17892840</doc-number><date>20220822</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>4439</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>45</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>9</main-group><subgroup>12</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>4439</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>45</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>9</main-group><subgroup>12</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>0019</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>0073</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>0053</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">COMPOSITION AND METHODS FOR TREATING HERITABLE PULMONARY ARTERY HYPERTENSION ASSOCIATED WITH NONSENSE MUTATIONS</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>16800152</doc-number><date>20200225</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>11419858</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>17892840</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>62810210</doc-number><date>20190225</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Lundquist Institute for Biomedical Innovation  at Harbor-UCLA Medical Center</orgname><address><city>Torrance</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Rehan</last-name><first-name>Virender K.</first-name><address><city>Torrance</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Doherty</last-name><first-name>Terence M.</first-name><address><city>Corona</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present disclosure relates generally to compositions and methods for treating, preventing, or slowing the rate of development of a disease or condition mediated by a nonsense mutation in the bone morphogenetic protein receptor type II (Bmpr2) in a subject in need thereof. The method entails administering to the subject a compound of the present disclosure, such as GJ103 and a salt thereof.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="80.94mm" wi="147.74mm" file="US20230000850A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="208.20mm" wi="119.72mm" file="US20230000850A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="181.61mm" wi="159.77mm" file="US20230000850A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="194.82mm" wi="161.63mm" file="US20230000850A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="196.60mm" wi="149.78mm" file="US20230000850A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">CROSS REFERENCE TO RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application is a continuation of U.S. application Ser. No. 16/800,152, filed Feb. 25, 2020, which claims the benefit under 35 U.S.C. &#xa7; 119(e) of U.S. Provisional Application No. 62/810,210, filed Feb. 25, 2019, the content of each of which is incorporated by reference in its entirety into the present disclosure.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">BACKGROUND</heading><p id="p-0003" num="0002">Inherited nonsense mutations cause or contribute to many diseases, most of which are catastrophic, lethal, or both. Nonsense mutations in a gene encode premature termination codons (PTCs) in their corresponding mRNA transcripts, which then cause synthesis of a truncated protein or no protein at all. If a truncated protein is produced, it is typically either nonfunctional, or rapidly degraded (usually both). Pulmonary artery hypertension (PAH) is a very deadly disease (5-year mortality after diagnosis is well over 50%). PAH is a generic designation for an array of specific diseases that have one thing in common: very high (sometimes over 100 mm Hg) blood pressure in the pulmonary arteries, which usually have quite low (&#x2dc;25 mm Hg or so) pressures. These high pressures eventually cause irreversible heart failure that leads to death. PAH can result from numerous causes, most of them acquired rather than inherited. Inherited (or possibly also acquired) nonsense mutations in the Bmpr2 gene are known to cause one specific form of PAH: heritable pulmonary artery hypertension (hPAH) in humans.</p><heading id="h-0003" level="1">SUMMARY</heading><p id="p-0004" num="0003">A lead readthrough compound, GJ103, was identified as efficacious and safe in overcoming the nonsense mutations in the human BMPR2 gene, leading to increased expression and functional restoration of the BMPR2 protein. By contrast, another readthrough compound, G418 (an aminoglycoside antibiotic, also referred to as Geneticin and having the chemical name of (2R,3S,4R,5R,6S)-5-Amino-6-[(1R,2S,3S,4R,6S)-4,6-diamino-3-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-methylaminooxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-2-(1-hydroxyethyl)oxane-3,4-diol), was unable to increase the expression of functional BMPR2 mRNA. Yet another readthrough compound, PTC-124 (Ataluren, with a chemical name of 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid), showed only modest increases. Both PTC-124 and G418 have been well-studied and considered promising therapeutic agents for diseases medicated by nonsense mutations. The identification of GJ103 as a lead and successful candidate for treating mutant BMPR2-mediated diseases, therefore, is surprising and unexpected.</p><p id="p-0005" num="0004">In one embodiment, therefore, the present disclosure provides a method for treating, preventing, or slowing the rate of development of a disease or condition mediated by a nonsense mutation in the bone morphogenetic protein receptor type II (Bmpr2) in a subject in need thereof, comprising administering to the subject a compound of the present disclosure. In some embodiments, the compound is GJ103 or a salt thereof.</p><p id="p-0006" num="0005">In some embodiments, the nonsense mutation decreases or eliminates the expression and activity of Bmpr2. Non-limiting examples include R584X, R321X, R899X and combinations thereof.</p><p id="p-0007" num="0006">In some embodiments, the disease or condition is pulmonary artery hypertension (PAH), or pulmonary veno-occlusive disease (PVOD).</p><p id="p-0008" num="0007">In some embodiments, the subject has the disease or condition. In some embodiments, the subject has the mutation and is at risk of developing the disease or condition.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0004" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0009" num="0008"><figref idref="DRAWINGS">FIG. <b>1</b></figref> shows that GJ103 increased mRNA expression levels in blood outgrowth endothelial cells (BOECs) from a patient with hPAH harboring a nonsense mutation (R584X) in the Bmpr2 gene (N=3). By contrast, two other tested readthrough compounds, PTC124 showed much less pronounced effect and G418 exhibited no effect.</p><p id="p-0010" num="0009"><figref idref="DRAWINGS">FIG. <b>2</b></figref> shows that GJ103 induced roughly half normal or more BMPR2 protein expression levels in BOECs from a patient with hPAH harboring a nonsense mutation (R584X) in the Bmpr2 gene (N=3; Representative Western Blots are shown).</p><p id="p-0011" num="0010"><figref idref="DRAWINGS">FIG. <b>3</b></figref> shows that GJ103 induced BMPR2 protein expression. BOECs from a patient with hPAH harboring a nonsense mutation (R584X) in the Bmpr2 gene expressed markedly reduced BMPR2 protein levels, which was greatly enhanced with GJ103 treatment (N=3; Representative immunofluorescence staining is shown).</p><p id="p-0012" num="0011"><figref idref="DRAWINGS">FIG. <b>4</b></figref> shows that GJ103 normalized BMPR2 protein levels in BOECs from a patient with hPAH with R584X mutation in the Bmpr2 gene, along with the normalization of Smad1/5 and VE-cadherin, important downstream targets of BMP signaling (N=3; Representative Western blots are shown).</p><p id="p-0013" num="0012"><figref idref="DRAWINGS">FIG. <b>5</b></figref> shows that GJ103 demonstrated a trend towards blockage of LPS-induced increase in endothelial cell vascular permeability in R584X mutant BOEC obtained from a patient with hPAH, but not affected in WT endothelial cells (N=4 in triplicates) (*p&#x3c;0.05 vs. LPS group).</p><p id="p-0014" num="0013"><figref idref="DRAWINGS">FIG. <b>6</b></figref> shows that lung homogenates of Bmpr2+/R899X and Bmpr2+/R584X mice expressed &#x2dc;25-33% BMPR2 protein vs. untreated WT (Bmpr2+/+) littermate controls. GJ103 administered once daily &#xd7;5 significantly increased BMPR2 expression in lung homogenates vs. controls. Total protein and loading control is shown (N=4); Representative Western blots are shown.</p><p id="p-0015" num="0014"><figref idref="DRAWINGS">FIG. <b>7</b></figref> shows that GJ103 restores in vivo LPS-induced increase in vascular/endothelial permeability in Bmpr2+/R899X mice but not WT controls. Images of lungs isolated from mice injected with 4 mg/kg LPS or vehicle and GJ103 (50 mg/kg) 22 hours prior to Evans blue dye injection (all injected i.p.), which was delivered 2 hours prior to sacrifice are shown (A). Quantitative assessment of extravascular Evans blue dye in the lungs of the mice are shown (B); N=2, 4 lungs for each condition).</p><p id="p-0016" num="0015"><figref idref="DRAWINGS">FIG. <b>8</b></figref> shows that GJ103 blocked increased lung apoptosis in Bmpr2+/R899X mice. Lung apoptosis, as determined by BCL-2/Bax ratio in lung homogenates of Bmpr2+/R899X and WT control mice showed increased apoptosis in Bmpr2 mutant mice, which was dose-dependently blocked with GJ103 (N=3); Representative Western blots are shown.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><p id="p-0017" num="0016">It will be recognized that some or all of the figures are schematic representations for purpose of illustration.</p><heading id="h-0005" level="1">DETAILED DESCRIPTION</heading><heading id="h-0006" level="1">Definitions</heading><p id="p-0018" num="0017">The following description sets forth exemplary embodiments of the present technology. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.</p><p id="p-0019" num="0018">As used in the present specification, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.</p><p id="p-0020" num="0019">&#x201c;Alkenyl&#x201d; means a straight or branched hydrocarbon radical containing from 2-10 carbon atoms and at least one double bond, in another example 2-6 carbon atoms and one or two double bonds. Illustrative examples include, but are not limited to, allyl.</p><p id="p-0021" num="0020">&#x201c;Alkoxy&#x201d; means an &#x2014;OR group where R is alkyl, as defined herein. Illustrative examples include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.</p><p id="p-0022" num="0021">&#x201c;Alkoxyalkyl&#x201d; means an alkyl group substituted with one or two alkoxy groups, as defined herein.</p><p id="p-0023" num="0022">&#x201c;Alkoxycarbonyl&#x201d; means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Illustrative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.</p><p id="p-0024" num="0023">&#x201c;Alkyl&#x201d; means a straight or branched saturated hydrocarbon radical containing from 1-10 carbon atoms, in another example 1-6 carbon atoms. Illustrative examples include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylhexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.</p><p id="p-0025" num="0024">&#x201c;Cycloalkyl&#x201d; means a monocyclic or fused bicyclic, saturated or partially unsaturated, hydrocarbon radical of three to ten carbon ring atoms. Fused bicyclic hydrocarbon radical includes bridged rings. Unless stated otherwise, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. One or two ring carbon atoms may be replaced by a &#x2014;C(O)&#x2014;, &#x2014;C(S)&#x2014;, or &#x2014;C(&#x2550;NH)&#x2014; group. Representative examples of cyclic include but are not limited to:</p><p id="p-0026" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="100.58mm" wi="70.44mm" file="US20230000850A1-20230105-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0027" num="0025">&#x201c;Aryl&#x201d; means a monovalent, monocyclic or fused bicyclic hydrocarbon radical of 6 to 12 ring atoms, wherein the ring comprising a monocyclic radical ring is aromatic and wherein at least one of the fused rings comprising a bicyclic radical is aromatic. Fused bicyclic hydrocarbon radical includes bridged ring systems. Unless otherwise stated, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. For example, the term aryl includes, but is not limited to, phenyl, naphthyl, indanyl (including, for example, indan-5-yl, or indan-2-yl, and the like) or tetrahydronaphthyl (including, for example, tetrahydronaphth-1-yl, or tetrahydronaphth-2-yl, and the like), and the like.</p><p id="p-0028" num="0026">&#x201c;Arylalkyl&#x201d; means an alkyl group, as defined herein, substituted with one or two aryl groups as defined herein.</p><p id="p-0029" num="0027">&#x201c;Haloalkyl&#x201d; means an alkyl group substituted with one or more halo atoms, in another example by 1, 2, 3, 4, 5, or 6 halo atoms, in another example by 1, 2, or 3 halo atoms. Examples include, but are not limited to, trifluoromethyl, chloromethyl, and the like.</p><p id="p-0030" num="0028">&#x201c;Heteroaryl&#x201d; means monocyclic, fused bicyclic, or fused tricyclic, radical of 5 to 14 ring atoms containing one or more, in another example one, two, three, or four ring heteroatoms independently selected from &#x2014;O&#x2014;, &#x2014;S(O)<sub>n</sub>&#x2014; (n is 0, 1, or 2), &#x2014;N&#x2014;, and &#x2014;N(R<sup>200</sup>)&#x2014;, and the remaining ring atoms being carbon, wherein the ring comprising a monocyclic radical is aromatic and wherein at least one of the fused rings comprising a bicyclic or tricyclic radical is aromatic. One or two ring carbon atoms of any nonaromatic rings comprising a bicyclic or tricyclic radical may be replaced by a &#x2014;C(O)&#x2014;, &#x2014;C(S)&#x2014;, or &#x2014;C(&#x2550;NH)&#x2014; group. R<sup>200 </sup>is hydrogen, alkyl, hydroxy, alkoxy, acyl, or alkylsulfonyl. Fused bicyclic radical includes bridged ring systems. Unless stated otherwise, the valency may be located on any atom of any ring of the heteroaryl group, valency rules permitting. In particular, when the point of valency is located on a nitrogen, R<sup>200 </sup>is absent. The term heteroaryl includes, but is not limited to, 1,2,4-triazolyl, phthalimidyl, pyridinyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, 2,3-dihydro-1H-indolyl (including, for example, 2,3-dihydro-1H-indol-2-yl or 2,3-dihydro-1H-indol-5-yl, and the like), pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isooxazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl (including, for example, tetrahydroisoquinolin-4-yl or tetrahydroisoquinolin-6-yl, and the like), pyrrolo[3,2-c]pyridinyl (including, for example, pyrrolo[3,2-c]pyridin-2-yl or pyrrolo[3,2-c]pyridin-7-yl, and the like), benzopyranyl, thiazolyl, methylenedioxyphenyl (including, for example, methylenedioxyphen-5-yl), and the derivatives thereof, or N-oxide or a protected derivative thereof.</p><p id="p-0031" num="0029">&#x201c;Heteroarylalkyl&#x201d; means an alkyl group, as defined herein, substituted with one or two heteroaryl groups, as defined herein.</p><p id="p-0032" num="0030">&#x201c;Heterocyclyl&#x201d; means a saturated or partially unsaturated (but not aromatic) monocyclic group of 3 to 8 ring atoms or a saturated or partially unsaturated (but not aromatic) fused or bridged bicyclic or tricyclic group of 5 to 12 ring atoms in which one or more (specifically one, two, three, or four) ring atoms is a heteroatom independently selected from &#x2014;O&#x2014;, &#x2014;S(O)<sub>n</sub>&#x2014; (n is 0, 1, or 2), &#x2014;N&#x2550;, and &#x2014;NH&#x2014; and the remaining ring atoms being carbon. One or two ring carbon atoms may be replaced by a &#x2014;C(O)&#x2014;, &#x2014;C(S)&#x2014;, or &#x2014;C(&#x2550;NH)&#x2014; group. Unless otherwise stated, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. Illustrative examples include lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, More specifically the term heterocyclyl includes, but is not limited to, azetidinyl, pyrrolinyl, pyrrolidinyl, 2-oxopyrrolidinyl, 2,5-dioxo-1H-pyrrolyl, 2,5-dioxo-pyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, piperidinyl, 4-piperidonyl, morpholinyl, piperazinyl, 2-oxopiperazinyl, dioxopiperazinyl, pyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,3-dioxinyl, 1,3-dioxanyl, 1,4-dioxinyl, 1,4-dioxanyl, 2-oxopiperidinyl, thiomorpholinyl, thiamorpholinyl, perhydroazepinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 2,4-dioxo-imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, oxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolinyl, thiazolidinyl, quinuclidinyl, isothiazolidinyl, octahydroindolyl, octahydroisoindolyl, decahydroisoquinolyl, 1,3-oxathianyl, 1,4-oxathiinyl, 1,4-oxathianyl, tetrahydro-1,4-thiazinyl, 2H-1,2-oxazinyl, tetrahydrofuryl, 2,4,6-trioxo-(1H,3H,5H)pyrimidinyl, 4,6-dioxo-2-(1H,5H)thioxodihydropyrimidinyl, 2,4(1H,3H)-dioxo-dihydropyrimidinyl, trioxanyl, hexahydro-1,3,5-triazinyl, tetrahydrothienyl, tetrahydrofuranyl, pyrazolinyl, 1,3-dioxolyl, 1,3-dioxolanyl, 1,3-dithiolyl, 1,3-dithiolanyl, isoxazolinyl, isoxazolidinyl, oxazolidinonyl, 1,3-oxathiolanyl, 2(3H)-oxo-dihydrothienyl, 2(3H)-oxo-dihydrofuranyl, 1,1-dioxo-tetrahydrothienyl, 2-oxo-1,3-dioxolanyl, 4,5-dihydrooxazolyl, oxiranyl, (1s,4s)-7-oxabicyclo[2.2.1]heptanyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 4H-1,4-thiazinyl, octahydro-1H-quinolizinyl, and tetrahydropyranyl, and the derivatives thereof and N-oxide or a protected derivative thereof. Additional examples include</p><p id="p-0033" num="0000"><chemistry id="CHEM-US-00002" num="00002"><img id="EMI-C00002" he="45.72mm" wi="64.35mm" file="US20230000850A1-20230105-C00002.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0034" num="0031">&#x201c;Hydroxyalkyl&#x201d; means an alkyl group, as defined herein, substituted with 1, 2, 3, or 4 hydroxy groups.</p><p id="p-0035" num="0032">&#x201c;Pseudohalo&#x201d; means a cyano, cyanate (&#x2014;N&#x2550;C&#x2550;O), thiocyanate group (&#x2014;S&#x2550;C&#x2550;N), or azide.</p><p id="p-0036" num="0033">&#x201c;Thioalkoxy&#x201d; means an &#x2014;SR group where R is alkyl, as defined herein.</p><p id="p-0037" num="0034">The terms &#x201c;optional&#x201d; or &#x201c;optionally&#x201d; means that the subsequently described event or circumstance may or may not occur and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term &#x201c;optionally substituted&#x201d; refers to any one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.</p><p id="p-0038" num="0035">The term &#x201c;substituted&#x201d; used herein means any of the above groups (i.e., alkyl, alkenyl, alkynyl, alkylene, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, and/or heteroalkyl) wherein at least one (e.g., 1 to 5 or 1 to 3) hydrogen atom is replaced by a bond to a non-hydrogen atom such as, but not limited to alkyl, alkenyl, alkynyl, alkoxy, alkylthio, acyl, amido, amino, amidino, aryl, aralkyl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, cycloalkyl, cycloalkylalkyl, guanadino, halo, haloalkyl, haloalkoxy, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, &#x2014;NHNH<sub>2</sub>, &#x2550;NNH<sub>2</sub>, imino, imido, hydroxy, oxo, oxime, nitro, sulfonyl, sulfinyl, alkylsulfonyl, alkylsulfinyl, thiocyanate, &#x2014;S(O)OH, &#x2014;S(O)<sub>2</sub>OH, sulfonamido, thiol, thioxo, N-oxide, or &#x2014;Si(R<sup>y</sup>)<sub>3</sub>, wherein each R<sup>y </sup>is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl.</p><p id="p-0039" num="0036">In certain embodiments, &#x201c;substituted&#x201d; includes any of the above alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl groups in which one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms are independently replaced with deuterium, halo, cyano, nitro, azido, oxo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, &#x2014;NR<sup>g</sup>R<sup>h</sup>, &#x2014;NR<sup>g</sup>C(O)R<sup>h</sup>, &#x2014;NR<sup>g</sup>C(O)NR<sup>g</sup>R<sup>h</sup>, &#x2014;NR<sup>g</sup>C(O)OR<sup>h</sup>, &#x2014;NR<sup>g</sup>S(O)<sub>1-2</sub>R<sup>h</sup>, &#x2014;C(O)R<sup>g</sup>, &#x2014;C(O)OR<sup>g</sup>, &#x2014;OC(O)OR<sup>g</sup>, &#x2014;OC(O)R<sup>g</sup>, &#x2014;C(O)NR<sup>g</sup>R<sup>h</sup>, &#x2014;OC(O)NR<sup>g</sup>R<sup>h</sup>, &#x2014;OR<sup>g</sup>, &#x2014;SR<sup>g</sup>, &#x2014;S(O)R<sup>g</sup>, &#x2014;S(O)<sub>2</sub>R<sup>g</sup>, &#x2014;OS(O)<sub>1-2</sub>R<sup>g</sup>, &#x2014;S(O)<sub>1-2</sub>OR<sup>g</sup>, &#x2014;NR<sup>g</sup>S(O)<sub>1-2</sub>NR<sup>g</sup>R<sup>h</sup>, &#x2550;NSO<sub>2</sub>R<sup>g</sup>, &#x2550;NOR<sup>g</sup>, &#x2014;S(O)<sub>1-2</sub>NR<sup>g</sup>R<sup>h</sup>, &#x2014;SF<sub>5</sub>, &#x2014;SCF<sub>3</sub>, or &#x2014;OCF<sub>3</sub>. In certain embodiments, &#x201c;substituted&#x201d; also means any of the above groups in which one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms are replaced with &#x2014;C(O)R<sup>g</sup>, &#x2014;C(O)OR<sup>g</sup>, &#x2014;C(O)NR<sup>g</sup>R<sup>h</sup>, &#x2014;CH<sub>2</sub>SO<sub>2</sub>R<sup>g</sup>, or &#x2014;CH<sub>2</sub>SO<sub>2</sub>NR<sup>g</sup>R<sup>h</sup>. In the foregoing, R<sup>g </sup>and R<sup>h </sup>are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and/or heteroarylalkyl. In certain embodiments, &#x201c;substituted&#x201d; also means any of the above groups in which one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms are replaced by a bond to an amino, cyano, hydroxy, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl,</p><p id="p-0040" num="0000">N-heterocyclyl, heterocyclylalkyl, heteroaryl, and/or heteroarylalkyl, or two of R<sup>g </sup>and R<sup>h </sup>and R<sup>i </sup>are taken together with the atoms to which they are attached to form a heterocyclyl ring optionally substituted with oxo, halo, or alkyl optionally substituted with oxo, halo, amino, hydroxy, or alkoxy.</p><p id="p-0041" num="0037">Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. Unless otherwise noted, the maximum number of serial substitutions in compounds described herein is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to ((substituted aryl)substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. When used to modify a chemical group, the term &#x201c;substituted&#x201d; may describe other chemical groups defined herein.</p><p id="p-0042" num="0038">In certain embodiments, as used herein, the phrase &#x201c;one or more&#x201d; refers to one to five. In certain embodiments, as used herein, the phrase &#x201c;one or more&#x201d; refers to one to three.</p><p id="p-0043" num="0039">Any compound or structure given herein, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. These forms of compounds may also be referred to as &#x201c;isotopically enriched analogs.&#x201d; Isotopically labeled compounds have structures depicted herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as <sup>2</sup>H, <sup>3</sup>H, <sup>11</sup>C, <sup>13</sup>C, <sup>14</sup>C, <sup>13</sup>N, <sup>15</sup>N, <sup>15</sup>O, <sup>17</sup>O, <sup>18</sup>O, <sup>31</sup>P, <sup>32</sup>P, <sup>35</sup>S, <sup>18</sup>F, <sup>36</sup>Cl, <sup>123</sup>I, and <sup>125</sup>I, respectively. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as <sup>3</sup>H and <sup>14</sup>C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.</p><p id="p-0044" num="0040">The term &#x201c;isotopically enriched analogs&#x201d; includes &#x201c;deuterated analogs&#x201d; of compounds described herein in which one or more hydrogens is/are replaced by deuterium, such as a hydrogen on a carbon atom. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound when administered to a mammal, particularly a human. See, for example, Foster, &#x201c;Deuterium Isotope Effects in Studies of Drug Metabolism,&#x201d; Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.</p><p id="p-0045" num="0041">Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism, and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements, and/or an improvement in therapeutic index. An <sup>18</sup>F, <sup>3</sup>H, <sup>11</sup>C labeled compound may be useful for PET or SPECT or other imaging studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in a compound described herein.</p><p id="p-0046" num="0042">The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as &#x201c;H&#x201d; or &#x201c;hydrogen&#x201d;, the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium.</p><p id="p-0047" num="0043">In many cases, the compounds of this disclosure are capable of forming acid and/or base salts by virtue of the presence of amino, and/or carboxyl groups, or groups similar thereto.</p><p id="p-0048" num="0044">Provided are also or a pharmaceutically acceptable salt, isotopically enriched analog, deuterated analog, stereoisomer, mixture of stereoisomers, and prodrugs of the compounds described herein. &#x201c;Pharmaceutically acceptable&#x201d; or &#x201c;physiologically acceptable&#x201d; refer to compounds, salts, compositions, dosage forms, and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.</p><p id="p-0049" num="0045">The term &#x201c;pharmaceutically acceptable salt&#x201d; of a given compound refers to salts that retain the biological effectiveness and properties of the given compound and which are not biologically or otherwise undesirable. &#x201c;Pharmaceutically acceptable salts&#x201d; or &#x201c;physiologically acceptable salts&#x201d; include, for example, salts with inorganic acids, and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Salts derived from inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, e.g., acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, such as alkyl amines (i.e., NH<sub>2</sub>(alkyl)), dialkyl amines (i.e., HN(alkyl)<sub>2</sub>), trialkyl amines (i.e., N(alkyl)<sub>3</sub>), substituted alkyl amines (i.e., NH<sub>2</sub>(substituted alkyl)), di(substituted alkyl) amines (i.e., HN(substituted alkyl)<sub>2</sub>), tri(substituted alkyl) amines (i.e., N(substituted alkyl)<sub>3</sub>), alkenyl amines (i.e., NH<sub>2</sub>(alkenyl)), dialkenyl amines (i.e., HN(alkenyl)<sub>2</sub>), trialkenyl amines (i.e., N(alkenyl)<sub>3</sub>), substituted alkenyl amines (i.e., NH<sub>2</sub>(substituted alkenyl)), di(substituted alkenyl) amines (i.e., HN(substituted alkenyl)<sub>2</sub>), tri(substituted alkenyl) amines (i.e., N(substituted alkenyl)<sub>3</sub>, mono-, di- or tri-cycloalkyl amines (i.e., NH<sub>2</sub>(cycloalkyl), HN(cycloalkyl)<sub>2</sub>, N(cycloalkyl)<sub>3</sub>), mono-, di- or tri-arylamines (i.e., NH<sub>2</sub>(aryl), HN(aryl)<sub>2</sub>, N(aryl)<sub>3</sub>), or mixed amines, etc. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.</p><p id="p-0050" num="0046">&#x201c;Prodrugs&#x201d; means any compound which releases an active parent drug according to a structure described herein in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound described herein are prepared by modifying functional groups present in the compound described herein in such a way that the modifications may be cleaved in vivo to release the parent compound. Prodrugs may be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds described herein wherein a hydroxy, amino, carboxyl, or sulfhydryl group in a compound described herein is bonded to any group that may be cleaved in vivo to regenerate the free hydroxy, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), amides, guanidines, carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups in compounds described herein, and the like. Preparation, selection, and use of prodrugs is discussed in T. Higuchi and V. Stella, &#x201c;Pro-drugs as Novel Delivery Systems,&#x201d; Vol. 14 of the A.C.S. Symposium Series; &#x201c;Design of Prodrugs,&#x201d; ed. H. Bundgaard, Elsevier, 1985; and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, each of which are hereby incorporated by reference in their entirety.</p><p id="p-0051" num="0047">The terms &#x201c;optional&#x201d; or &#x201c;optionally&#x201d; means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term &#x201c;optionally substituted&#x201d; refers to any one or more hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.</p><p id="p-0052" num="0048">As used herein, &#x201c;pharmaceutically acceptable carrier&#x201d; or &#x201c;pharmaceutically acceptable excipient&#x201d; includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.</p><heading id="h-0007" level="1">Treatment of Mutant BMPR2-Mediated Diseases</heading><p id="p-0053" num="0049">The present disclosure provides compositions and methods for treating diseases and conditions mediated by the human Bmpr2 gene with a mutation resulting in a premature termination codon (PTC). An example is the heritable pulmonary artery hypertension (hPAH) in humans. The methods, in some embodiments, employ a SMRT (Small Molecule Read-Through) compound that can read through the PTC in transcripts specified by the Bmpr2 gene. Such readthrough, as demonstrated herein, can markedly attenuate or even normalize high pulmonary artery pressures in those at risk of developing hPAH.</p><p id="p-0054" num="0050">Currently, there are no effective therapies for this disease; all known treatments merely slow the inexorable rate of progression of the disease and forestall their inevitable lethality. PTC-124 (Ataluren, with a chemical name of 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid), for instance, was once a promising candidate SMRT, but the FDA rejected the new drug application twice, mostly based on lack of evidence for efficacy in Duchenne's muscular dystrophy.</p><p id="p-0055" num="0051">In a surprising and unexpected discovery herein, GJ103 was identified as a lead compound, and was efficacious and safe in overcoming the nonsense mutations (R899X, R584X and R321X) in the human BMPR2 gene, leading to increased expression and functional restoration of the BMPR2 protein. By contrast, two well-known read-through compounds, G418 (Geneticin) and PTC-124 (PTC-124), were much less effective.</p><p id="p-0056" num="0052">GJ103 has a chemical name of 2-((4-(3-methoxyphenyl)-5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid, and can be used as a salt. The structures of GJ103 and a sodium salt are shown below.</p><p id="p-0057" num="0000"><chemistry id="CHEM-US-00003" num="00003"><img id="EMI-C00003" he="85.51mm" wi="41.49mm" file="US20230000850A1-20230105-C00003.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0058" num="0053">GJ103's effectiveness in treating hPAH was unexpected for at least the following reasons. First, SMRT compounds may or may not read through all PTCs in all genes. Second, even if a SMRT can read through a PTC, the rate at which the SMRT compound reads through the FTC might not be sufficient to overcome potential degradation of mutant mRNA transcripts caused by nonsense-mediated decay (NMD) mechanisms. Third, NMD might be so rapid and efficient that no mRNA transcripts stable enough to traffic to the ribosomes are produced. If mRNA transcript half-lives are too short, SMRT compounds would be completely ineffective. NMD efficiency and rapidity varies widely in different situations and diseases, and remains an empiric question for any one gene and transcript.</p><p id="p-0059" num="0054">Fourth, even if a SMRT compound reads through a PTC in one or more of these genes efficiently and produce protein, that protein may or may not be functional. Fifth, SMRT compounds may or may not effect translation of sufficient quantities of protein to significantly impact the pathology caused by lack of one or more of these genes. Sixth, even if a functional protein is induced by a SMRT compound, it might still be ineffective. For example, it might not be possible to reverse the disease process underlying the pathology. Finally, a SMRT compound can insert a random amino acid at the FTC site. If the SMRT compound reads through PTCs in one or more of these genes efficiently, the protein produced will most likely contain an amino acid substitution at the site of the FTC, may therefore not fold into a correct three-dimensional conformation, and might therefore be nonfunctional and susceptible to degradation by the unfolded protein response. The success of GJ103, and its variants as disclosed herein, in the treatment of hPAH, therefore, is entirely surprising and unexpected.</p><p id="p-0060" num="0055">In one embodiment, the present disclosure provides compositions and methods for treating or preventing a disease or condition mediated by a mutation in the bone morphogenetic protein receptor type II (Bmpr2). In some embodiments, the disease or condition is pulmonary artery hypertension (PAH). In some embodiments, the disease or condition is pulmonary veno-occlusive disease (PVOD).</p><p id="p-0061" num="0056">Pulmonary arterial hypertension (PAH) is a condition characterized by abnormally high blood pressure (hypertension) in the blood vessel that carries blood from the heart to the lungs (the pulmonary artery). Many BMPR2 gene mutations can cause heritable PAH (hPAH). About half of the mutations involved in this condition disrupt the assembly of Bmpr2, reducing the amount of this protein in cells. Other mutations prevent bone morphogenetic protein receptor type 2 from reaching the cell surface or alter its structure so it cannot receive or transmit signals.</p><p id="p-0062" num="0057">Pulmonary veno-occlusive disease (PVOD) is characterized by the blockage (occlusion) of the blood vessels that carry oxygen-rich (oxygenated) blood from the lungs to the heart (the pulmonary veins). The occlusion is caused by a buildup of abnormal fibrous tissue in the small veins in the lungs, which narrows the vessels and impairs blood flow. Bmpr2 mutations have been identified that cause heritable PVOD (hPVOD).</p><p id="p-0063" num="0058">In some embodiments, the patient being treated has a nonsense mutation in the BMPR2 gene. Examples of such mutations include, without limitation, R584X, R321X, and R899X. In one embodiment, the patient has hPAH and has a R584X mutation. In one embodiment, the patient has hPAH and has a R321X mutation. In one embodiment, the patient has hPAH and has a R899X mutation.</p><p id="p-0064" num="0059">&#x201c;Treatment&#x201d; or &#x201c;treating&#x201d; is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (e.g., metastasis) of the disease or condition); and/or c) relieving the disease, that is, causing the regression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.</p><p id="p-0065" num="0060">&#x201c;Prevention&#x201d; or &#x201c;preventing&#x201d; means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.</p><p id="p-0066" num="0061">&#x201c;Subject&#x201d; refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and/or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human.</p><p id="p-0067" num="0062">The term &#x201c;therapeutically effective amount&#x201d; or &#x201c;effective amount&#x201d; of a compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression. For example, a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition. The therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art.</p><p id="p-0068" num="0063">The methods described herein may be applied to cell populations in vivo or ex vivo. &#x201c;In vivo&#x201d; means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual. &#x201c;Ex vivo&#x201d; means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. In this context, the compounds and compositions described herein may be used for a variety of purposes, including therapeutic and experimental purposes. For example, the compounds and compositions described herein may be used ex vivo to determine the optimal schedule and/or dosing of administration of a compound of the present disclosure for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the compounds and compositions described herein may be suited are described below or will become apparent to those skilled in the art. The selected compounds may be further characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art.</p><p id="p-0069" num="0064">In some embodiments, the composition includes a SMRT (Small Molecule Read-Through) compound, such as those disclosed herein. In one embodiment, the SMRT compound is a compound of Formula I. II or II, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof:</p><p id="p-0070" num="0000"><chemistry id="CHEM-US-00004" num="00004"><img id="EMI-C00004" he="87.46mm" wi="63.84mm" file="US20230000850A1-20230105-C00004.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0071" num="0065">wherein:</p><p id="p-0072" num="0066">X, Y, and Z are each independently O, S, or NR<sup>10</sup>; wherein R<sup>10 </sup>is hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, where each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</p><p id="p-0073" num="0067">A is N or CR<sup>11</sup>; wherein R<sup>11 </sup>is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</p><p id="p-0074" num="0068">B is N or CR<sup>12</sup>; wherein R<sup>12 </sup>is hydrogen, halo, pseudohalo, alkyl, alkoxy, or thioalkoxy;</p><p id="p-0075" num="0069">D is N or CR<sup>13</sup>; wherein R<sup>13 </sup>is hydrogen, halo, pseudohalo, alkyl, alkoxy, or thioalkoxy;</p><p id="p-0076" num="0070">R<sup>1 </sup>is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</p><p id="p-0077" num="0071">R<sup>2 </sup>is C<sub>1-3</sub>alkylene, C<sub>3-10</sub>cycloalkylene, or heterocyclylene of 3 to 10 atoms;</p><p id="p-0078" num="0072">R<sup>3 </sup>is hydroxy, alkoxy, &#x2014;NR<sup>6</sup>R<sup>6a</sup>, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</p><p id="p-0079" num="0073">R<sup>4 </sup>is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</p><p id="p-0080" num="0074">R<sup>5 </sup>is &#x2014;NR<sup>5a</sup>R<sup>5b</sup>, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</p><p id="p-0081" num="0075">R<sup>5a </sup>is hydrogen or alkyl;</p><p id="p-0082" num="0076">R<sup>5b </sup>is alkyl, alkoxyalkyl, alkenyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; wherein the aryl or heteroaryl, either alone or as part of arylalkyl and heteroarylalkyl, are optionally substituted with 1, 2, or 3 groups independently selected from alkyl, halo, haloalkyl, hydroxy, and alkoxy;</p><p id="p-0083" num="0077">R<sup>6 </sup>is hydrogen or alkyl; and</p><p id="p-0084" num="0078">R<sup>6a </sup>is &#x2014;NHC(O)(arylalkyl), alkyl, hydroxyalkyl, cycloalkyl, heteroaryl, or aryl, wherein each aryl, arylalkyl, or heteroaryl are optionally substituted with 1, 2, or 3 groups selected from hydroxy, halo, haloalkyl, alkyl, alkoxy, carboxy, or alkoxycarbonyl.</p><p id="p-0085" num="0079">In certain embodiments, the compound is a compound of Formula Ia, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof:</p><p id="p-0086" num="0000"><chemistry id="CHEM-US-00005" num="00005"><img id="EMI-C00005" he="35.22mm" wi="58.50mm" file="US20230000850A1-20230105-C00005.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0087" num="0080">wherein:</p><p id="p-0088" num="0081">R<sup>1a </sup>is 2-hydroxylphenyl, 2-alkoxyphenyl, 3-hydroxylphenyl, or 3-alkoxyphenyl;</p><p id="p-0089" num="0082">X<sup>1 </sup>is S, O, NH, or N(C<sub>1-3</sub>-alkyl);</p><p id="p-0090" num="0083">R<sup>2a </sup>is (CH<sub>2</sub>)<sub>m</sub>;</p><p id="p-0091" num="0084">m is 1, 2, or 3;</p><p id="p-0092" num="0085">Y<sup>1 </sup>is O, S, or NH;</p><p id="p-0093" num="0086">R<sup>3a </sup>is hydroxy or &#x2014;NR<sup>7</sup>R<sup>7a</sup>;</p><p id="p-0094" num="0087">R<sup>7 </sup>is hydrogen or C<sub>1-3</sub>alkyl;</p><p id="p-0095" num="0088">R<sup>7a </sup>is hydroxyalkyl; phenyl substituted with 1, 2, or 3 R<sup>8 </sup>groups; phenyl substituted with two independently selected halo:</p><p id="p-0096" num="0089">each R<sup>8 </sup>is independently hydroxy or haloalkyl; and</p><p id="p-0097" num="0090">each R<sup>9</sup>, when present, is independently hydroxy, alkoxy, halo, haloalkyl, or C<sub>1-6</sub>-alkyl; and</p><p id="p-0098" num="0091">provided that 1) when X<sup>1 </sup>is S, R<sup>2a </sup>is &#x2014;CH<sub>2</sub>&#x2014;, Y<sup>1 </sup>is O, and R<sup>3a </sup>is &#x2014;NR<sup>7</sup>R<sup>7a </sup>and R<sup>7 </sup>is hydrogen, then R<sup>7a </sup>is not 2-methoxyphenyl; and 2) when R<sup>1a </sup>is 2-methoxyphenyl, X<sup>1 </sup>is S, R<sup>2a </sup>is &#x2014;CH<sub>2</sub>&#x2014;, Y<sup>1 </sup>is O, and R<sup>3 </sup>is &#x2014;NR<sup>7</sup>R<sup>7a </sup>and R<sup>7 </sup>is hydrogen, then R<sup>7a </sup>is not 4-methoxyphenyl.</p><p id="p-0099" num="0092">In some embodiments, compounds of Formula I, II, III, Ia, and analogs or derivatives thereof, and methods of their synthesis, are described in U.S. Pat. No. 9,598,395, which is incorporated herein by reference.</p><p id="p-0100" num="0093">In certain embodiments, the method utilizes a compound of formula:</p><p id="p-0101" num="0000"><chemistry id="CHEM-US-00006" num="00006"><img id="EMI-C00006" he="31.75mm" wi="39.29mm" file="US20230000850A1-20230105-C00006.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0102" num="0094">or a pharmaceutically acceptable salt, isotopically enriched analog, or prodrug thereof.</p><p id="p-0103" num="0095">In certain embodiments, utilizes a compound of formula:</p><p id="p-0104" num="0000"><chemistry id="CHEM-US-00007" num="00007"><img id="EMI-C00007" he="31.67mm" wi="41.49mm" file="US20230000850A1-20230105-C00007.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0105" num="0096">or an isotopically enriched analog, or prodrug thereof.</p><p id="p-0106" num="0097">In come embodiments, the treatment or composition further includes a drug useful for treating PAH or PVOD. Examples of such drugs include, without limitation, ambrisentan (Letairis), bocentan (Tracleer), macitentan (Opsumit), riociguat (Adempas), selexipag (Uptravi), sildenafil (Revatio), tadalafil (Adcirca), treprostinil (Orenitram), Iloprost tromethamine (Ventavis), treprostinil (Tyvaso), epopostenol sodium (Flolan, Veletri), and treprostinil.</p><p id="p-0107" num="0098">It is further contemplated that the co-administration of an agent that inhibits nonsense-mediated decay (NMD) can further enhance the therapeutic effect of the presently disclosed compounds. Abnormal transcripts such as those transcribed with a premature termination codon are generally detected by a cellular &#x201c;housekeeping&#x201d; system and targeted for degradation. It is contemplated that inhibiting this mechanism can enhance availability of mutant transcripts, which in turn favorably affect yield of the normal protein.</p><p id="p-0108" num="0099">A RNA surveillance mechanism exists to minimize the translation and regulates the RNA stability of nonsense RNAs containing PTC mutations. This surveillance mechanism, referred to as &#x201c;nonsense-mediated mRNA decay&#x201d; (&#x201c;NMD),&#x201d; a post transcriptional mechanism that is operational in both normal cells (e.g., B and T cells) and cells with genetic mutations (i.e., cells with mutations in genes controlling cellular proliferation).</p><p id="p-0109" num="0100">There are three main factors in NMD: UPF1, UPF2 and UPF3 (UPF3A and UPF3B in humans), that make up the conserved core of the NMD pathway. All three of these factors are trans-acting elements called up-frameshift (UPF) proteins. In mammals, UPF2 and UPF3 are part of the &#x201c;exon-exon junction complex&#x201d; (EJC) bound to mRNA after splicing along with other proteins which also function in NMD. UPF1 phosphorylation is controlled by the proteins SMG-1, SMG-5, SMG-6 and SMG-7.</p><p id="p-0110" num="0101">A NMD inhibitor may be an inhibitor of one or more proteins associated with the NMD degradation complex (such as, but not limited to, UPF1, UPF2, UPF3, eIF4AIII, MLN51, the Y14/MAGOH heterodimer, SMG-1, SMG-5, SMG-6 and/or SMG-7). As used herein, the phrase &#x201c;NMD degradation complex&#x201d; refers to any one of the intracellular proteins that participates in NMD of an mRNA bearing a PTC (such as, but not limited to, one or more of UPF1, UPF2, UPF3, UPF3BI, RNPS1, eIF4AIII, MLN51, the Y14/MAGOH heterodimer, RENT1, RENT2, SMG-1, SMG-5, SMG-6 and/or SMG-7). As such, the compound inhibits the function of one or more NMD degradation complex proteins, thereby allowing a PTC-bearing mRNA to be translated into a polypeptide.</p><p id="p-0111" num="0102">Candidate compounds can be, without limitation, small molecule chemical compounds (such as any of the small molecules described above), antibodies, proteins, or any combination thereof. In one embodiment, the compound is not an inhibitory nucleic acid (such as, but not limited to, an antisense oligonucleotide or a small inhibitory RNA (siRNA)). In another embodiment, the compound is not any of the compounds disclosed in U.S. Patent Application Publication No. 2013/0224237.</p><p id="p-0112" num="0103">In some aspects, the compound binds (such as preferentially binds) to a one or more NMD degradation complex proteins (such as, but not limited to, UPF1, UPF2, UPF3, UPF3BI, RNPS1, eIF4AIII, MLN51, the Y14/MAGOH heterodimer, RENT1, RENT2, SMG-1, SMG-5, SMG-6 and/or SMG-7) and is an antibody. In some embodiments, the antibodies are NMD degradation complex protein antagonists and can inhibit NMD.</p><p id="p-0113" num="0104">In some aspects, the NMDI binds to a one or more NMD degradation complex proteins (such as, but not limited to, UPF1, UPF2, UPF3, UPF3BI, RNPS1, eIF4AIII, MLN51, the Y14/MAGOH heterodimer, RENT1, RENT2, SMG-1, SMG-5, SMG-6 and/or SMG-7) and is a non-antibody binding polypeptide. In some embodiments, the non-antibody binding polypeptide is a NMD degradation complex protein antagonist and can inhibit NMD.</p><p id="p-0114" num="0105">Binding polypeptides may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for screening polypeptide libraries for binding polypeptides that are capable of binding to a polypeptide target are well known in the art (see, e.g., U.S. Pat. Nos. 5,556,762, 5,750,373, 4,708,871, 4,833,092, 5,223,409, 5,403,484, 5,571,689, 5,663,143; PCT Application Publication Nos. WO 84/03506 and WO84/03564; Geysen et al, <i>Proc. Natl. Acad. Sci. U.S.A., </i>81:3998-4002 (1984); Geysen et al, <i>Proc. Natl. Acad. Sci. U.S.A., </i>82: 178-182 (1985); Geysen et al., <i>J. Immunol. Meth, </i>102:259-274 (1987); Clackson, T. et al., (1991) <i>Nature, </i>352: 624; Kang, A. S. et al., (1991) <i>Proc. Natl. Acad. Sci. USA, </i>88:8363, and Smith, G. P. (1991) <i>Current Opin. Biotechnol, </i>2:668, the disclosures of each of which are incorporated by reference herein.</p><p id="p-0115" num="0106">Methods for generating peptide libraries and screening these libraries are also disclosed in U.S. Pat. Nos. 5,723,286, 5,432,018, 5,580,717, 5,427,908, 5,498,530, 5,770,434, 5,734,018, 5,698,426, 5,763,192, and 5,723,323, the disclosures of each of which are incorporated by reference herein.</p><p id="p-0116" num="0107">Binding polypeptides can be modified to enhance their inhibitory and/or therapeutic effect (including, for example, enhanced affinity, improved pharmacokinetic properties such as half-life, stability, and clearance rate, reduced toxicity, etc.). Such modifications include, without limitation, glycosylation, pegylation, substitution with non-naturally occurring but functionally equivalent amino acid, linking groups, etc.</p><p id="p-0117" num="0108">Examples of NMDIs can include, for example, NMDI14, NMDI19 and/or NMDI25 or any other NMDI disclosed in Martin et al., (Cancer research, 2014, 74(11):3104-13) or in U.S. Patent Application Publication No. 2014/0094457, the disclosures of each of which are incorporated by reference herein.</p><heading id="h-0008" level="1">Pharmaceutical Compositions and Modes of Administration</heading><p id="p-0118" num="0109">Compounds provided herein are usually administered in the form of pharmaceutical compositions. Thus, provided herein are also pharmaceutical compositions that contain one or more of the compounds described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants and excipients. Suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. Such compositions are prepared in a manner well known in the pharmaceutical art. See, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G. S. Banker &#x26; C. T. Rhodes, Eds.).</p><p id="p-0119" num="0110">The pharmaceutical compositions may be administered in either single or multiple doses. The pharmaceutical composition may be administered by various methods including, for example, rectal, buccal, intranasal and transdermal routes. In certain embodiments, the pharmaceutical composition may be administered by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.</p><p id="p-0120" num="0111">One mode for administration is parenteral, for example, by injection. The forms in which the pharmaceutical compositions described herein may be incorporated for administration by injection include, for example, aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.</p><p id="p-0121" num="0112">Oral administration may be another route for administration of the compounds described herein. Administration may be via, for example, capsule or enteric coated tablets. In making the pharmaceutical compositions that include at least one compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof, the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.</p><p id="p-0122" num="0113">Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. The formulations can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.</p><p id="p-0123" num="0114">The compositions that include at least one compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Pat. Nos. 3,845,770; 4,326,525; 4,902,514; and 5,616,345. Another formulation for use in the methods disclosed herein employ transdermal delivery devices (&#x201c;patches&#x201d;). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds described herein in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.</p><p id="p-0124" num="0115">For preparing solid compositions such as tablets, the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof. When referring to these preformulation compositions as homogeneous, the active ingredient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.</p><p id="p-0125" num="0116">The tablets or pills of the compounds described herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can include an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.</p><p id="p-0126" num="0117">Compositions for inhalation or insufflation may include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described herein. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. In other embodiments, compositions in pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.</p><heading id="h-0009" level="1">Dosing</heading><p id="p-0127" num="0118">The specific dose level of a compound of the present application for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease in the subject undergoing therapy. For example, a dosage may be expressed as a number of milligrams of a compound described herein per kilogram of the subject's body weight (mg/kg). Dosages of between about 0.1 and 150 mg/kg may be appropriate. In some embodiments, about 0.1 and 100 mg/kg may be appropriate. In other embodiments a dosage of between 0.5 and 60 mg/kg may be appropriate. Normalizing according to the subject's body weight is particularly useful when adjusting dosages between subjects of widely disparate size, such as occurs when using the drug in both children and adult humans or when converting an effective dosage in a non-human subject such as dog to a dosage suitable for a human subject.</p><p id="p-0128" num="0119">The daily dosage may also be described as a total amount of a compound described herein administered per dose or per day. Daily dosage of a compound of Formula I may be between about 1 mg and 4,000 mg, between about 2,000 to 4,000 mg/day, between about 1 to 2,000 mg/day, between about 1 to 1,000 mg/day, between about 10 to 500 mg/day, between about 20 to 500 mg/day, between about 50 to 300 mg/day, between about 75 to 200 mg/day, or between about 15 to 150 mg/day.</p><p id="p-0129" num="0120">When administered orally, the total daily dosage for a human subject may be between 1 mg and 1,000 mg, between about 1,000-2,000 mg/day, between about 10-500 mg/day, between about 50-300 mg/day, between about 75-200 mg/day, or between about 100-150 mg/day.</p><p id="p-0130" num="0121">The compounds of the present application or the compositions thereof may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. Treatment cycles are well known in cancer chemotherapy, and are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous.</p><p id="p-0131" num="0122">In a particular embodiment, the method comprises administering to the subject an initial daily dose of about 1 to 800 mg of a compound described herein and increasing the dose by increments until clinical efficacy is achieved. Increments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose. The dosage can be increased daily, every other day, twice per week, or once per week.</p><heading id="h-0010" level="1">EXAMPLES</heading><p id="p-0132" num="0123">The following examples are included to demonstrate specific embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques to function well in the practice of the disclosure, and thus can be considered to constitute specific modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.</p><heading id="h-0011" level="1">Example 1. GJ103 Increased Expression of BMPR2 mRNA and Protein Levels</heading><p id="p-0133" num="0124">Readthrough compounds such as PTC-124 and G418 (an aminoglycoside antibiotic) have shown significant increases in the expression of BMPR2 mRNA and protein in human cells containing the BMPR2 R899X nonsense mutation (data not shown).</p><p id="p-0134" num="0125">This example sought to determine whether the readthrough compound GJ103 can achieve readthrough when treating blood outgrowth endothelial cells (BOECs) obtained from patients with hPAH caused by one of three distinct nonsense mutations in the BMPR2 gene (R899X, R584X and R321X).</p><p id="p-0135" num="0126">Two other readthrough compounds, PTC-124 (Ataluren, with a chemical name of 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid) and G418 (an aminoglycoside antibiotic, also referred to as Geneticin and having a chemical name of (2R,3S,4R,5R,6S)-5-Amino-6-[(1R,2S,3S,4R,6S)-4,6-diamino-3-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-methylaminooxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-2-(1-hydroxyethyl)oxane-3,4-diol), were used as references. Both PTC-124 and G418 have shown readthrough effectiveness in previous studies.</p><p id="p-0136" num="0127">Positive controls were BOECs obtained from non-affected control individuals. Negative controls were untreated mutant cells. Compared with WT control cells, untreated mutant cells showed significantly reduced BMPR2 mRNA and protein levels. Following treatment of mutant cells with GJ103 and PTC-124 (to a much lesser degree), but not G418, this example observed enhanced BMPR2 mRNA and protein levels using qRT-PCR and Western blot analysis, respectively. Data on BOECs bearing the R584X mutation are shown in <figref idref="DRAWINGS">FIGS. <b>1</b> and <b>2</b></figref>. Reduced BMPR2 protein expression in R584 mutants (vs. WT controls) and increase in BMPR2 protein levels on GJ103 treatment was corroborated using immunofluorescence staining (<figref idref="DRAWINGS">FIG. <b>3</b></figref>).</p><heading id="h-0012" level="1">Example 2. GJ103 Increased Levels of BMPR2 Downstream Targets, Indicating the Receptor and Downstream BMP Signaling is Functionally Active</heading><p id="p-0137" num="0128">Having observed increased BMPR2 mRNA and protein levels on treatment of human BMPR2 mutant cells with GJ103, this example sought to determine whether GJ103-induced increases in BMPR2 protein levels is associated with active BMP signaling and induction of its downstream gene targets.</p><p id="p-0138" num="0129">In theory, it is possible that BMPR2 is expressed, but is non-functional. This can occur for several reasons, such as misfolding of the protein, or dysfunctional trafficking to the cell surface. In a pleasant surprise, this example observed that GJ103 treatment of BOECs (isolated from a patient with hPAH harboring the R584X mutation) induced near normal protein expression of BMPR2 (<figref idref="DRAWINGS">FIG. <b>4</b>A</figref>), Smad1 (<figref idref="DRAWINGS">FIG. <b>4</b>B</figref>), a BMP signaling intermediate, and VE-cadherin (<figref idref="DRAWINGS">FIG. <b>4</b>C</figref>), a gene readout of activation of BMP signaling. Note only a &#x2dc;25% reduction in BMPR2 protein levels (vs. almost 50% reduction shown in <figref idref="DRAWINGS">FIG. <b>2</b></figref>) in untreated mutant control vs. WT positive control cells (<figref idref="DRAWINGS">FIG. <b>4</b>A</figref>), suggesting wide variability in molecular phenotype, which is consistent with clinical variability in human hPAH patients harboring the same nonsense mutation (R584X).</p><p id="p-0139" num="0130">This example therefore demonstrates that GJ103 produced significant amounts of functionally active BMPR2 protein in cells derived from clinical hPAH subjects.</p><heading id="h-0013" level="1">Example 3. GJ103 Restored Endothelial Permeability</heading><p id="p-0140" num="0131">Loss of endothelial BMPR2 signaling is associated with compromised vascular integrity and exacerbation of inflammation-induced vascular permeability. This example sought to determine whether GJ103 can partially or fully normalize this functional response.</p><p id="p-0141" num="0132">The effect of GJ103 on the LPS-induced increase in vascular permeability was tested in both WT control and R584X mutant cells (<figref idref="DRAWINGS">FIG. <b>5</b></figref>). GJ103 showed a trend towards amelioration of LPS-induced increase in vascular permeability in mutant cells, but had no effect in WT cells, indicating specificity of GJ103 effect on cells bearing a nonsense mutation. As with the experiments in Examples 1-2, these data again show that GJ103 not only induces protein translation, but that the BMPR2 protein will be functional as well.</p><heading id="h-0014" level="1">Example 4. In Vivo Safety Testing</heading><p id="p-0142" num="0133">Following the above in vitro data, this example proceeded to test in vivo safety and efficacy of GJ103.</p><p id="p-0143" num="0134">Both acute (a single dose of GJ103 administration) and chronic (4 weekly doses of GJ103 administration) in vivo toxicity studies were performed.</p><p id="p-0144" num="0135">Acute Safety/Toxicity. The acute safety/toxicity of GJ103 study involved 3-month old WT (C57BL/6J) mice (N=30). Mice were administered GJ103 intraperitoneally (i.p.) at doses of 10, 25, 50 or 250 mg/kg (N=5 per group) and sacrificed 1 week later. Untreated or vehicle treated mice served as controls. GJ103 treated mice did not show any overt signs of toxicity (feeding, behavioral changes, changes in body weight, and breathing). VetScan Comprehensive Diagnostic profile, and HM5 hematology systems (Abaxis, Inc) were used to perform complete blood count, basal metabolic profile (serum electrolytes and glucose), liver [total protein, albumin, globulin, total bilirubin, serum alanine aminotransferase (ALT), serum aspartate transferase (AST), alkaline phosphatase (ALP), and serum amylase (AMY)], renal [blood urea nitrogen (BUN), and creatinine (CRE)], and lipid panels (cholesterol and triglyceride). These pilot toxicology experiments produced no evidence of significant toxicity (Table 1).</p><p id="p-0145" num="0136">Chronic safety/toxicity. Mice (N=5 per group) were injected once a week for 4 weeks i.p. at doses of 25 or 50 mg/kg of GJ103, animals were sacrificed 1 week after the last injection, and the CBC and chemistries were repeated as outlined in the acute safety/toxicity study. Untreated or vehicle treated mice served as controls. Again, this example found no significant changes in any of the parameters determined (Table 2). This example also assessed LDH levels in lung, liver, kidney and heart tissue lysates in both the acute and chronic studies, but found no statistically significant differences between GJ103 treated mice and either untreated or vehicle treated controls.</p><p id="p-0146" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="378pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Blood biochemistry profile a week foliowing one dose of G103</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="9"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><colspec colname="8" colwidth="35pt" align="center"/><colspec colname="9" colwidth="56pt" align="center"/><tbody valign="top"><row><entry>Treatment</entry><entry>BUN</entry><entry>CRE</entry><entry>Cholesterol </entry><entry>Triglyceride </entry><entry>NA+</entry><entry>PHOS</entry><entry>CA+</entry><entry>GLU</entry></row><row><entry>Group</entry><entry>mg/dL</entry><entry>mg/dL</entry><entry>mg/dL</entry><entry>mg/dL</entry><entry>mM</entry><entry>mg/dL</entry><entry>mg/dL</entry><entry>mg/dL</entry></row><row><entry namest="1" nameend="9" align="center" rowsep="1"/></row><row><entry>Untreated</entry><entry>26 &#xb1; 3.11</entry><entry>0.3 &#xb1; 0.06 </entry><entry>&#x3c;100</entry><entry>83 &#xb1; 3.21</entry><entry>150 &#xb1; 2.50</entry><entry>6.2 &#xb1; 0.45</entry><entry>10.3 &#xb1; 0.48</entry><entry>&#x2009;168 &#xb1; 7.99</entry></row><row><entry>Vehicle</entry><entry>24 &#xb1; 2.31</entry><entry>0.4 &#xb1; 0.07 </entry><entry>&#x3c;100</entry><entry>79 &#xb1; 6.78</entry><entry>153 &#xb1; 4.58</entry><entry>7.4 &#xb1; 0.42</entry><entry>10.1 &#xb1; 1.11</entry><entry>&#x2002;&#x2009;161 &#xb1; 13.20</entry></row><row><entry>&#x2002;GJ103 10 mg/kg</entry><entry>27 &#xb1; 2.51</entry><entry>0.3 &#xb1; 0.05 </entry><entry>&#x3c;100</entry><entry>79 &#xb1; 6.78</entry><entry>149 &#xb1; 1.48</entry><entry>7.4 &#xb1; 1.36</entry><entry>&#x2002;9.9 &#xb1; 0.82</entry><entry>&#x2009;155 &#xb1; 13.1</entry></row><row><entry>&#x2002;GJ103 25 mg/kg</entry><entry>19 &#xb1; 3.79</entry><entry>0.3 &#xb1; 0.07 </entry><entry>&#x3c;100</entry><entry>71 &#xb1; 8.80</entry><entry>151 &#xb1; 1.73</entry><entry>7.5 &#xb1; 0.35</entry><entry>10.5 &#xb1; 0.59</entry><entry>&#x2009;134 &#xb1; 4.58</entry></row><row><entry>&#x2002;GJ103 50 mg/kg</entry><entry>20 &#xb1; 1.53</entry><entry>0.2 &#xb1; 0.06 </entry><entry>&#x3c;100</entry><entry>79 &#xb1; 7.30</entry><entry>149 &#xb1; 2.00</entry><entry>8.4 &#xb1; 0.92</entry><entry>10.0 &#xb1; 0.35</entry><entry>&#x2002;&#x2009;184 &#xb1; 30.27</entry></row><row><entry>GJ103 250 mg/kg</entry><entry>24 &#xb1; 2.31</entry><entry>0.3 &#xb1; 0.07 </entry><entry>&#x3c;100</entry><entry>66 &#xb1; 9.57</entry><entry>149 &#xb1; 3.00</entry><entry>8.1 &#xb1; 2.48</entry><entry>10.6 &#xb1; 0.60</entry><entry>&#x2002;&#x2009;191 &#xb1; 63.58</entry></row><row><entry namest="1" nameend="9" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="42pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><colspec colname="8" colwidth="56pt" align="center"/><tbody valign="top"><row><entry>Treatment</entry><entry>TP</entry><entry>ALB</entry><entry>ALP</entry><entry>ALT</entry><entry>TBIL</entry><entry>GLOB</entry><entry>AMY</entry></row><row><entry>Group</entry><entry>g/dL</entry><entry>g/dL</entry><entry>g/dL</entry><entry>g/dL</entry><entry>mg/dL</entry><entry>mM</entry><entry>mg/dL</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row><row><entry>Untreated</entry><entry>5.7 &#xb1; 0.29</entry><entry>&#x2002;4.2 &#xb1; 0.18</entry><entry>55 &#xb1; 12.43</entry><entry>31 &#xb1; 3.13</entry><entry>0.3 &#xb1; 0.05</entry><entry>1.5 &#xb1; 0.30</entry><entry>&#x2009;&#x2002;728 &#xb1; 30.36</entry></row><row><entry>Vehicle</entry><entry>5.7 &#xb1; 0.00</entry><entry>4.2 &#xb1; 0.1</entry><entry>57 &#xb1; 22.41</entry><entry>25 &#xb1; 4.16</entry><entry>0.2 &#xb1; 0.00</entry><entry>1.5 &#xb1; 0.06</entry><entry>&#x2009;&#x2002;647 &#xb1; 50.93</entry></row><row><entry>&#x2002;GJ103 10 mg/kg</entry><entry>5.1 &#xb1; 0.66</entry><entry>&#x2002;4.1 &#xb1; 0.37</entry><entry>47 &#xb1; 12.14</entry><entry>29 &#xb1; 5.13</entry><entry>0.2 &#xb1; 0.00</entry><entry>1.5 &#xb1; 0.49</entry><entry>&#x2009;&#x2002;720 &#xb1; 41.44</entry></row><row><entry>&#x2002;GJ103 25 mg/kg</entry><entry>5.7 &#xb1; 0.12</entry><entry>&#x2002;4.0 &#xb1; 0.30</entry><entry>42 &#xb1; 27.15</entry><entry>24 &#xb1; 2.12</entry><entry>0.2 &#xb1; 0.06</entry><entry>1.6 &#xb1; 0.31</entry><entry>&#x2009;&#x2002;833 &#xb1; 73.45</entry></row><row><entry>&#x2002;GJ103 50 mg/kg</entry><entry>5.4 &#xb1; 0.23</entry><entry>&#x2002;4.1 &#xb1; 0.30</entry><entry>56 &#xb1; 22.14</entry><entry>30 &#xb1; 2.83</entry><entry>0.2 &#xb1; 0.06</entry><entry>1.2 &#xb1; 0.12</entry><entry>&#x2003;&#x2009;796 &#xb1; 129.55</entry></row><row><entry>GJ103 250 mg/kg</entry><entry>5.7 &#xb1; 0.26</entry><entry>&#x2002;4.4 &#xb1; 0.21</entry><entry>43 &#xb1; 10.54</entry><entry>34 &#xb1; 7.07</entry><entry>0.3 &#xb1; 0.00</entry><entry>1.4 &#xb1; 0.06</entry><entry>&#x2002;&#x2009;1178 &#xb1; 480.67</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0147" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="441pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Blood biochemistry 1 week following 4 weekly GJ103 injections</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="9"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><colspec colname="5" colwidth="49pt" align="center"/><colspec colname="6" colwidth="42pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><colspec colname="8" colwidth="42pt" align="center"/><colspec colname="9" colwidth="56pt" align="center"/><tbody valign="top"><row><entry>Treatment</entry><entry>BUN</entry><entry>CRE </entry><entry>Cholesterol</entry><entry>Triglyceride</entry><entry>NA+</entry><entry>PHOS</entry><entry>CA+</entry><entry>GLU</entry></row><row><entry>Group</entry><entry>mg/dL</entry><entry>mg/dL</entry><entry>mg/dL</entry><entry>mg/dL</entry><entry>mM</entry><entry>mg/dL</entry><entry>mg/dL</entry><entry>mg/dL</entry></row><row><entry namest="1" nameend="9" align="center" rowsep="1"/></row><row><entry>Untreated</entry><entry>25 &#xb1; 13.06</entry><entry>0.3 &#xb1; 10.06 </entry><entry>&#x3c;100</entry><entry>&#x2002;&#x2009;90 &#xb1; 4.27</entry><entry>149 &#xb1; 1.00</entry><entry>6.6 &#xb1; 0.78</entry><entry>10.0 &#xb1; 0.21</entry><entry>&#x2002;&#x2009;167 &#xb1; 17.16</entry></row><row><entry>Vehicle</entry><entry>23 &#xb1; 13.79</entry><entry>0.4 &#xb1; 10.15 </entry><entry>&#x3c;100</entry><entry>&#x2002;&#x2009;73 &#xb1; 8.45</entry><entry>149 &#xb1; 1.53</entry><entry>6.5 &#xb1; 0.15</entry><entry>&#x2002;9.7 &#xb1; 0.06</entry><entry>&#x2009;180 &#xb1; 12.7</entry></row><row><entry>GJ103 25 mg/kg</entry><entry>19 &#xb1; 13.05</entry><entry>0.3 &#xb1; 10.08 </entry><entry>&#x3c;100</entry><entry>&#x2002;&#x2009;62 &#xb1; 10.6</entry><entry>149 &#xb1; 3.19</entry><entry>6.7 &#xb1; 0.99</entry><entry>9.9 &#xb1; 0.4</entry><entry>&#x2002;&#x2009;173 &#xb1; 19.14</entry></row><row><entry>GJ103 50 mg/kg</entry><entry>20 &#xb1; 13.40</entry><entry>0.3 &#xb1; 10.06 </entry><entry>&#x3c;100</entry><entry>&#x2003;&#x2009;61 &#xb1; 13.38</entry><entry>149 &#xb1; 2.50</entry><entry>7.1 &#xb1; 1.95</entry><entry>&#x2002;9.9 &#xb1; 0.54</entry><entry>&#x2002;&#x2009;176 &#xb1; 15.52</entry></row><row><entry namest="1" nameend="9" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><colspec colname="5" colwidth="56pt" align="center"/><colspec colname="6" colwidth="42pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><colspec colname="8" colwidth="56pt" align="center"/><tbody valign="top"><row><entry>Treatment</entry><entry>TP</entry><entry>ALB</entry><entry>ALP</entry><entry>ALT</entry><entry>TBiL</entry><entry>GLOB</entry><entry>AMY</entry></row><row><entry>Group</entry><entry>g/dL</entry><entry>g/dL</entry><entry>g/dL</entry><entry>g/dL</entry><entry>mg/dL</entry><entry>mM</entry><entry>mg/dL</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row><row><entry>Untreated</entry><entry>5.6 &#xb1; 0.06</entry><entry>4.2 &#xb1; 0.15</entry><entry>&#x2003;&#x2009;78 &#xb1; 10.07</entry><entry>&#x2002;27 &#xb1; 1.73</entry><entry>0.2 &#xb1; 0.06</entry><entry>1.4 &#xb1; 0.10</entry><entry>&#x2009;&#x2002;726 &#xb1; 44.56</entry></row><row><entry>Veh ide</entry><entry>5.4 &#xb1; 0.06</entry><entry>4.0 &#xb1; 0.15</entry><entry>&#x2002;&#x2009;83 &#xb1; 2.65</entry><entry>&#x2002;27 &#xb1; 0.58</entry><entry>0.2 &#xb1; 0.06</entry><entry>1.4 &#xb1; 0.06</entry><entry>&#x2009;&#x2002;680 &#xb1; 81.99</entry></row><row><entry>GJ103 25 mg/kg</entry><entry>5.7 &#xb1; 0.18</entry><entry>4.2 &#xb1; 0.27</entry><entry>&#x2003;&#x2009;69 &#xb1; 17.52</entry><entry>&#x2002;27 &#xb1; 4.38</entry><entry>0.2 &#xb1; 0.04</entry><entry>1.8 &#xb1; 0.88</entry><entry>&#x2009;&#x2002;605 &#xb1; 72.39</entry></row><row><entry>GJ103 50 mg/kg</entry><entry>5.6 &#xb1; 0.39</entry><entry>4.1 &#xb1; 0.36</entry><entry>&#x2003;&#x2009;71 &#xb1; 13.00</entry><entry>&#x2003;&#x2009;30 &#xb1; 12.48</entry><entry>0.2 &#xb1; 0.05</entry><entry>1.5 &#xb1; 0.38</entry><entry>&#x2003;&#x2009;742 &#xb1; 101.74</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0015" level="1">Example 5. In Vivo Efficacy Testing</heading><p id="p-0148" num="0137">Having determined apparent in vivo safety of GJ103, this example next assessed if GJ103 administered i.p. improves BMPR2 proteins levels and activates BMP signaling in the pulmonary arteries of mice with a nonsense mutation. This example shows that GJ103 induced in vivo expression of BMPR2 in the lungs of Bmpr2<sup>+/R899X </sup>and Bmpr2<sup>+/R584X </sup>mice</p><p id="p-0149" num="0138">To test this, Bmpr2<sup>+/R899X </sup>and Bmpr2<sup>+/R584X </sup>mice were administered vehicle, 25 mg/kg or 50 mg/kg GJ103 i.p. once daily for 5 days. Mice were then sacrificed and lung homogenates probed for BMPR2 protein levels (<figref idref="DRAWINGS">FIG. <b>6</b></figref>). Compared to WT (Bmpr2+/+) littermate controls, both Bmpr2<sup>+/R899X </sup>and Bmpr2<sup>+/R584X </sup>mice expressed &#x2dc;25-33% of WT BMPR2 protein levels. It therefore shows that GJ103 significantly increased BMPR2 expression vs. untreated controls to levels that could potentially prevent or normalize the hPAH phenotype.</p><p id="p-0150" num="0139">This example next tested the function of GJ103-induced expression of BMPR2 protein using an in vivo LPS vascular permeability assay and Evans blue dye as a marker of vascular leakage and showed that GJ103 restored LPS-induced Increase in pulmonary vascular/endothelial permeability in vivo in Bmpr2<sup>+/R899X </sup>mice.</p><p id="p-0151" num="0140">Bmpr2<sup>+/R899X </sup>and WT mice injected with LPS developed pulmonary vascular leakage (<figref idref="DRAWINGS">FIG. <b>7</b>A</figref>), which was quantified by extravasation of Evans blue dye into lung tissue (<figref idref="DRAWINGS">FIG. <b>7</b>B</figref>). Bmpr2<sup>+/R899X </sup>mice demonstrated much greater increase in dye extravasation compared to WT littermates, but this was significantly blocked with GJ103 (50 mg/kg). There was no effect of GJ103 on LPS-induced leakage in WT controls. Collectively, these findings are consistent with the interpretation that BMPR2 protein induced by treatment with GJ103 in Bmpr2<sup>+/R899X </sup>mice was functionally active. Based on this finding, it is contemplated that GJ103-induced expression of BMPR2 can slow or prevent development of hPAH pathology.</p><p id="p-0152" num="0141">Pulmonary endothelial cell apoptosis is thought to initiate development of hPAH by triggering vaso-occlusive fibroproliferation. Therefore, this example next determined the effect of GJ103 on BCL-2 and Bax lung protein levels in WT and Bmpr2<sup>+/R899X </sup>mice, and assessed how GJ103 affects spontaneous apoptosis in Bmpr2<sup>+/R899X </sup>mice lungs. Consistent with GJ103's effects on BMPR2 expression (<figref idref="DRAWINGS">FIGS. <b>1</b>-<b>4</b> and <b>6</b></figref>) as well as the restoration of endothelial cell integrity (<figref idref="DRAWINGS">FIGS. <b>5</b> and <b>7</b></figref>), GJ103 also blocked spontaneous apoptosis in Bmpr2<sup>+/R899X </sup>mice lungs (<figref idref="DRAWINGS">FIG. <b>8</b></figref>).</p><p id="p-0153" num="0142">The above examples, in summary, demonstrate that, in an appropriate mouse model of hPAH developed herein, a lead SMRT compound candidate (GJ103) has been identified. GJ103 is water soluble, readily administered, and reads through all three clinically relevant nonsense mutations to produce significant amounts of BMPR2 protein. GJ103 induces increased expression of BMP pathway signaling intermediates (Smads) and downstream gene targets (Id1 and VE-cadherin) of BMPR2-mediated signaling, indicating that BMPR2 protein is indeed functional. GJ103 induces translation of significant quantities of BMPR2 protein in human BOECs obtained from patients with hPAH caused by nonsense mutations in the BMPR2 gene, thus establishing clinical relevance. GJ103 restores endothelial permeability in vitro in an LPS-induced functional assay and shows no evidence of toxicity thus far at doses that produce in vivo readthrough. Moreover, GJ103 induces expression of significant BMPR2 protein in the lungs of Bmpr2<sup>+/R899X </sup>and Bmpr2<sup>+/R584X </sup>mice, partially blunts LPS-induced increases in endothelial permeability, and blocks lung apoptosis, which is also consistent with GJ103-induced expression of functionally active BMPR2 protein.</p><p id="p-0154" num="0143">Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.</p><p id="p-0155" num="0144">The inventions illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms &#x201c;comprising&#x201d;, &#x201c;including,&#x201d; &#x201c;containing&#x201d;, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.</p><p id="p-0156" num="0145">Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification, improvement and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications, improvements and variations are considered to be within the scope of this invention. The materials, methods, and examples provided here are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention.</p><p id="p-0157" num="0146">The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.</p><p id="p-0158" num="0147">In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.</p><p id="p-0159" num="0148">All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety, to the same extent as if each were incorporated by reference individually. In case of conflict, the present specification, including definitions, will control.</p><p id="p-0160" num="0149">It is to be understood that while the disclosure has been described in conjunction with the above embodiments, that the foregoing description and examples are intended to illustrate and not limit the scope of the disclosure. Other aspects, advantages and modifications within the scope of the disclosure will be apparent to those skilled in the art to which the disclosure pertains.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-chemistry idref="CHEM-US-00001" cdx-file="US20230000850A1-20230105-C00001.CDX" mol-file="US20230000850A1-20230105-C00001.MOL"/><us-chemistry idref="CHEM-US-00002" cdx-file="US20230000850A1-20230105-C00002.CDX" mol-file="US20230000850A1-20230105-C00002.MOL"/><us-chemistry idref="CHEM-US-00003" cdx-file="US20230000850A1-20230105-C00003.CDX" mol-file="US20230000850A1-20230105-C00003.MOL"/><us-chemistry idref="CHEM-US-00004" cdx-file="US20230000850A1-20230105-C00004.CDX" mol-file="US20230000850A1-20230105-C00004.MOL"/><us-chemistry idref="CHEM-US-00005" cdx-file="US20230000850A1-20230105-C00005.CDX" mol-file="US20230000850A1-20230105-C00005.MOL"/><us-chemistry idref="CHEM-US-00006" cdx-file="US20230000850A1-20230105-C00006.CDX" mol-file="US20230000850A1-20230105-C00006.MOL"/><us-chemistry idref="CHEM-US-00007" cdx-file="US20230000850A1-20230105-C00007.CDX" mol-file="US20230000850A1-20230105-C00007.MOL"/><us-chemistry idref="CHEM-US-00008" cdx-file="US20230000850A1-20230105-C00008.CDX" mol-file="US20230000850A1-20230105-C00008.MOL"/><us-chemistry idref="CHEM-US-00009" cdx-file="US20230000850A1-20230105-C00009.CDX" mol-file="US20230000850A1-20230105-C00009.MOL"/><us-chemistry idref="CHEM-US-00010" cdx-file="US20230000850A1-20230105-C00010.CDX" mol-file="US20230000850A1-20230105-C00010.MOL"/><us-chemistry idref="CHEM-US-00011" cdx-file="US20230000850A1-20230105-C00011.CDX" mol-file="US20230000850A1-20230105-C00011.MOL"/><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A method for treating, preventing, or slowing the rate of development of a disease or condition mediated by a nonsense mutation in the bone morphogenetic protein receptor type II (Bmpr2) in a subject in need thereof, comprising administering to the subject a compound of Formula I, II or III, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof:</claim-text><claim-text><chemistry id="CHEM-US-00008" num="00008"><img id="EMI-C00008" he="87.46mm" wi="63.84mm" file="US20230000850A1-20230105-C00008.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein:</claim-text><claim-text>X, Y, and Z are each independently O, S, or NR<sup>10</sup>; wherein R<sup>10 </sup>is hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, where each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</claim-text><claim-text>A is N or CR<sup>11</sup>; wherein R<sup>11 </sup>is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</claim-text><claim-text>B is N or CR<sup>12</sup>; wherein R<sup>12 </sup>is hydrogen, halo, pseudohalo, alkyl, alkoxy, or thioalkoxy;</claim-text><claim-text>D is N or CR<sup>13</sup>; wherein R<sup>13 </sup>is hydrogen, halo, pseudohalo, alkyl, alkoxy, or thioalkoxy;</claim-text><claim-text>R<sup>1 </sup>is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</claim-text><claim-text>R<sup>2 </sup>is C<sub>1-3</sub>alkylene, C<sub>3-10</sub>cycloalkylene, or heterocyclylene of 3 to 10 atoms;</claim-text><claim-text>R<sup>3 </sup>is hydroxy, alkoxy, &#x2014;NR<sup>6</sup>R<sup>6a</sup>, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</claim-text><claim-text>R<sup>4 </sup>is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</claim-text><claim-text>R<sup>5 </sup>is &#x2014;NR<sup>5a</sup>R<sup>5b</sup>, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is independently optionally substituted;</claim-text><claim-text>R<sup>5a </sup>is hydrogen or alkyl;</claim-text><claim-text>R<sup>5b </sup>is alkyl, alkoxyalkyl, alkenyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; wherein the aryl or heteroaryl, either alone or as part of arylalkyl and heteroarylalkyl, are optionally substituted with 1, 2, or 3 groups independently selected from alkyl, halo, haloalkyl, hydroxy, and alkoxy;</claim-text><claim-text>R<sup>6 </sup>is hydrogen or alkyl; and</claim-text><claim-text>R<sup>6a </sup>is &#x2014;NHC(O)(arylalkyl), alkyl, hydroxyalkyl, cycloalkyl, heteroaryl, or aryl, wherein each aryl, arylalkyl, or heteroaryl are optionally substituted with 1, 2, or 3 groups selected from hydroxy, halo, haloalkyl, alkyl, alkoxy, carboxy, or alkoxycarbonyl.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the compound is of Formula Ia, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof:</claim-text><claim-text><chemistry id="CHEM-US-00009" num="00009"><img id="EMI-C00009" he="35.22mm" wi="58.50mm" file="US20230000850A1-20230105-C00009.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein:</claim-text><claim-text>R<sup>1a </sup>is 2-hydroxylphenyl, 2-alkoxyphenyl, 3-hydroxylphenyl, or 3-alkoxyphenyl;</claim-text><claim-text>X<sup>1 </sup>is S, O, NH, or N(C<sub>1-3</sub>-alkyl);</claim-text><claim-text>R<sup>2a </sup>is (CH<sub>2</sub>)<sub>m</sub>;</claim-text><claim-text>m is 1, 2, or 3;</claim-text><claim-text>Y<sup>1 </sup>is O, S, or NH;</claim-text><claim-text>R<sup>3a </sup>is hydroxy or &#x2014;NR<sup>7</sup>R<sup>7a</sup>;</claim-text><claim-text>R<sup>7 </sup>is hydrogen or C<sub>1-3</sub>-alkyl;</claim-text><claim-text>R<sup>7a </sup>is hydroxyalkyl; phenyl substituted with 1, 2, or 3 R<sup>8 </sup>groups; phenyl substituted with two independently selected halo;</claim-text><claim-text>each R<sup>8 </sup>is independently hydroxy or haloalkyl; and</claim-text><claim-text>each R<sup>9</sup>, when present, is independently hydroxy, alkoxy, halo, haloalkyl, or C<sub>1-6</sub>-alkyl; and</claim-text><claim-text>provided that 1) when X<sup>1 </sup>is S, R<sup>2a </sup>is &#x2014;CH<sub>2</sub>&#x2014;, Y<sup>1 </sup>is O, and R<sup>3a </sup>is &#x2014;NR<sup>7</sup>R<sup>7a </sup>and R<sup>7 </sup>is hydrogen, then R<sup>7a </sup>is not 2-methoxyphenyl; and 2) when R<sup>1a </sup>is 2-methoxyphenyl, X<sup>1 </sup>is S, R<sup>2a </sup>is &#x2014;CH<sub>2</sub>&#x2014;, Y<sup>1 </sup>is O, and R<sup>3a </sup>is &#x2014;NR<sup>7</sup>R<sup>7a </sup>and R<sup>7 </sup>is hydrogen, then R<sup>7a </sup>is not 4-methoxyphenyl.</claim-text></claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the compound is of formula:</claim-text><claim-text><chemistry id="CHEM-US-00010" num="00010"><img id="EMI-C00010" he="31.75mm" wi="39.29mm" file="US20230000850A1-20230105-C00010.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>or a pharmaceutically acceptable salt, isotopically enriched analog, or prodrug thereof.</claim-text></claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The method of <claim-ref idref="CLM-00003">claim 3</claim-ref>, wherein the compound is</claim-text><claim-text><chemistry id="CHEM-US-00011" num="00011"><img id="EMI-C00011" he="31.67mm" wi="41.49mm" file="US20230000850A1-20230105-C00011.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>or an isotopically enriched analog, or prodrug thereof.</claim-text></claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising to the subject an effective amount of a drug selected from the group consisting of ambrisentan, bocentan, macitentan, riociguat, selexipag, sildenafil, tadalafil, treprostinil, Iloprost tromethamine, treprostinil, epopostenol sodium, treprostinil and combinations thereof.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising to the subject an effective amount of a nonsense-mediated decay inhibitor (NMDI).</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the nonsense mutation decreases or eliminates the expression and activity of Bmpr2.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the nonsense mutation is selected from the group consisting of R584X, R321X, R899X and combinations thereof.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the nonsense mutation is R584X.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the nonsense mutation is R321X.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the nonsense mutation is R899X.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the disease or condition is pulmonary artery hypertension (PAH).</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the disease or condition is pulmonary veno-occlusive disease (PVOD).</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the administration is oral.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the administration is by injection.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the administration is by inhalation.</claim-text></claim></claims></us-patent-application>